

CITATION REPORT

List of articles citing

Sorafenib in advanced hepatocellular carcinoma

DOI: 10.1056/nejmoa0708857

New England Journal of Medicine, 2008, 359, 378-90.

Source: <https://exaly.com/paper-pdf/43837561/citation-report.pdf>

Version: 2023-03-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2225	Assessment and triage of hepatocellular carcinoma. 85-90		
2224	Hepatic intra-arterial chemotherapy in patients with advanced primary liver tumours. 2012 , 6, 280		2
2223	Proctolin: a peptide transmitter candidate in insects. 1975 , 17, 1241-52		171
2222	Markers of arterial stiffness are risk factors for progression to end-stage renal disease among patients with chronic kidney disease stages 4 and 5. 2007 , 107, c177-81		67
2221	Effective palliation of advanced cholangiocarcinoma with sorafenib: a two-patient case report. 2007 , 38, 154-6		13
2220	Standards und neue Aspekte der Diagnostik und Therapie des hepatozellulären Karzinoms. 2008 , 1, 109-119		
2219	Systemic therapy of hepatocellular carcinoma: are we making progress?. 2008 , 25, 1089-104		61
2218	Hepatocarcinoma: from pathogenic mechanisms to target therapy. 2008 , 2, 214-222		2
2217	The management of cancer in the elderly: targeted therapies in oncology. 2008 , 5, 16		9
2216	A new prognostic score system in patients with advanced hepatocellular carcinoma not amendable to locoregional therapy: implication for patient selection in systemic therapy trials. 2008 , 113, 2742-51		53
2215	The angiogenic makeup of human hepatocellular carcinoma does not favor vascular endothelial growth factor/angiopoietin-driven sprouting neovascularization. 2008 , 48, 1517-27		30
2214	Molecular targeted therapies in hepatocellular carcinoma. 2008 , 48, 1312-27		794
2213	Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents. 2008 , 28, 1269-77		51
2212	Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794]. 2008 , 8, 349		73
2211	MicroRNA involvement in hepatocellular carcinoma. 2008 , 12, 2189-204		209
2210	Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: a case report. 2008 , 1, 18		43
2209	Pivotal role of mTOR signaling in hepatocellular carcinoma. 2008 , 135, 1972-83, 1983.e1-11		562

2208	Drug-eluting particles in the treatment of HCC: chemoembolization with doxorubicin-loaded DC Bead. 2008 , 8, 1643-50	40
2207	Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. 2008 , 68, 6779-88	458
2206	Sorafenib in advanced hepatocellular carcinoma - We have won a battle not the war. 2008 , 49, 871-3	22
2205	Optimizing management strategies in patients with chronic hepatitis B. Introduction. 2008 , 121, S1-2	5
2204	Demography and presentation of chronic hepatitis B virus infection. 2008 , 121, S3-11	17
2203	Diagnosis of chronic hepatitis B and the implications of viral variants and mutations. 2008 , 121, S12-21	1
2202	Assessment of the newly diagnosed patient with chronic hepatitis B virus infection. 2008 , 121, S22-32	2
2201	Therapeutic strategies for chronic hepatitis B virus infection in 2008. 2008 , 121, S33-44	6
2200	Implementing evidenced-based practice guidelines for the management of chronic hepatitis B virus infection. 2008 , 121, S45-52	3
2199	Title page. 2008 , 121, i-OBC	
2198	Faculty List. 2008 , 121, i-OBC	
2197	CME Title/Divider page. 2008 , 121, i-OBC	
2196	CME Quiz. 2008 , 121, i-OBC	
2195	CME Answer Sheet. 2008 , 121, i-OBC	
2194	CME Evaluation Form. 2008 , 121, i-OBC	
2193	CME Information. 2008 , 121, i-OBC	
2192	Faculty Disclosures. 2008 , 121, i-OBC	
2191	Sorafenib in advanced hepatocellular carcinoma. <i>New England Journal of Medicine</i> , 2008 , 359, 2497-8; author reply 2498-9	57.2 38

2190	Sorafenib in liver cancer--just the beginning. <i>New England Journal of Medicine</i> , 2008 , 359, 420-2	57.2	90
2189	Potential role of sorafenib in the treatment of acute myeloid leukemia. 2008 , 49, 2246-55		42
2188	Hepatitis B virus genotype and mutants: risk factors for hepatocellular carcinoma. 2008 , 100, 1121-3		14
2187	Re: Design and endpoints of clinical trials in hepatocellular carcinoma. 2008 , 100, 1557; author reply 1557-8		13
2186	Adalimumab in juvenile rheumatoid arthritis. <i>New England Journal of Medicine</i> , 2008 , 359, 2495; author reply 2496-7	57.2	2
2185	The current STATE of biomarkers to predict the response to anti-angiogenic therapies. 2008 , 7, 2004-6		2
2184	PIVKA-II is the best prognostic predictor in patients with hepatocellular carcinoma after radiofrequency ablation therapy. 2008 , 75 Suppl 1, 91-8		19
2183	Systemic chemotherapy of hepatocellular carcinoma--Korean experience. 2008 , 75 Suppl 1, 114-8		14
2182	Evidence-based diagnosis and locoregional therapy for hepatocellular carcinoma. 2008 , 2, 761-84		11
2181	Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. 2008 , 7, 3129-40		1057
2180	Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease. 2008 , 8, 1743-9		68
2179	Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. 2008 , 13, 1001-11		273
2178	Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy. 2008 , 75 Suppl 1, 1-12		94
2177	Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. 2008 , 7, 3670-84		259
2176	Sorafenib in hepatocellular carcinoma: separating the hype from the hope. 2008 , 26, 5845-8		26
2175	Angiogenesis inhibition in non-GIST soft tissue sarcomas. 2008 , 13, 1193-200		20
2174	Sorafenib for the treatment of unresectable hepatocellular carcinoma. 2008 , 2, 779-88		32
2173	Recent Publications on Medications and Pharmacy. 2008 , 43, 846-852		

2172	CLINICAL NEWS. 2008 , 69, 496-499	2
2171	Aggressive Resection of Hepatocellular Carcinoma with Right Atrial Involvement. 2009 , 75, 1104-1108	23
2170	Article Commentary: Clinical Medicine: Endocrinology and Diabetes: Insulin ResistanceâLink between Inflammation and Hepatocarcinogenesis?. 2009 , 2, CMED.S3497	
2169	Systemic therapies for advanced hepatocellular carcinoma. 97-121	
2168	Hepatocellular Carcinoma. 2009 , 72-82	
2167	Safety and efficacy of sorafenib in the treatment of hepatocellular carcinoma. 2009 , 2, 261-7	6
2166	Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers. 2009 , 429	
2165	[Fundamental and translational research on hepatocellular carcinoma in 2008: forces and priorities]. 2009 , 96, 45-50	1
2164	[Epidemiology, prevention, screening and diagnosis of hepatocellular carcinoma]. 2009 , 96, 35-43	13
2163	[Targeted therapies in hepatocellular carcinomas: recent results and future development]. 2009 , 96, 553-61	7
2162	Challenge and hope in radiotherapy of hepatocellular carcinoma. 2009 , 50, 601-12	46
2161	[Hand-foot syndrome and sorafenib]. 2009 , 96, 191-7	1
2160	[Management of hepatocellular carcinoma. Where are we now? What's next?]. 2009 , 96, 19-34	3
2159	Hepatocellular carcinoma in Keio affiliated hospitals--diagnosis, treatment, and prognosis of this disease. 2009 , 58, 161-75	6
2158	Novel developments in angiogenesis cancer therapy. 2009 , 16, 50-4	11
2157	Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers. 2009 , 2009, 567486	83
2156	Sorafenib in a patient with advanced hepatocellular carcinoma and serious impairment of left ventricular function: a case report. 2009 , 2, 9133	3
2155	Sorafenib in Hepatocellular Carcinoma. 2009 , 1, CMT.S2314	

2154	[Targeting KRAS pathway in NSCLC therapy]. 2009 , 96 Suppl, S69-74	1
2153	Hepatocellular carcinoma: Epidemiological profile from a cohort of federal employees in Mexico. 2009 , 8, 212-219	12
2152	Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. 2009 , 27, 3027-35	418
2151	A review on the treatment of relapsed/metastatic head and neck cancer. 2009 , 10, 2625-32	5
2150	The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008. 2009 , 20 Suppl 7, vii1-vii6	80
2149	Pazopanib: an antiangiogenic drug in perspective. 2009 , 5, 1335-48	20
2148	Multimodal approaches to the treatment of hepatocellular carcinoma. 2009 , 6, 159-69	58
2147	Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). 2009 , 27, 3126-32	521
2146	Portal vein tumor thrombosis revascularization during sorafenib treatment for hepatocellular carcinoma. 2009 , 104, 1852-4	23
2145	Targeting multiple kinases in glioblastoma multiforme. 2009 , 18, 277-92	36
2144	Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. 2009 , 14, 70-6	144
2143	Sorafenib reveals efficacy in sequential treatment of metastatic renal cell cancer. 2009 , 9, 1429-34	11
2142	Erlotinib: applications in therapy and current status of research. 2009 , 2, 15-36	1
2141	Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. 2009 , 27, 3969-74	80
2140	Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma. 2009 , 14, 717-25	83
2139	Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. 2009 , 27, 5734-42	180
2138	Distinguishing between anti-neutrophil cytoplasmic antibody patterns in inflammatory bowel disease: is the "atypical pattern" adding more information?. 2009 , 104, 1854-5	8
2137	Adaptive immunity in hepatocellular carcinoma: prognostic and therapeutic implications. 2009 , 9, 1499-510	21

2136	Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma. 2009 , 15, 5445-56	137
2135	Sunitinib in hepatocellular carcinoma: redefining appropriate dosing, schedule, and activity end points. 2009 , 27, e248-50; author reply e251-2	30
2134	Current status of therapy for hepatocellular carcinoma. 2009 , 2, 45-57	11
2133	Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. 2009 , 27, 4274-80	172
2132	Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. 2009 , 77, 257-71	142
2131	Novel designs and end points for phase II clinical trials. 2009 , 15, 1866-72	58
2130	Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. 2009 , 15, 6250-7	142
2129	Commentary: Sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy. 2009 , 14, 67-9	27
2128	Angiogenesis inhibitors in the treatment of non-small cell lung cancer. 2009 , 1, 95-107	6
2127	Testing molecular therapies in hepatocellular carcinoma: the need for randomized phase II trials. 2009 , 27, 833-5	29
2126	Thrombotic events in patients with cancer receiving antiangiogenesis agents. 2009 , 27, 4865-73	164
2125	Diffusion-weighted MRI of advanced hepatocellular carcinoma during sorafenib treatment: initial results. 2009 , 193, W301-7	87
2124	Image-guided interstitial high-dose-rate brachytherapy in hepatocellular carcinoma. 2009 , 27, 170-4	14
2123	Treatment of hepatocellular carcinoma. 2009 , 77 Suppl 1, 43-9	3
2122	Remission of paraneoplastic dermatomyositis associated with hepatocellular carcinoma under prednisolone and azathiopin, and concomittant sorafenib. 2009 , 32, 50-3	4
2121	Systemic therapies in hepatocellular carcinoma. 2009 , 27, 175-88	51
2120	A one, two punch for liver cancer: anti-angiogenesis with a death receptor agonist. 2009 , 8, 463-4	1
2119	Which questions remain unanswered following the successful development of sorafenib in hepatocellular carcinoma?. 2009 , 6, 64-5	4

2118	Mode of action and clinical impact of VEGF signaling inhibitors. 2009 , 9, 649-62	22
2117	Changing the clinical picture of challenging tumors: tales becoming reality?. 2009 , 5, 785-802	1
2116	Safety, tolerability and biological effects of long-term metronomic administration of non-cytotoxic anti-angiogenic agents. 2009 , 77, 358-65	8
2115	Sunitinib and PF-562,271 (FAK/Pyk2 inhibitor) effectively block growth and recovery of human hepatocellular carcinoma in a rat xenograft model. 2009 , 8, 856-65	55
2114	Clinical profile, etiology and therapeutic outcome in 324 hepatocellular carcinoma patients at a tertiary care center in India. 2009 , 77, 162-71	36
2113	[Gastrointestinal oncology - therapy update 2008 / 2009]. 2009 , 47, 296-306	
2112	Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization. 2009 , 250, 324-6	5
2111	Modular protein engineering in emerging cancer therapies. 2009 , 15, 893-916	32
2110	Transcatheter arterial chemoembolization combined with or without Chinese herbal therapy for hepatocellular carcinoma: meta-analysis. 2009 , 18, 617-35	23
2109	Early development of sunitinib in hepatocellular carcinoma. 2009 , 9, 143-50	25
2108	Bevacizumab: current indications and future development for management of solid tumors. 2009 , 9, 507-17	54
2107	Emerging Raf inhibitors. 2009 , 14, 633-48	30
2106	Current status of cediranib: the rapid development of a novel anti-angiogenic therapy. 2009 , 5, 421-32	35
2105	Sorafenib induces preferential apoptotic killing of a drug- and radio-resistant Hep G2 cells through a mitochondria-dependent oxidative stress mechanism. 2009 , 8, 1904-13	56
2104	[Sorafenib for the treatment of HCC--the beginning of a new era in the treatment of HCC]. 2009 , 47, 55-60	2
2103	[Hepatology 2009]. 2009 , 134, 1335-9	0
2102	Neue chirurgische Ansätze beim hepatozellulären Karzinom. 2009 , 30, 89-95	
2101	New approaches in hepatocellular carcinoma treatment: 18th World Congress of the International Association of Surgeons, Gastroenterologists and Oncologists, 8-11 October 2008, Istanbul, Turkey. 2009 , 5, 9-11	

2100	The metastatic process: methodological advances and pharmacological challenges. 2009 , 16, 1704-17	26
2099	Targeted therapies in solid tumours: pinpointing the tumour's Achilles heel. 2009 , 15, 207-42	9
2098	[New surgical approaches in the treatment of hepatocellular carcinoma]. 2009 , 47, 61-7	2
2097	[Selective internal radiotherapy (radioembolization) and radiation therapy for HCC--current status and perspectives]. 2009 , 47, 37-54	20
2096	A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. 2009 , 15, 5895-901	90
2095	Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors. 2009 , 27, 4169-76	38
2094	Systemic therapy for advanced renal cell carcinoma. 2009 , 1, 15-27	7
2093	Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma. 2009 , 15, 5820-8	29
2092	Translating the metastasis paradigm from scientific theory to clinical oncology. 2009 , 15, 2588-93	23
2091	New kids on the block: diagnostic and prognostic microRNAs in hepatocellular carcinoma. 2009 , 8, 1686-93	59
2090	Lack of somatic mutations in VEGFR-2 tyrosine kinase domain in hepatocellular carcinoma. 2009 , 48, 628-30	
2089	Hepatocellular carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. 2009 , 20 Suppl 4, 41-5	25
2088	Hepatocellular Carcinoma. 2009 ,	
2087	Sorafenib and sunitinib. 2009 , 14, 800-5	46
2086	Commentary: Sorafenib -- the end of a long journey in search of systemic therapy for hepatocellular carcinoma, or the beginning?. 2009 , 14, 92-4	10
2085	Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval. 2009 , 27, 5868-73	79
2084	Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. 2009 , 27, 843-50	280
2083	Targeted therapy in renal cancer. 2009 , 1, 183-205	13

2082	Overactivation of the MEK/ERK pathway in liver tumor cells confers resistance to TGF- β -induced cell death through impairing up-regulation of the NADPH oxidase NOX4. 2009 , 69, 7595-602	89
2081	Alternate endpoints for screening phase II studies. 2009 , 15, 1873-82	72
2080	Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma. 2009 , 20, 1402-7	41
2079	Angiogenesis as a therapeutic target in malignant gliomas. 2009 , 14, 621-36	90
2078	Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs). 2009 , 14, 291-302	83
2077	Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. 2009 , 27, 1800-5	167
2076	Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. 2009 , 27, 3557-65	224
2075	Sorafenib-induced acute myocardial infarction due to coronary artery spasm. 2009 , 54, 512-5	43
2074	Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib. 2009 , 9, 208	59
2073	Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: results from a multicenter study. 2009 , 9, 249	40
2072	Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study. 2009 , 7, 41	100
2071	Predicting the response to sorafenib in hepatocellular carcinoma: where is the evidence for phosphorylated extracellular signaling-regulated kinase (pERK)? 2009 , 7, 42	10
2070	Novel agents on the horizon for cancer therapy. 2009 , 59, 111-37	241
2069	Oncolytic virotherapy for advanced liver tumours. 2009 , 13, 1238-47	12
2068	Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. 2009 , 13, 2673-2683	104
2067	A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. 2009 , 9, 1920-8	447
2066	Apparent remission of a solitary metastatic pulmonary lesion in a liver transplant recipient treated with sorafenib. 2009 , 9, 2851-4	48
2065	Rho GTPases in hepatocellular carcinoma. 2009 , 1795, 137-51	50

2064	Translating preclinical findings of (endothelial) progenitor cell mobilization into the clinic; from bedside to bench and back. 2009 , 1796, 41-9	7
2063	Models for prevention and treatment of cancer: problems vs promises. 2009 , 78, 1083-94	109
2062	[Targeted biotherapies in digestive oncology: management of adverse effects]. 2009 , 33, 306-22	9
2061	[Hepatocellular carcinoma management in the era of sorafenib]. 2009 , 33, 327-33	
2060	Natural history and therapeutic management of recurrent hepatocellular carcinoma after liver transplantation. 2009 , 33, 361-9	35
2059	[Hepatocellular carcinoma: increasing incidence and optimized management]. 2009 , 33, 830-9	9
2058	Panaxydol inhibits the proliferation and induces the differentiation of human hepatocarcinoma cell line HepG2. 2009 , 181, 138-43	27
2057	Lymphotoxins: new targets for hepatocellular carcinoma. 2009 , 16, 272-3	16
2056	Cancer therapy targeted at cellular signal transduction mechanisms: strategies, clinical results, and unresolved issues. 2009 , 625, 6-22	18
2055	Targeting tumor angiogenesis. 2009 , 36, S12-9	32
2054	[Sorafenib: effectiveness versus safety. Prevention of hand-foot syndrome]. 2009 , 33, 288-9	1
2053	Issues regarding improving the impact of antiangiogenic drugs for the treatment of breast cancer. 2009 , 18 Suppl 3, S41-7	29
2052	Sorafenib: A glimmer of hope for unresectable hepatocellular carcinoma?. 2009 , 49, 332-4	9
2051	Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. 2009 , 49, 1245-56	232
2050	Inhibition of c-Jun NH2-terminal kinase switches Smad3 signaling from oncogenesis to tumor-suppression in rat hepatocellular carcinoma. 2009 , 49, 1944-53	74
2049	Antiangiogenic therapy: not just for cancer anymore?. 2009 , 49, 1066-8	26
2048	Targeting heat shock protein 90 with non-quinone inhibitors: a novel chemotherapeutic approach in human hepatocellular carcinoma. 2009 , 50, 102-12	57
2047	S-adenosylmethionine in the chemoprevention and treatment of hepatocellular carcinoma in a rat model. 2009 , 50, 462-71	73

2046	Inhibition of transforming growth factor beta receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation. 2009 , 50, 1140-51	88
2045	Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis. 2009 , 50, 1475-83	315
2044	Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2. 2009 , 50, 1861-70	92
2043	Where are we in the chemoprevention of hepatocellular carcinoma?. 2010 , 51, 734-6	23
2042	Selective targeting by preS1 domain of hepatitis B surface antigen conjugated with phosphorylcholine-based amphiphilic block copolymer micelles as a biocompatible, drug delivery carrier for treatment of human hepatocellular carcinoma with paclitaxel. 2009 , 124, 2460-7	22
2041	Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. 2009 , 115, 428-36	116
2040	Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?. 2009 , 115, 616-23	359
2039	Hepatocellular carcinoma with main portal vein tumor thrombus: treatment with 3-dimensional conformal radiotherapy after portal vein stenting and transarterial chemoembolization. 2009 , 115, 1245-52	61
2038	Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. 2009 , 115, 4090-5	116
2037	Vascular endothelial growth factor in the management of hepatocellular carcinoma: a review of literature. 2009 , 115, 4895-906	88
2036	Accelerated treatment using intensity-modulated radiation therapy plus concurrent capecitabine for unresectable hepatocellular carcinoma. 2009 , 115, 5117-25	53
2035	Proton beam therapy for hepatocellular carcinoma: the University of Tsukuba experience. 2009 , 115, 5499-506	101
2034	Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. 2009 , 115, 5651-61	300
2033	Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area. 2009 , 135, 617-25	49
2032	High expressions of vascular endothelial growth factor and platelet-derived endothelial cell growth factor predict poor prognosis in alpha-fetoprotein-negative hepatocellular carcinoma patients after curative resection. 2009 , 135, 1359-67	13
2031	XXVIIIe congrès du CREGG, 25-26 septembre 2009, Marne-la-Vallée. 2009 , 39, 265-321	
2030	Efficacy and safety profiles of cetuximab in Chinese patients with colorectal cancer. 2009 , 8, 526-530	3
2029	Molecular targeted therapy for hepatocellular carcinoma. 2009 , 44 Suppl 19, 136-41	80

2028	Antiangiogenic strategies for treatment of malignant gliomas. 2009 , 6, 513-26	30
2027	Surgical treatment for hepatocellular carcinoma in cirrhotic patients. Guide to the selection and decision-making process in a context of multimodal strategy. 2009 , 11, 20-7	1
2026	Role of stereotactic body radiotherapy in the management of primary hepatocellular carcinoma. Rationale, technique and results. 2009 , 11, 276-83	14
2025	Das hepatozelluläre Karzinom. 2009 , 4, 33-41	
2024	Treating hepatocellular carcinoma without liver transplantation. 2009 , 11, 69-75	
2023	Erratum to: The Role of Interferon Therapy in Patients With Hepatocellular Carcinoma. 2009 , 8, 35-42	
2022	VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy. 2009 , 11, 94-101	103
2021	Das hepatozelluläre Karzinom aus der Sicht des Internisten und des Chirurgen. 2009 , 4, 301-311	
2020	Transarterielle Chemoembolisation bei hepatozellulärem Karzinom âneue Entwicklungen. 2009 , 4, 330-339	1
2019	Interventionelle Radiotherapie bei hepatozellulärem und cholangiozellulärem Karzinom. 2009 , 4, 340-346	
2018	Mitteilungen der GARPS. 2009 , 4, 259-260	
2017	Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors. 2009 , 4, 67-76	25
2016	Renal toxicity of targeted therapies. 2009 , 4, 121-33	40
2015	Targeting mitogen-activated protein kinase kinase (MEK) in solid tumors. 2009 , 4, 267-73	19
2014	Imperative of continual support by the European Community for future advances in paediatric oncology in Europe: meeting report of the EC-funded science-communication project DIRECT âOvercoming Cancer with Researchâ 2009 , 2, 234-245	2
2013	Generalized convulsions due to sorafenib-induced hypocalcemia. 2009 , 28, 158-9	2
2012	Genotype 1 hepatitis C virus infection predominates among patients with chronic kidney failure and renal allograft recipients in India. 2009 , 28, 159-60	2
2011	[Sorafenib in advanced hepatocellular carcinoma]. 2009 , 50, 1290-2	

2010	A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. 2009 , 64, 777-83	228
2009	UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib. 2009 , 65, 1-4	54
2008	Proteomics, pathway array and signaling network-based medicine in cancer. 2009 , 4, 20	46
2007	Molecularly targeted therapy for hepatocellular carcinoma. 2009 , 100, 1-8	88
2006	(-)-Epigallocatechin gallate suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the vascular endothelial growth factor-vascular endothelial growth factor receptor axis. 2009 , 100, 1957-62	91
2005	Transcatheter arterial chemoembolization vs. chemoinfusion for unresectable hepatocellular carcinoma in patients with major portal vein thrombosis. 2009 , 29, 1291-8	52
2004	FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib. 2009 , 23, 845-51	98
2003	Cancer: The nuances of therapy. 2009 , 458, 290-2	49
2002	Biomarkers of response and resistance to antiangiogenic therapy. 2009 , 6, 327-38	491
2001	Molecular therapy for the treatment of hepatocellular carcinoma. 2009 , 100, 19-23	60
2000	Palliative chemotherapy for patients with recurrent hepatocellular carcinoma after liver transplantation. 2009 , 24, 800-5	31
1999	Successful topical treatment of sorafenib-induced hand-foot skin reaction in a child with hepatocellular carcinoma. 2009 , 26, 349-50	6
1998	Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis. 2009 , 157, 258-70	65
1997	A multicenter retrospective cohort study of practice patterns and clinical outcome on radiotherapy for hepatocellular carcinoma in Korea. 2009 , 29, 147-52	56
1996	Potential and future strategies for radiotherapy in hepatocellular carcinoma. 2009 , 29, 145-6	6
1995	Management of advanced hepatocellular carcinoma in the era of targeted therapy. 2009 , 29, 10-7	56
1994	New drugs for the treatment of hepatocellular carcinoma. 2009 , 29 Suppl 1, 148-58	19
1993	Protons or photons for hepatocellular carcinoma? Let's move forward together. 2009 , 74, 661-3	16

1992	Surgical treatment of hepatocellular carcinoma. 2009 , 39, 833-43	37
1991	Liver resection improves the survival of patients with multiple hepatocellular carcinomas. 2009 , 16, 848-55	91
1990	GLUT1 as a therapeutic target in hepatocellular carcinoma. 2009 , 13, 1411-27	132
1989	Hepatocellular carcinoma in Central, Eastern, and Southern Europe. What Future after the SHARP Trial?. 2009 , 4, 138-139	
1988	Targeted therapy for hepatocellular carcinoma. 2009 , 6, 423-32	94
1987	Gestione del carcinoma epatocellulare: le linee guida internazionali. 2009 , 3, 136-147	
1986	Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver. 2009 , 193, 1044-52	152
1985	Validation of novel imaging methodologies for use as cancer clinical trial end-points. 2009 , 45, 290-9	96
1984	Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial. 2009 , 45, 579-87	65
1983	Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study. 2009 , 45, 1788-97	52
1982	Will children with cancer benefit from the new European Paediatric Medicines Regulation?. 2009 , 45, 1535-46	20
1981	Fibrolamellar hepatocellular carcinoma: prolonged survival with multimodality therapy. 2009 , 35, 617-21	67
1980	Targeting tumor angiogenesis with histone deacetylase inhibitors. 2009 , 280, 145-53	193
1979	Targeting the RAF-MEK-ERK pathway in cancer therapy. 2009 , 283, 125-34	363
1978	Cancers of the pancreas and hepatobiliary system. 2009 , 25, 76-92	11
1977	Orthotopic liver transplantation for hepatocellular carcinoma: one center's experience in the Northeast of Brazil. 2009 , 41, 1740-2	11
1976	Sorafenib inhibits nuclear factor kappa B, decreases inducible nitric oxide synthase and cyclooxygenase-2 expression, and restores working memory in APP ^{swe} mice. 2009 , 162, 1220-31	52
1975	[Targeted therapies and their indications in solid neoplasias]. 2009 , 30, 416-24	4

1974	The histologic spectrum of epithelial neoplasms induced by sorafenib. 2009 , 61, 522-7	46
1973	[Diagnosis and treatment of hepatocellular carcinoma]. 2009 , 132, 272-87	34
1972	The burden of illness associated with hepatocellular carcinoma in the United States. 2009 , 50, 89-99	110
1971	Hepatocellular cancer care: cost is important but only one factor of disease burden. 2009 , 50, 10-2	9
1970	Angiogenesis in liver disease. 2009 , 50, 604-20	443
1969	Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage. 2009 , 50, 958-68	125
1968	Hepatocellular carcinoma in HIV-infected patients comes of age: The convergence of epidemiology and treatment effectiveness. 2009 , 50, 655-8	23
1967	Clinical research in hepatocellular carcinoma: study design and endpoints. 2009 , 50, 850-3	3
1966	Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. 2009 , 51, 725-33	184
1965	Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma. 2009 , 51, 315-21	70
1964	Show me your signaling--and I'll tell you who you are. 2009 , 51, 638-9	2
1963	Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats. 2009 , 51, 865-73	86
1962	The evasive promise of antiangiogenic therapy. 2009 , 51, 970-2	3
1961	Sunitinib in solid tumors. 2009 , 18, 821-34	85
1960	Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. 2009 , 104, 1802-29	186
1959	Minimal inhibitory concentration (MIC) values and different point mutations in the 23S rRNA gene for clarithromycin resistance in <i>Helicobacter pylori</i> . 2009 , 41, 610-1	24
1958	Hyperkeratosis of nipple skin during sorafenib treatment. 2009 , 41, 611	2
1957	Hepatocellular carcinoma: The beginning of a long journey. 2009 , 41, 707-8	

1956	Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab. 2009 , 9, 503-9	81
1955	Role of alpha-fetoprotein in hepatocellular carcinoma: prognostication, treatment monitoring or both?. 2009 , 5, 889-99	27
1954	Targeted therapies: Role of sorafenib in HCC patients with compromised liver function. 2009 , 6, 505-6	30
1953	From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. 2009 , 50 Suppl 1, 122S-50S	2450
1952	MicroRNA expression, survival, and response to interferon in liver cancer. <i>New England Journal of Medicine</i> , 2009 , 361, 1437-47	57.2 682
1951	Modelos experimentales de hepatocarcinoma. 2009 , 8, 91-95	
1950	Sorafenib en el tratamiento del carcinoma hepatocelular avanzado. 2009 , 8, 104-106	
1949	Impacto de los inhibidores de la angiogénesis en el tratamiento de la hipertensión portal. 2009 , 8, 312-317	
1948	Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma. 2009 , 137, 682-90	127
1947	A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. 2009 , 137, 850-5	374
1946	Deciphering hepatocellular carcinoma: from bench to bedside and back. 2009 , 137, 786-8	3
1945	Role of placental growth factor in mesenteric neoangiogenesis in a mouse model of portal hypertension. 2009 , 137, 2112-24.e1-6	54
1944	Sorafenib: a review of its use in advanced hepatocellular carcinoma. 2009 , 69, 223-40	342
1943	New pharmacological developments in the treatment of hepatocellular cancer. 2009 , 69, 2533-40	8
1942	Upper gastrointestinal malignancies: a new era in clinical colorectal cancer. 2009 , 8, 185-9	1
1941	Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. 2009 , 7, 20-3	88
1940	Safety and efficacy of sorafenib therapy in patients with metastatic kidney cancer with impaired renal function. 2009 , 7, E10-5	16
1939	Updates in Gastrointestinal Oncology - insights from the 2008 44th annual meeting of the American Society of Clinical Oncology. 2009 , 2, 9	19

1938	Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. 2009 , 3, 353-67	220
1937	Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors. 2009 , 9, 263-71	90
1936	Epithelial-mesenchymal transition in hepatocellular carcinoma. 2009 , 5, 1169-79	259
1935	Adverse effects of anticancer agents that target the VEGF pathway. 2009 , 6, 465-77	389
1934	Octreotide treatment of patients with hepatocellular carcinoma--a retrospective single centre controlled study. 2009 , 28, 142	4
1933	Targeting targeted agents: open issues for clinical trial design. 2009 , 28, 66	15
1932	Multitarget drugs: the present and the future of cancer therapy. 2009 , 10, 589-600	53
1931	Checkpoint Controls and Targets in Cancer Therapy. 2009 ,	4
1930	Imaging approach for evaluation of focal liver lesions. 2009 , 7, 624-34	9
1929	MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. 2009 , 284, 32015-27	386
1928	Current status and future prospects for anti-angiogenic therapies in cancer. 2009 , 4, 961-79	24
1927	Sorafenib for the treatment of hepatocellular carcinoma across geographic regions. 2009 , 2, 129-36	8
1926	Molecular markers and hepatocellular carcinoma: lending a helping hand in liver transplantation?. 2009 , 3, 211-3	2
1925	PDGFRalpha: a new therapeutic target in the treatment of hepatocellular carcinoma?. 2009 , 13, 443-54	36
1924	Lestaurtinib: a multi-targeted FLT3 inhibitor. 2009 , 2, 17-26	12
1923	Sorafenib: a guide to its use in advanced hepatocellular carcinoma. 2009 , 25, 5-8	1
1922	Molecular profiling to predict hepatocellular carcinoma outcome. 2009 , 3, 101-3	32
1921	Development of novel agents for bladder cancer. 2009 , 3, 160-169	

1920	Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. 2009 , 8, 118	130
1919	Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. 2009 , 10, 25-34	4124
1918	Sorafenib for liver cancer: the horizon broadens. 2009 , 10, 4-5	13
1917	Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. 2009 , 10, 794-800	250
1916	Sunitinib and the benefits of a negative study. 2009 , 10, 743-4	10
1915	Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. 2009 , 10, 967-74	215
1914	Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. 2009 , 10, 1111-8	327
1913	A Case of Liver Metastasis From Colon Cancer Mimicking Infiltrating Hepatoma With Portal Vein Thrombosis. 2009 , 17, 212-217	
1912	Gastrointestinal toxicities of novel agents in cancer therapy. 2009 , 45 Suppl 1, 332-42	23
1911	Major achievements in hepatocellular carcinoma. 2009 , 373, 614-6	243
1910	Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial. 2009 , 9, 739-45	93
1909	Current management of hepatocellular carcinoma. 2009 , 93, 885-900, viii	45
1908	Modern diagnosis and management of hepatocellular carcinoma. 2009 , 13, 233-47	32
1907	Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model. 2009 , 11, 934-44	53
1906	Dynamic contrast-enhanced MR imaging of the liver: current status and future directions. 2009 , 17, 339-49	48
1905	New therapeutic agents in ovarian cancer. 2009 , 21, 44-53	15
1904	Liver transplantation: an update 2009. 2009 , 25, 202-8	8
1903	Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies. 2009 , 15, 263-8	29

1902	Stable disease is a valid end point in clinical trials. 2009 , 15, 374-8	13
1901	Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook. 2009 , 21, 445-54	33
1900	Target therapy for hepatocellular carcinoma: is sorafenib for everybody?. 2009 , 43, 389-90	4
1899	Pathogenesis of hepatocellular carcinoma and molecular therapies. 2009 , 25, 186-94	107
1898	Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States. 2009 , 15, 526-32	102
1897	Time to target evaluation criteria of targeted therapies. 2009 , 30, 487-9	1
1896	Editorial. 2009 , 20 Spec No 1, S1-3	82
1895	Other paradigms: randomized discontinuation trial design. 2009 , 15, 431-4	7
1894	NCCN clinical practice guidelines in oncology: hepatobiliary cancers. 2009 , 7, 350-91	390
1893	[Standard chemotherapy for solid cancers. 3) Liver and kidney cancers]. 2009 , 98, 1874-9	
1892	Influence of E3 region on conditionally replicative adenovirus mediated cytotoxicity in hepatocellular carcinoma cells. 2009 , 8, 1125-32	4
1891	Sorafenib in Advanced Hepatocellular Carcinoma. 2009 , 2009, 218-219	2
1890	Sorafenib in Advanced Hepatocellular Carcinoma. 2009 , 2009, 459-461	
1889	Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. 2009 , 113, 6567-71	217
1888	Hyperammonemic encephalopathy: a rare presentation of fibrolamellar hepatocellular carcinoma. 2009 , 338, 522-4	26
1887	Angiogenesis Inhibition: State of the Art, Forgotten Strategies and New Perspectives in Cancer Therapy. 2009 , 5, 203-216	1
1886	Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. 2009 , 43, 489-95	125
1885	Sorafenib tosylate in advanced kidney cancer: past, present and future. 2009 , 20, 409-15	17

1884	Traitements radiologiques des tumeurs hépatiques. 2009 , 4, 1-27	
1883	Sunitinib (SUTENT, SU11248) suppresses tumor growth and induces apoptosis in xenograft models of human hepatocellular carcinoma. 2009 , 9, 738-47	30
1882	Spontaneous regression of hepatocellular carcinoma: a systematic review. 2009 , 21, 254-7	57
1881	Molecular signature for HCC: role in predicting outcomes after liver transplant and selection for potential adjuvant treatment. 2010 , 15, 277-82	20
1880	Antiangiogenesis agents in colorectal cancer. 2010 , 22, 374-80	24
1879	Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. 2010 , 22, 391-8	56
1878	Do not say ever never more: the ins and outs of antiangiogenic therapies. 2010 , 16, 3932-57	36
1877	Strategies for overcoming chemotherapy resistance in enterohepatic tumours. 2010 , 10, 467-85	12
1876	Trends in the Treatment of Hepatocellular Carcinoma. 2010 , 5, 118-121	
1875	Gemox: a widely useful therapy against solid tumors-review and personal experience. 2010 , 22, 298-303	5
1874	Efficacy and safety of sorafenib in advanced hepatocellular carcinoma under daily practice conditions. 2010 , 22, 205-11	12
1873	Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials. 2010 , 21, 326-32	43
1872	Unfolded protein response activation contributes to chemoresistance in hepatocellular carcinoma. 2010 , 22, 1099-105	56
1871	Recent advances in the treatment of hepatocellular carcinoma. 2010 , 26, 189-95	34
1870	Phase I study of hepatic arterial infusion of oxaliplatin in advanced hepatocellular cancer: a brown university oncology group study. 2010 , 33, 43-6	18
1869	Tumor response evaluation in oncology: current update. 2010 , 34, 479-84	38
1868	Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor. 2010 , 22, 351-5	126
1867	Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC. 2010 , 33, 211-8	110

1866	Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib. 2010 , 22, 1106-10	59
1865	Complete response of hepatocellular carcinoma with systemic combination chemotherapy: not to get out the chemotherapy?. 2010 , 22, 1015-8	11
1864	Sorafenib-induced severe acute hepatitis in a stable liver transplant recipient. 2010 , 90, 98-9	26
1863	Sorafenib Decreases Extrahepatic Collaterals in Hepatocellular Carcinoma: Implication of the Synergistic Effect of Sorafenib and Transcatheter Chemoembolization. 2010 , 6, 191-193	
1862	[Treatment of primary hepatocellular carcinoma]. 2010 , 151, 1445-9	1
1861	Systemic therapy for advanced hepatocellular carcinoma: past, present, and future. 2010 , 17, 120-9	32
1860	A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. 2010 , 5, 1655-61	102
1859	Sorafenib in hepatocellular carcinoma. 2010 , 71, 451-6	13
1858	[Interests in angiogenesis inhibitor drugs approved for the treatment of cancers]. 2010 , 65, 95-105	1
1857	Multifaceted role of vascular endothelial growth factor signaling in adult tissue physiology: an emerging concept with clinical implications. 2010 , 17, 206-12	20
1856	Nanoparticles for Cancer Detection and Therapy. 2010 , 51	5
1855	Selective aldosterone blocker ameliorates the progression of non-alcoholic steatohepatitis in rats. 2010 ,	4
1854	A patient with advanced hepatocellular carcinoma treated with sorafenib tosylate showed massive tumor lysis with avoidance of tumor lysis syndrome. 2010 , 49, 991-4	26
1853	[New possibilities of targeted therapy in the treatment of hepatocellular carcinoma with the help of molecular biology]. 2010 , 151, 1763-8	2
1852	Transarterial Embolization for Patients with Hepatocellular Carcinoma. 139-150	
1851	Hepatocellular carcinoma: fighting the rising tide. 2010 , 17, 68-9	
1850	Interventional radiological treatment of hepatocellular carcinoma. 2010 , 17, 87-99	15
1849	Nonsurgical options for hepatocellular carcinoma: evolving role of external beam radiotherapy. 2010 , 17, 100-10	19

1848	Hepatocellular carcinomas in cirrhotic and noncirrhotic human livers share angiogenic characteristics. 2010 , 17, 1564-71	17
1847	Systemic treatment of hepatocellular carcinoma: dawn of a new era?. 2010 , 17, 1247-56	49
1846	Surgical resection of high-risk hepatocellular carcinoma: patient selection, preoperative considerations, and operative technique. 2010 , 17, 1219-25	70
1845	Recent concepts of antiangiogenic therapy. 2010 , 40, 494-500	13
1844	Immune responses in hepatocellular carcinoma. 2010 , 28, 150-4	35
1843	First experience of hepatic radioembolization using microspheres labelled with yttrium-90 (TheraSphere): practical aspects concerning its implementation. 2010 , 37, 453-61	34
1842	FDG PET as a prognostic predictor in the early post-therapeutic evaluation for unresectable hepatocellular carcinoma. 2010 , 37, 468-82	50
1841	Yttrium-90 radioembolization in the management of liver tumors: expanding the global experience. 2010 , 37, 451-2	4
1840	Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. 2010 , 33, 41-52	1067
1839	Zoledronic acid in the treatment of bone metastases by hepatocellular carcinoma: a case series. 2010 , 65, 1137-43	21
1838	A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma. 2010 , 65, 373-82	46
1837	Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study. 2010 , 66, 837-44	60
1836	Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer. 2010 , 66, 203-7	45
1835	[Molecular mechanisms of progression in human hepatocarcinogenesis]. 2010 , 31 Suppl 2, 170-6	2
1834	[Hepatocellular carcinoma and cholangiocarcinoma]. 2010 , 81, 941-52; quiz 953	3
1833	[Differentiated therapy of liver tumors]. 2010 , 51, 53-62	
1832	[Multimodality treatment for hepatocellular carcinoma]. 2010 , 51, 1374-81	1
1831	Role of hypoxia-inducible transcription factor 1alpha for progression and chemosensitivity of murine hepatocellular carcinoma. 2010 , 88, 817-27	31

1830	Strategies for kinome profiling in cancer and potential clinical applications: chemical proteomics and array-based methods. 2010 , 397, 3163-71	25
1829	Feasibility of (125)I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma. 2010 , 136, 1633-40	23
1828	Current status of molecularly targeted therapy for hepatocellular carcinoma: basic science. 2010 , 15, 235-41	15
1827	Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice. 2010 , 15, 242-55	26
1826	Traitements du carcinome hpatocellulaire non accessible ^ un traitement curatif: actualit\$. 2010 , 12, 615-622	
1825	Efficacy and safety of viscum fraxini-2 in advanced hepatocellular carcinoma: a phase II study. 2010 , 9, 452-458	
1824	Capecitabine plus cisplatin treatment in patients with advanced hepatocellular carcinoma. 2010 , 9, 718-723	
1823	Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?. 2010 , 13, 1-14	325
1822	Advancement in HCC imaging: diagnosis, staging and treatment efficacy assessments: hepatocellular carcinoma: imaging in assessing treatment efficacy. 2010 , 17, 374-9	18
1821	Surgical technique: new advancements for expanding indications and safety: the Western experience. 2010 , 17, 394-8	4
1820	Medical treatments: in association or alone, their roles and their future perspectives: the Western experience. 2010 , 17, 420-1	1
1819	Medical treatments: in association or alone, their role and their future perspectives: novel molecular-targeted therapy for hepatocellular carcinoma. 2010 , 17, 413-9	8
1818	Transcatheter arterial infusion chemotherapy with cisplatin-lipiodol suspension in patients with hepatocellular carcinoma. 2010 , 45, 60-7	20
1817	Attenuation of insulin-resistance-based hepatocarcinogenesis and angiogenesis by combined treatment with branched-chain amino acids and angiotensin-converting enzyme inhibitor in obese diabetic rats. 2010 , 45, 443-50	30
1816	Molecular signatures of noncancerous liver tissue can predict the risk for late recurrence of hepatocellular carcinoma. 2010 , 45, 146-52	63
1815	Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives. 2010 , 45, 794-807	50
1814	Biomarkers of angiogenesis and their role in clinical oncology. 2010 , 3, 27-32	2
1813	Hepatocellular carcinoma ^ new trends. 2010 , 3, 113-118	

1812	Minimally invasive image-guided therapy for inoperable hepatocellular carcinoma: What is the evidence today?. 2010 , 1, 167-81	15
1811	Adjuvante Therapie gastrointestinaler Tumoren. 2010 , 5, 423-429	
1810	Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: a case report. 2010 , 5, 59-63	35
1809	Vascular endothelial growth factor inhibitors in malignant gliomas. 2010 , 5, 167-74	9
1808	Sequential therapy of transarterial chemoembolisation and sorafenib in intermediate stage hepatocellular carcinoma. 2010 , 41, 149-52	3
1807	Downstaging of hepatocellular carcinoma prior to liver transplant: is there a role for adjuvant sorafenib in locoregional therapy?. 2010 , 41, 217-20	15
1806	Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. 2010 , 4, 439-74	835
1805	Angiogenesis: multiple masks in hepatocellular carcinoma and liver regeneration. 2010 , 4, 537-47	30
1804	Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. 2010 , 12, 218-25	225
1803	Targeting cytoskeleton reorganisation as antimetastatic treatment. 2010 , 12, 662-9	12
1802	Biomarkers for Therapies Directed at Angiogenesis. 2010 , 6, 133-143	4
1801	Vascular endothelial growth factor polymorphisms: role in response and toxicity of tyrosine kinase inhibitors. 2010 , 12, 102-8	33
1800	Current management of hepatocellular cancer. 2010 , 12, 186-92	39
1799	„Targeted therapies“ in der Behandlung solider Tumoren. 2010 , 3, 48-51	
1798	Chitosan-alginate scaffold culture system for hepatocellular carcinoma increases malignancy and drug resistance. 2010 , 27, 1939-48	70
1797	Hepatocellular carcinoma immunopathogenesis: clinical evidence for global T cell defects and an immunomodulatory role for soluble CD25 (sCD25). 2010 , 55, 484-95	24
1796	Phase II study of darinafarsin in patients with advanced hepatocellular carcinoma. 2010 , 28, 670-6	38
1795	The epothilone B analogue ixabepilone in patients with advanced hepatobiliary cancers: a trial of the University of Chicago Phase II Consortium. 2010 , 28, 854-8	5

1794	Yttrium-90 radioembolization in the management of liver malignancies. 2010 , 37, 94-101	14
1793	Transarterial chemoembolization, transarterial chemotherapy, and intra-arterial chemotherapy for hepatocellular carcinoma treatment. 2010 , 37, 89-93	34
1792	Hepatocellular carcinoma: current management. 2010 , 47, 10-67	59
1791	Cardiac toxicity from systemic cancer therapy: a comprehensive review. 2010 , 53, 94-104	126
1790	[Percutaneous and intra-arterial treatment of hepatocellular carcinoma]. 2010 , 52, 399-413	0
1789	[Hepatocellular carcinoma: diagnosis, staging, and treatment strategy]. 2010 , 52, 385-98	7
1788	Survival analysis in clinical trials: old tools or new techniques. 2010 , 19, 55-8; discussion 61	8
1787	Thymostimulin versus placebo for palliative treatment of locally advanced or metastasised hepatocellular carcinoma: a phase III clinical trial. 2010 , 10, 457	11
1786	Application of tumor-node-metastasis staging 2002 version in locally advanced hepatocellular carcinoma: is it predictive of surgical outcome?. 2010 , 10, 535	7
1785	Eastern Asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinoma. 2010 , 10, 620	4
1784	Lack of association between excretion of sorafenib in sweat and hand-foot skin reaction. 2010 , 30, 52-6	30
1783	Molecularly targeted therapy in hepatocellular carcinoma. 2010 , 80, 550-60	98
1782	Oncostatin M up-regulates the ER chaperone Grp78/BiP in liver cells. 2010 , 80, 2066-73	9
1781	Obesity, inflammatory signaling, and hepatocellular carcinoma-an enlarging link. 2010 , 17, 115-7	42
1780	[Use of sorafenib in patients with hepatocellular or renal carcinoma]. 2010 , 34, 161-7	3
1779	Survival improvement in Child-Pugh C cirrhotic patients with hepatocellular carcinoma diagnosed during 1990-2002. 2010 , 34, 288-96	1
1778	Markedly effective local control of hepatocellular carcinoma with a poor prognosis by combined multimodal therapy with sorafenib as a neoadjuvant approach. 2010 , 34, 314-8	5
1777	Antiangiogenic therapies in portal hypertension: a breakthrough in hepatology. 2010 , 34, 446-9	10

1776	The Thalidomide renaissance. 2010 , 34, 426-8	1
1775	Trial design for evaluation of novel targeted therapies. 2010 , 116, 173-6	12
1774	A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia. 2010 , 117, 37-40	77
1773	Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. 2010 , 116, 4590-6	122
1772	Intra-arterial iodine-131-lipiodol for unresectable hepatocellular carcinoma. 2010 , 116, 4069-77	19
1771	Phase 1-2 trial of PTK787/ZK222584 combined with intravenous doxorubicin for treatment of patients with advanced hepatocellular carcinoma: implication for antiangiogenic approach to hepatocellular carcinoma. 2010 , 116, 5022-9	21
1770	A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326. 2010 , 116, 5686-93	32
1769	Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety. 2010 , 51, 165-73	76
1768	Down-regulation of connective tissue growth factor by inhibition of transforming growth factor beta blocks the tumor-stroma cross-talk and tumor progression in hepatocellular carcinoma. 2010 , 51, 523-34	124
1767	Multifaceted perspective of the waiting list for liver transplantation: the value of pharmacokinetic models. 2010 , 51, 12-5	22
1766	Sorafenib inhibits the shedding of major histocompatibility complex class I-related chain A on hepatocellular carcinoma cells by down-regulating a disintegrin and metalloproteinase 9. 2010 , 51, 1264-73	96
1765	Targeting mitogen-activated protein kinase kinase with the inhibitor PD0325901 decreases hepatocellular carcinoma growth in vitro and in mouse model systems. 2010 , 51, 1218-25	22
1764	A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. 2010 , 51, 1274-83	285
1763	Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-beta. 2010 , 51, 1635-44	161
1762	Sorafenib: where do we go from here?. 2010 , 52, 360-9	79
1761	CD151 modulates expression of matrix metalloproteinase 9 and promotes neoangiogenesis and progression of hepatocellular carcinoma. 2010 , 52, 183-96	96
1760	Drug therapy: sorafenib. 2010 , 51, 1843-9	18
1759	Twelve-week posttreatment follow-up predicts a sustained virological response to pegylated interferon and ribavirin therapy. 2010 , 52, 1170-1	6

1758	Possible role of adipocytokines in the development of nonalcoholic steatohepatitis-related hepatocellular carcinoma. 2010 , 52, 1172	
1757	Sorafenib therapy in patients with hepatocellular carcinoma before liver transplantation. 2010 , 52, 1171-2	4
1756	Loco-regional treatment of hepatocellular carcinoma. 2010 , 52, 762-73	376
1755	"Normal" alanine aminotransferase and Christopher Boorse. 2010 , 52, 1173	3
1754	Treating fatty liver for the prevention of cardiovascular diseases. 2010 , 52, 1174-5	4
1753	Optimal dosage of ribavirin. 2010 , 52, 1174	
1752	The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib. 2010 , 52, 1310-21	109
1751	Generation of human induced pluripotent stem cells from liver progenitor cells by only small molecules. 2010 , 52, 1169; author reply 1169-70	6
1750	Reply:. 2010 , 52, 1169-1170	3
1749	Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. 2010 , 52, 1741-9	304
1748	Is radioembolization ready for the barcelona clinic liver cancer staging system?. 2010 , 52, 1528-30	4
1747	Chemotherapy-induced apoptosis in hepatocellular carcinoma involves the p53 family and is mediated via the extrinsic and the intrinsic pathway. 2010 , 126, 2049-66	68
1746	Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo. 2010 , 127, 2949-58	37
1745	Anti-angiogenic therapy: adapting strategies to overcome resistant tumors. 2010 , 111, 543-53	22
1744	LAPTM4B-35 is a novel prognostic factor of hepatocellular carcinoma. 2010 , 101, 363-9	42
1743	Sorafenib induces growth inhibition and apoptosis of human chondrosarcoma cells by blocking the RAF/ERK/MEK pathway. 2010 , 102, 821-6	20
1742	Is it time to reconsider the BCLC/AASLD therapeutic flow-chart?. 2010 , 102, 868-76	22
1741	Sorafenib combined vitamin K induces apoptosis in human pancreatic cancer cell lines through RAF/MEK/ERK and c-Jun NH2-terminal kinase pathways. 2010 , 224, 112-9	17

1740	Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation. 2010 , 16, 658-67	68
1739	Survival and cost-effectiveness analysis of competing strategies in the management of small hepatocellular carcinoma. 2010 , 16, 1186-94	44
1738	Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis. 2010 , 34, 379-86	23
1737	Inherited hepatocellular carcinoma. 2010 , 24, 725-34	17
1736	Neoplastic stem cells: current concepts and clinical perspectives. 2010 , 76, 79-98	23
1735	The potential role of sunitinib in gastrointestinal cancers other than GIST. 2010 , 76, 36-43	2
1734	Current problems with systemic treatment of advanced hepatocellular cancer. 2010 , 34, 131-49	3
1733	Radiation-associated liver injury. 2010 , 76, S94-100	459
1732	Analysis of prognostic factors after yttrium-90 radioembolization of advanced hepatocellular carcinoma. 2010 , 77, 1441-8	45
1731	Computed tomography-guided high-dose-rate brachytherapy in hepatocellular carcinoma: safety, efficacy, and effect on survival. 2010 , 78, 172-9	82
1730	Angiogenic blockade and radiotherapy in hepatocellular carcinoma. 2010 , 78, 188-93	42
1729	Combination of transarterial chemoembolization and three-dimensional conformal radiotherapy for hepatocellular carcinoma with inferior vena cava tumor thrombus. 2010 , 78, 180-7	82
1728	Sorafenib and radiation: a promising combination in colorectal cancer. 2010 , 78, 213-20	29
1727	Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/II study. 2010 , 5, 12	30
1726	Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. 2010 , 55, 1126-33	46
1725	Stimulatory effects of the multi-kinase inhibitor sorafenib on human bladder cancer cells. 2010 , 160, 1690-8	24
1724	Alpha-fetoprotein and tumour size are associated with microvascular invasion in explanted livers of patients undergoing transplantation with hepatocellular carcinoma. 2010 , 12, 56-61	86
1723	Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement. 2010 , 12, 313-20	56

1722	Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus conference. 2010 , 12, 321-2	1
1721	Longterm follow-up after transarterial chemotherapy for hepatocellular carcinoma in a Scandinavian centre. 2010 , 12, 637-43	7
1720	Hepatocarcinoma cells stimulate the growth, migration and expression of pro-angiogenic genes in human hepatic stellate cells. 2010 , 30, 31-41	39
1719	Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: experts' opinion. 2010 , 30, 1427-38	32
1718	Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study. 2010 , 64, 1034-41	57
1717	Hepatic arterial infusion of chemotherapy for advanced hepatocellular carcinoma. 2010 , 6, 80-8	24
1716	Influence of hepatic artery occlusion on tumor growth and metastatic potential in a human orthotopic hepatoma nude mouse model: relevance of epithelial-mesenchymal transition. 2010 , 101, 120-8	42
1715	It takes two to tango: combinations of conventional cytotoxics with compounds targeting the vascular endothelial growth factor-vascular endothelial growth factor receptor pathway in patients with solid malignancies. 2010 , 101, 7-15	22
1714	Phase I/II study of the pharmacokinetics, safety and efficacy of S-1 in patients with advanced hepatocellular carcinoma. 2010 , 101, 2606-11	26
1713	Review article: the management of hepatocellular carcinoma. 2010 , 31, 461-76	152
1712	Intra-arterial therapy with cisplatin suspension in lipiodol and 5-fluorouracil for hepatocellular carcinoma with portal vein tumour thrombosis. 2010 , 32, 543-50	26
1711	Pilot study: rapamycin in advanced hepatocellular carcinoma. 2010 , 32, 763-8	15
1710	The role of signaling pathways in the development and treatment of hepatocellular carcinoma. 2010 , 29, 4989-5005	644
1709	RKTG inhibits angiogenesis by suppressing MAPK-mediated autocrine VEGF signaling and is downregulated in clear-cell renal cell carcinoma. 2010 , 29, 5404-15	62
1708	CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells. 2010 , 29, 6257-66	132
1707	Viral hepatocarcinogenesis. 2010 , 29, 2309-24	205
1706	Overexpression of transcriptional coactivator AIB1 promotes hepatocellular carcinoma progression by enhancing cell proliferation and invasiveness. 2010 , 29, 3386-97	46
1705	Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. 2010 , 102, 68-72	173

1704	Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. 2010 , 102, 8-18	187
1703	Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity. 2010 , 102, 495-9	50
1702	Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. 2010 , 102, 981-6	108
1701	A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients. 2010 , 103, 954-60	116
1700	Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma. 2010 , 103, 837-44	26
1699	Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours. 2010 , 103, 987-92	16
1698	A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension. 2010 , 87, 303-10	71
1697	A phase I clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma. 2010 , 17, 837-43	92
1696	Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. 2010 , 10, 241-53	407
1695	The 2008 Okuda lecture: Management of hepatocellular carcinoma: from surveillance to molecular targeted therapy. 2010 , 25, 439-52	78
1694	Locoregional therapies for hepatocellular carcinoma: which patients are most likely to gain a survival advantage?. 2010 , 25, 1299-305	4
1693	Current controversies surrounding liver transplantation for hepatocellular carcinoma. 2010 , 25, 1217-26	15
1692	Systemic treatment in advanced/metastatic hepatocellular carcinoma in the era of targeted therapy. 2010 , 25, 1023-5	5
1691	Optimal management of hepatocellular carcinoma: challenges and opportunities. 2010 , 25, 1336-8	9
1690	Economic evaluation of sorafenib in unresectable hepatocellular carcinoma. 2010 , 25, 1739-46	38
1689	Loco-regional interventional treatment of hepatocellular carcinoma: techniques, outcomes, and future prospects. 2010 , 23, 698-703	24
1688	The challenges of liver transplantation for hepatocellular carcinoma on cirrhosis. 2010 , 23, 712-22	40
1687	. 2010 ,	1

- 1686 Hepatocellular Carcinoma. **2010**, 144-151
- 1685 Drug utilization, adherence, and unique side effects of targeted therapy in older adults. 41-51
- 1684 Diagnosis and management of hepatocellular carcinoma: results of a consensus meeting of The Ottawa Hospital Cancer Centre. **2010**, 17, 6-12 6
- 1683 Article Commentary: Fundamentals of Liver Surgery for the Practicing General Surgeon. **2010**, 76, 461-469 1
- 1682 Transarterial Radioembolization with Yttrium-90 for Regional Management of Hepatocellular Cancer: The Early Results of a Nontransplant Center. **2010**, 76, 1079-1083
- 1681 Novel systemic approaches to treatment of HCC. **2010**, 1, 23-30
- 1680 The role of perfusion CT as a follow-up modality after transcatheter arterial chemoembolization: an experimental study in a rabbit model. **2010**, 45, 427-36 49
- 1679 Critical appraisal of the role of sorafenib in the management of hepatocellular carcinoma. **2010**, 2, 147-55 3
- 1678 Anti-angiogenesis therapies: their potential in cancer management. **2010**, 3, 69-82 32
- 1677 Molecular and clinical aspects of targeting the VEGF pathway in tumors. **2010**, 2010, 652320 15
- 1676 A long-lasting response to sorafenib treatment in an advanced hepatocellular carcinoma patient. **2010**, 23, 951-4 4
- 1675 An evidence-based multidisciplinary approach to the management of hepatocellular carcinoma (HCC): the Alberta HCC algorithm. **2010**, 24, 643-50 28
- 1674 Rosuvastatin counteracts vessel arterialisatation and sinusoid capillarisation, reduces tumour growth, and prolongs survival in murine hepatocellular carcinoma. **2010**, 2010, 640797 9
- 1673 Hypoxia, angiogenesis and liver fibrogenesis in the progression of chronic liver diseases. **2010**, 16, 281-8 78
- 1672 A phase II trial of sorafenib in metastatic melanoma with tissue correlates. **2010**, 5, e15588 77
- 1671 Progress in the development of a therapeutic vaccine for breast cancer. **2010**, 2, 25-36 6
- 1670 Sustained remission with the kinase inhibitor sorafenib in stage IV metastatic adrenocortical carcinoma. **2010**, 16, 441-5 17
- 1669 Long-lasting Response with Metronomic Capecitabine in Advanced Hepatocellular Carcinoma. **2010**, 96, 768-770 9

1668	Durable Complete Response of Hepatocellular Carcinoma after Metronomic Capecitabine. 2010 , 96, 1028-1030	11
1667	Survival analysis of Sorafenib in patients with advanced hepatocellular carcinoma. 2010 , 51, 684-685	
1666	Update on new approaches in the management of hepatocellular carcinoma. 2010 , 2, 163-73	5
1665	Raf inhibitors as therapeutic agents against neurodegenerative diseases. 2010 , 9, 120-7	6
1664	Induction of DNA damage-inducible gene GADD45beta contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells. 2010 , 70, 9309-18	70
1663	Sorafenib for the treatment of advanced hepatocellular carcinoma. 2010 , 14 Suppl 1, 17-21	22
1662	Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors. 2010 , 16, 2187-97	11
1661	Expression, cellular distribution, and prognostic relevance of TRAIL receptors in hepatocellular carcinoma. 2010 , 16, 5529-38	41
1660	Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. 2010 , 15, 1198-204	78
1659	Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. 2010 , 28, 3994-4005	306
1658	Immunotherapy of hepatocellular carcinoma. 2010 , 4, 345-53	15
1657	Fatal hemobilia in advanced hepatocellular carcinoma invading biliary tract after treatment with sorafenib and biliary stenting. 2010 , 21, 1381-1382	9
1656	Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. 2010 , 15, 85-92	137
1655	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. 2010 , 56, e1-48	161
1654	HIV/hepatitis B virus co-infection: current challenges and new strategies. 2010 , 65, 10-7	44
1653	Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?. 2010 , 15, 130-41	94
1652	Targeted therapies for non-small cell lung cancer: an evolving landscape. 2010 , 9, 1931-44	62
1651	BAD, a proapoptotic member of the BCL2 family, is a potential therapeutic target in hepatocellular carcinoma. 2010 , 8, 1116-25	37

1650	Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin. 2010 , 16, 3795-804	44
1649	Activation of beta-catenin by hypoxia in hepatocellular carcinoma contributes to enhanced metastatic potential and poor prognosis. 2010 , 16, 2740-50	141
1648	Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort. 2010 , 255, 955-65	131
1647	Sorafenib therapy for hepatocellular carcinoma in an HIV-HCV coinfecting patient: a case report. 2010 , 15, 142-5	17
1646	Reply to D.J. Stewart. 2010 , 28, e652-e653	3
1645	Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now?. 2010 , 16, 390-7	92
1644	Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. 2010 , 28, 2280-5	345
1643	Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies. 2010 , 3, 55-66	59
1642	Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies. 2010 , 12, 304-16	109
1641	A case of recurred hepatocellular carcinoma refractory to doxorubicin after liver transplantation showing response to herbal medicine product, <i>Rhus verniciflua</i> Stokes extract. 2010 , 9, 100-4	13
1640	Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. 2010 , 49, 287-97	216
1639	Palliative chemoradiation in advanced hepatocellular carcinoma. 2010 , 28, e231-2	
1638	Quantitative parametric perfusion images using 15O-labeled water and a clinical PET/CT scanner: test-retest variability in lung cancer. 2010 , 51, 1684-90	36
1637	Traf2- and Nck-interacting kinase is essential for Wnt signaling and colorectal cancer growth. 2010 , 70, 5024-33	90
1636	Current status and problems in development of molecular target agents for gastrointestinal malignancy in Japan. 2010 , 40, 183-7	2
1635	Hepatocellular carcinoma: the place of new medical therapies. 2010 , 3, 259-67	7
1634	Hunting and trapping the vascular endothelial growth factor. 2010 , 28, 185-7	11
1633	Liver Cancer Working Group report. 2010 , 40 Suppl 1, i19-27	52

1632	Cyberknife stereotactic body radiation therapy for nonresectable tumors of the liver: preliminary results. 2010 , 2010,	36
1631	hsa-miR-191 is a candidate oncogene target for hepatocellular carcinoma therapy. 2010 , 70, 8077-87	131
1630	New strategies in hepatocellular carcinoma: genomic prognostic markers. 2010 , 16, 4688-94	105
1629	Symposium abstracts. 2010 , 21, ix1-ix10	
1628	Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24. 2010 , 21, 2220-2226	37
1627	Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. 2010 , 30, 35-51	233
1626	Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. 2010 , 303, 1062-9	146
1625	Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. 2010 , 304, 2154-60	342
1624	Metabolism, excretion, and pharmacokinetics of oral brivanib in patients with advanced or metastatic solid tumors. 2010 , 38, 1962-6	24
1623	Combined functional genome survey of therapeutic targets for hepatocellular carcinoma. 2010 , 16, 2518-28	132
1622	MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. 2010 , 70, 5184-93	345
1621	Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort. 2010 , 9, 751-60	16
1620	Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates. 2010 , 21, 451-62	56
1619	Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). 2010 , 15, 285-92	86
1618	Sorafenib for recurrent hepatocellular carcinoma after liver transplantation. 2010 , 40, 768-73	64
1617	Hepatic arterial iodine-131-labeled metuximab injection combined with chemoembolization for unresectable hepatocellular carcinoma: interim safety and survival data from 110 patients. 2010 , 25, 657-63	19
1616	Peculiar features and tailored management of adult cancers occurring in pediatric age. 2010 , 10, 1837-51	21
1615	Neoplasms of the hepatobiliary system: clinical presentation, molecular pathways and diagnostics. 2010 , 10, 883-95	8

1614	Population-based risk factors and resource utilization for HCC: US perspective. 2010 , 26, 2183-91	222
1613	A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. 2010 , 70, 10202-12	610
1612	Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420. 2010 , 28, 3330-5	98
1611	An integrated genomic and epigenomic approach predicts therapeutic response to zebularine in human liver cancer. 2010 , 2, 54ra77	84
1610	New trends and novel treatment for hepatocellular carcinoma: a global perspective. 2010 , 15 Suppl 4, 1-4	6
1609	Treatment of hepatocellular carcinoma with intra-arterial injection of radionuclides. 2010 , 7, 41-9	41
1608	Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. 2010 , 28, 193-201	124
1607	Sorafenib (Nexavar): A Multikinase Inhibitor for Advanced Renal Cell Carcinoma and Unresectable Hepatocellular Carcinoma. 2010 , 73-85	
1606	Latest developments in targeted therapy for hepatocellular carcinoma. 2010 , 10, 1635-46	7
1605	Phase II clinical trials in oncology: are we hitting the target?. 2010 , 10, 427-38	6
1604	Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes. 2010 , 16, 957-66	96
1603	Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. 2010 , 16, 5189-99	137
1602	Sorafenib-induced bilateral osteonecrosis of femoral heads. 2010 , 28, e14	10
1601	Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer. 2010 , 28, 3131-7	122
1600	Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation. 2010 , 79, 62-6	47
1599	Response: Re: How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the \$440 Billion Question. 2010 , 102, 1207-1210	5
1598	Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2010 , 21 Suppl 5, v59-64	146
1597	Biological response modifiers: current use and future prospects in cancer therapy. 2010 , 47, 443-51	15

1596	Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. 2010 , 28, 2947-51	175
1595	Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved?. 2010 , 15 Suppl 4, 42-52	120
1594	Safety of transarterial chemoembolization plus sorafenib combination treatment in unresectable hepatocellular carcinoma. 2010 , 45, 511-2	5
1593	Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies. 2010 , 15, 683-94	32
1592	Toxicity of sorafenib: clinical and molecular aspects. 2010 , 9, 275-87	42
1591	Overexpressed Id-1 is associated with patient prognosis and HBx expression in hepatitis B virus-related hepatocellular carcinoma. 2010 , 10, 299-307	25
1590	Management of hepatocellular carcinoma: from prevention to molecular targeted therapy. 2010 , 78 Suppl 1, 1-6	17
1589	Loco-regional treatment of hepatocellular carcinoma in the era of molecular targeted therapies. 2010 , 78 Suppl 1, 107-12	32
1588	Chemoembolization for unresectable hepatocellular carcinoma in Japan. 2010 , 78 Suppl 1, 135-41	10
1587	Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma. 2010 , 78 Suppl 1, 148-53	70
1586	Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan. 2010 , 78 Suppl 1, 154-66	77
1585	Positioning and indication of sorafenib in the treatment algorithm and real practice setting: Western and eastern approach--Asian perspective. 2010 , 78 Suppl 1, 167-71	11
1584	Is there a role for adjuvant treatment after hepatic resection for hepatocellular carcinoma?. 2010 , 78, 161-71	14
1583	Rapid regression of advanced hepatocellular carcinoma associated with elevation of des-gamma-carboxy prothrombin after short-term treatment with sorafenib - a report of two cases. 2010 , 3, 298-303	17
1582	Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment. 2010 , 79, 85-92	33
1581	Complete Metabolic Response with Recanalization of Portal Vein Tumor Thrombosis after Sunitinib in a Patient with Advanced Hepatocellular Carcinoma. 2010 , 3, 391-396	5
1580	Hepatocellular carcinoma and non-alcoholic fatty liver disease: from a clinical to a molecular association. 2010 , 16, 741-52	54
1579	Platelet count less than SHARP: what does a case series reveal?. 2010 , 9, 1-8	5

1578	Interaction of tyrosine kinase inhibitors with the MDR- related ABC transporter proteins. 2010 , 11, 618-28	37
1577	Evaluation of response in malignant tumors treated with the multitargeted tyrosine kinase inhibitor sorafenib: a multitechnique imaging assessment. 2010 , 194, 5-14	30
1576	Definition of ubiquitination modulator COP1 as a novel therapeutic target in human hepatocellular carcinoma. 2010 , 70, 8264-9	58
1575	[Diagnosis and multimodal therapy for hepatocellular carcinoma]. 2010 , 48, 274-88	4
1574	Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. 2010 , 30, 52-60	2410
1573	Managing patients receiving sorafenib for advanced hepatocellular carcinoma: a case study. 2010 , 16, 249-54	1
1572	Epigenetic mechanisms involved in the pathogenesis of hepatobiliary malignancies. 2010 , 2, 233-243	20
1571	Developing better treatments in hepatocellular carcinoma. 2010 , 4, 551-60	20
1570	Signaling networks in human hepatocarcinogenesis--novel aspects and therapeutic options. 2010 , 97, 251-77	11
1569	Antiviral therapy for hepatitis C is associated with improved clinical outcomes in patients with advanced fibrosis. 2010 , 4, 535-9	9
1568	The efficacy and safety of sunitinib in korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction. 2010 , 40, 980-5	78
1567	Safety profile of new anticancer drugs. 2010 , 9, 301-17	15
1566	Diagnose und multimodale Therapie des hepatozellulären Karzinoms. 2010 , 31, 152-166	
1565	A 70-year-old woman with 10 years of markedly elevated alpha-fetoprotein measurements. 2010 , 30, 99-106	1
1564	Current strategy for staging and treatment: the BCLC update and future prospects. 2010 , 30, 61-74	757
1563	Hypoxia: a link between fibrogenesis, angiogenesis, and carcinogenesis in liver disease. 2010 , 30, 258-70	157
1562	Chemotherapy agents: a primer for the interventional radiologist. 2010 , 27, 384-90	9
1561	End-stage liver disease: challenges and practice implications. 2010 , 45, 411-26	17

1560	Sorafenib-induced destructive thyroiditis. 2010 , 20, 1043-4	11
1559	[Mechanisms of resistance to inhibitors of the VEGF pathway]. 2010 , 30, 40-1	
1558	Hepatic perfusion imaging: concepts and application. 2010 , 18, 465-75, x	12
1557	Randomized clinical trials in hepatocellular carcinoma. 2010 , 19, 151-62	3
1556	Novel targeted therapies for prostate cancer. 2010 , 37, 105-19, Table of Contents	8
1555	Targeted therapies for solid tumors: current status and future perspectives. 2010 , 24, 303-16	15
1554	Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy. 2010 , 12, 928-40	56
1553	Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma. 2010 , 12, 264-74	43
1552	Chronic hepatitis B and hepatocellular carcinoma. 2010 , 14, 461-76	56
1551	Longitudinal quality of life assessment of patients with hepatocellular carcinoma after primary transarterial chemoembolization. 2010 , 21, 1024-30	33
1550	Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib. 2010 , 11, 2187-98	11
1549	The WNT/ECatenin Pathway. 2010 , 367-391	
1548	Tumor initiation and progression in hepatocellular carcinoma: risk factors, classification, and therapeutic targets. 2010 , 31, 1409-20	127
1547	Recent advances in the research of hepatitis B virus-related hepatocellular carcinoma: epidemiologic and molecular biological aspects. 2010 , 108, 21-72	66
1546	Tyrosine kinase inhibitors to treat liver cancer. 2010 , 15, 13-26	19
1545	Targeted therapy of hepatocellular cancer. 2010 , 19, 265-74	46
1544	Sorafenib: a clinical and pharmacologic review. 2010 , 11, 1943-55	100
1543	Chemoprevention of hepatocellular carcinoma in chronic hepatitis C. 2011 , 188, 85-99	24

1542	Hepatocellular carcinoma--what's new?. 2010 , 147, e1-12	8
1541	Methodological aspects of lung cancer clinical trials in the era of targeted agents. 2010 , 67, 127-35	27
1540	Targeted therapy in non-small-cell lung cancer--is it becoming a reality?. 2010 , 7, 401-14	206
1539	Role of microRNA-199a-5p and discoidin domain receptor 1 in human hepatocellular carcinoma invasion. 2010 , 9, 227	143
1538	Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition. 2010 , 9, 256	38
1537	Gene expression in nontumoral liver tissue and recurrence-free survival in hepatitis C virus-positive hepatocellular carcinoma. 2010 , 9, 74	59
1536	Application of magnetic resonance imaging in transgenic and chemical mouse models of hepatocellular carcinoma. 2010 , 9, 94	17
1535	Recent advances in gastrointestinal oncology--updates and insights from the 2009 annual meeting of the American society of clinical oncology. 2010 , 3, 11	28
1534	Clinical overview of sorafenib in breast cancer. 2010 , 6, 655-63	20
1533	Treatment of early hepatocellular carcinoma: Towards personalized therapy. 2010 , 42 Suppl 3, S242-8	27
1532	Treatment of early hepatocellular carcinoma: How to predict and prevent recurrence. 2010 , 42 Suppl 3, S249-57	19
1531	The intermediate hepatocellular carcinoma stage: Should treatment be expanded?. 2010 , 42 Suppl 3, S258-63	45
1530	Molecular approaches to treatment of hepatocellular carcinoma. 2010 , 42 Suppl 3, S264-72	64
1529	The present and the future landscape of treatment of advanced hepatocellular carcinoma. 2010 , 42 Suppl 3, S273-80	20
1528	Does chemotherapy prevent HCV-related hepatocellular carcinoma? Pros. 2010 , 42 Suppl 3, S281-6	7
1527	Future perspectives in hepatocellular carcinoma. 2010 , 42 Suppl 3, S302-9	54
1526	Clinical Development and Future Direction for the Treatment of Hepatocellular Carcinoma. 2010 , 2, 93-103	17
1525	Hepatocellular Carcinoma: Diagnosis, staging, and treatment strategy. 2010 , 52, 385-398	5

1524	Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. 2010 , 138, 52-64	787
1523	Hepatitis C virus infection reduces hepatocellular polarity in a vascular endothelial growth factor-dependent manner. 2010 , 138, 1134-42	62
1522	Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. 2010 , 16, 3420-30	278
1521	Handbook of Evidence-Based Radiation Oncology. 2010 ,	32
1520	Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates. 2010 , 1, 12-25	198
1519	Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma. 2010 , 6, 1057-65	168
1518	Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. 2010 , 28, 2220-6	142
1517	Hepatocellular carcinoma: A global view. 2010 , 7, 448-58	982
1516	Antitumour and immune-adjuvant activities of protein-tyrosine kinase inhibitors. 2010 , 16, 184-92	26
1515	Survival comparison between glioblastoma multiforme and other incurable cancers. 2010 , 17, 417-21	113
1514	AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC). 2010 , 52, 79-87	73
1513	Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation. 2010 , 52, 88-95	61
1512	The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma. 2010 , 52, 63-71	61
1511	Liver cancer: from molecular pathogenesis to new therapies: summary of the EASL single topic conference. 2010 , 52, 296-304	37
1510	Cancer gene discovery in hepatocellular carcinoma. 2010 , 52, 921-9	152
1509	IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. 2010 , 52, 550-9	187
1508	New therapeutic targets in HCC: reptin ATPase and HCC senescence. 2010 , 52, 633-4	8
1507	The resurrection of alphafetoprotein. 2010 , 52, 939-40	29

1506	Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension. 2010 , 53, 558-67	135
1505	Is there an ideal prognostic classification for hepatocellular carcinoma? The quest for the Holy Grail. 2010 , 53, 23-4	6
1504	Epigenetic regulation of cancer stem cells in liver cancer: current concepts and clinical implications. 2010 , 53, 568-77	82
1503	PEBP1 downregulation is associated to poor prognosis in HCC related to hepatitis B infection. 2010 , 53, 872-9	74
1502	Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: new targets for the treatment of portal hypertension?. 2010 , 53, 976-80	200
1501	[Targeted therapies in hepatocellular carcinoma]. 2010 , 39, 753-64	2
1500	Mitochondria as targets in angiogenesis inhibition. 2010 , 31, 113-31	22
1499	Quoi de neuf dans la prise en charge du carcinome h�patocellulaire sur cirrhose?. 2010 , 147, 3-14	
1498	[Treatment of advanced hepatocellular carcinoma]. 2010 , 33, 461-8	2
1497	[Imaging techniques in hepatocellular carcinoma: diagnosis, extension and evaluation of therapeutic response]. 2010 , 33, 721-6	
1496	[Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma]. 2010 , 33, 741-52	7
1495	Novel targeted therapeutics for metastatic castration-resistant prostate cancer. 2010 , 291, 1-13	63
1494	Targeted therapies of cancer: angiogenesis inhibition seems not enough. 2010 , 299, 1-10	48
1493	[Nonsurgical management of hepatocellular carcinoma]. 2010 , 14, 469-73	
1492	Resveratrol in the chemoprevention and treatment of hepatocellular carcinoma. 2010 , 36, 43-53	150
1491	Exploiting cellular pathways to develop new treatment strategies for AML. 2010 , 36, 142-50	35
1490	Esophagogastric cancer: targeted agents. 2010 , 36, 235-48	47
1489	Progress in the surgical treatment of malignant liver tumors in children. 2010 , 36, 360-71	61

1488	Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma. 2010 , 46, 2753-62	72
1487	The dietary flavonoid kaempferol effectively inhibits HIF-1 activity and hepatoma cancer cell viability under hypoxic conditions. 2010 , 398, 74-8	66
1486	Reexpression of ARHI inhibits tumor growth and angiogenesis and impairs the mTOR/VEGF pathway in hepatocellular carcinoma. 2010 , 403, 417-21	24
1485	Geographic difference in survival outcome for advanced hepatocellular carcinoma: implications on future clinical trial design. 2010 , 31, 55-61	42
1484	Increased Lipiodol uptake in hepatocellular carcinoma possibly due to increased membrane fluidity by dexamethasone and tamoxifen. 2010 , 37, 777-84	13
1483	Management of hepatocellular carcinoma recurrence after liver transplantation. 2010 , 42, 660-2	74
1482	Treating hepatocellular carcinoma with sorafenib in liver transplant patients: an initial experience. 2010 , 42, 4582-4	14
1481	Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. 2010 , 61, 317-28	188
1480	Molecular targets for liver cancer therapy: From screening of target genes to clinical trials. 2010 , 40, 49-60	20
1479	Megestrol and embryonic extracts in the treatment of advanced hepatocellular carcinoma: A prospective randomized trial in the pre-sorafenib era. 2010 , 40, 153-60	6
1478	Docetaxel inhibits progression of human hepatoma cell line in vitro and is effective in advanced hepatocellular carcinoma. 2010 , 40, 304-10	5
1477	Selective aldosterone blocker, eplerenone, attenuates hepatocellular carcinoma growth and angiogenesis in mice. 2010 , 40, 540-9	14
1476	Management of hepatocellular carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009). 2010 , 40, 667-85	132
1475	Transcatheter chemoembolization for unresectable hepatocellular carcinoma and comparison of five staging systems. 2010 , 40, 1082-91	7
1474	Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal. 2010 , 42, 341-7	117
1473	Impact of miRNAs in gastrointestinal cancer diagnosis and prognosis. 2010 , 12, e33	38
1472	Targeted agents in ovarian cancer. 2010 , 6, 679-94	4
1471	A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. 2010 , 10, 209	138

1470	Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. 2010 , 53, 126-31	107
1469	Role of cadherin-17 in oncogenesis and potential therapeutic implications in hepatocellular carcinoma. 2010 , 1806, 138-45	28
1468	Forced expression of methionine adenosyltransferase 1A in human hepatoma cells suppresses in vivo tumorigenicity in mice. 2010 , 176, 2456-66	38
1467	Small interfering RNAs induce target-independent inhibition of tumor growth and vasculature remodeling in a mouse model of hepatocellular carcinoma. 2010 , 177, 3192-201	50
1466	Tumor Necrosis Factor-related apoptosis-inducing ligand (TRAIL) Receptor-1 and Receptor-2 agonists for cancer therapy. 2010 , 10, 1-18	42
1465	Novel inhibitors in development for hepatocellular carcinoma. 2010 , 19, 615-29	23
1464	STAT3: a target to enhance antitumor immune response. 2011 , 344, 41-59	85
1463	Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. 2010 , 2, 51-63	228
1462	Epidemiology and management of hepatocellular carcinoma. 2010 , 24, 899-919, viii	130
1461	Minimally Invasive Cancer Management. 2010 ,	2
1460	Late presentation of sorafenib-associated rash: a case report. 2010 , 4, 338	0
1459	Sorafenib: rays of hope in thyroid cancer. 2010 , 20, 1351-8	16
1458	Antiangiogenic drugs in oncology: a focus on drug safety and the elderly - a mini-review. 2010 , 56, 303-9	54
1457	Targeted treatments in colorectal cancer: state of the art and future perspectives. 2010 , 59, 838-58	37
1456	Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma. 2010 , 19, 663-72	20
1455	Angiogenesis and multiple myeloma: is there a role for angiogenic biomarkers in the context of autologous stem cell transplant?. 2011 , 52, 1173-5	2
1454	Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis. 2011 , 7, 1159-72	246
1453	Cautions regarding the fitting and interpretation of survival curves: examples from NICE single technology appraisals of drugs for cancer. 2011 , 29, 827-37	13

1452	An investigation of the effect of sorafenib on tumour growth and recurrence after liver cancer resection in nude mice independent of phosphorylated extracellular signal-regulated kinase levels. 2011 , 20, 1039-45	8
1451	Combination of branched-chain amino acids and angiotensin-converting enzyme inhibitor suppresses the cumulative recurrence of hepatocellular carcinoma: a randomized control trial. 2011 , 26, 1547-53	34
1450	End points for Phase II trials in recurrent glioblastoma: the cornerstone for a new era. 2011 , 11, 1713-7	2
1449	Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial. 2011 , 51, 1674-84	18
1448	The clinical development of FLT3 inhibitors in acute myeloid leukemia. 2011 , 20, 1377-95	46
1447	Advances in regional chemotherapy of the liver. 2011 , 8, 1057-69	15
1446	Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. 2011 , 29, 1997-2003	140
1445	Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. 2011 , 29, 2582-9	134
1444	Recent advances in cytogenetics and molecular biology of adult hepatocellular tumors: implications for imaging and management. 2011 , 258, 673-93	56
1443	Metronomic S-1 chemotherapy and vandetanib: an efficacious and nontoxic treatment for hepatocellular carcinoma. 2011 , 13, 187-97	29
1442	Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review. 2011 , 16, 432-44	68
1441	Hepatocellular carcinoma: locoregional and targeted therapies. 2011 , 40, 599-610	6
1440	Locoregional therapy for hepatocellular carcinoma. 2011 , 15, 395-421, vii-x	14
1439	Systemic therapy in hepatocellular carcinoma. 2011 , 15, 423-41, vii-x	23
1438	Liver transplantation for hepatocellular carcinoma: expanding frontiers and building bridges. 2011 , 15, 385-93, vii-x	5
1437	L'impact des thérapies ciblées chez le patient atteint de cancer au stade palliatif. 2011 , 10, 51-63	
1436	Treatment of advanced hepatocellular carcinoma with very low levels of amplitude-modulated electromagnetic fields. 2011 , 105, 640-8	46
1435	Factors that affect risk for hepatocellular carcinoma and effects of surveillance. 2011 , 9, 617-23.e1	97

1434	Sorafenib in hepatocellular carcinoma: efficacy and predictive factors. 2011 , 26, 324-334	3
1433	[Imaging features and evaluation of liver lesions after non-surgical therapy]. 2011 , 92, 632-58	4
1432	Bioengineered human arginase I with enhanced activity and stability controls hepatocellular and pancreatic carcinoma xenografts. 2011 , 4, 138-46	42
1431	Hepatocellular carcinoma: screening and staging. 2011 , 15, 323-34, vii-x	41
1430	Current management of small cell lung cancer. 2011 , 32, 853-63	25
1429	Diffusion MR imaging for monitoring of treatment response. 2011 , 19, 181-209	104
1428	Chemoembolization for hepatocellular carcinoma: multivariate analysis of predicting factors for tumor response and survival in a 362-patient cohort. 2011 , 22, 917-23	75
1427	Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. 2011 , 140, 497-507.e2	473
1426	Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. 2011 , 140, 1501-12.e2	306
1425	MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. 2011 , 140, 1618-28.e16	179
1424	Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. 2011 , 141, 526-35, 535.e1-2	133
1423	Doxorubicin and sorafenib for treatment of advanced hepatocellular cancer. 2011 , 141, e19-20; author reply e20-1	6
1422	Type 2 diabetes does not worsen prognosis in hepatocellular carcinoma. 2011 , 35, 214-20	5
1421	The Wnt/βcatenin pathway as a therapeutic target in human hepatocellular carcinoma. 2011 , 35, 709-13	69
1420	A stomach carpeted red. 2011 , 43, 334-5	1
1419	Myositis due to Sorafenib intake in a patient with hepatocellular carcinoma. 2011 , 43, 333-4	5
1418	Fatal gastric bleeding during sorafenib treatment for hepatocellular carcinoma recurrence after liver transplantation. 2011 , 43, 754	15
1417	A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma. 2011 , 43, 1015-21	7

1416	Epidermal Growth Factor Receptor (EGFR) Crosstalks in Liver Cancer. 2011 , 3, 2444-61	50
1415	Blocking the interaction of vascular endothelial growth factor receptors with their ligands and their effector signaling as a novel therapeutic target for cancer: time for a new look?. 2011 , 20, 1413-34	9
1414	Tyrosine kinase inhibitors with antiangiogenic properties for the treatment of non-small cell lung cancer. 2011 , 20, 61-74	9
1413	Radiotherapeutic strategies in the management of hepatocellular carcinoma. 2011 , 81 Suppl 1, 123-33	22
1412	Evolving strategies: future treatment of glioblastoma. 2011 , 11, 519-32	15
1411	Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. 2011 , 8, 210-21	536
1410	Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia. 2011 , 81 Suppl 1, 158-64	90
1409	Hepatocellular carcinoma in 2011 and beyond: from the pathogenesis to molecular targeted therapy. 2011 , 81 Suppl 1, 1-10	17
1408	Liver Tumor Targeting. 2011 , 1519-1568	
1407	Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1. 2011 , 25, 838-47	56
1406	Drug delivery strategies for therapeutic angiogenesis and antiangiogenesis. 2011 , 8, 485-504	37
1405	Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. 2011 , 29, 339-64	618
1404	Apoptotic and anti-angiogenic effects of Pulsatilla koreana extract on hepatocellular carcinoma. 2012 , 40, 452-60	7
1403	[New antitarget antineoplastic drugs. Clinical indications in the treatment of cancer]. 2011 , 137, 370-6	1
1402	Primary Hepatocellular Carcinoma. 2011 , 831-848	
1401	Hepatocellular carcinoma: molecular and genomic guideline for the clinician. 2011 , 15, 307-21, vii-x	15
1400	Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib. 2011 , 41, 296-302	59
1399	Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. 2011 , 50, 551-603	136

1398	Infection levels of proteocephalidean cestodes in <i>Cichla piquiti</i> (Osteichthyes: Cichlidae) of the Volta Grande Reservoir, Minas Gerais, Brazil, relative to host body weight and gender. 2011 , 85, 462-7	4
1397	Targeted therapies for hepatocellular carcinoma. 2011 , 140, 1410-26	362
1396	Efficacy of surgical microwave therapy in patients with unresectable hepatocellular carcinoma. 2011 , 18, 3650-6	24
1395	Hepatocellular carcinoma cells and their fibrotic microenvironment modulate bone marrow-derived mesenchymal stromal cell migration in vitro and in vivo. 2011 , 8, 1538-48	52
1394	Targeting the Wnt Pathway in Cancer. 2011 ,	5
1393	Post- α FMC-HGE. 2011 ,	
1392	Crosstalk of the Wnt Signaling Pathway. 2011 , 51-80	3
1391	Prise en charge des tumeurs primitives du foie et des voies biliaires. 2011 , 401-413	
1390	Cancer Immunology and Immunotherapy. 2011 ,	
1389	Reply. 2011 , 141, e20-e21	2
1388	Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib. 2011 , 18, 89-96	21
1387	Changes in liver and spleen volumes and liver function after radioembolization with yttrium-90 resin microspheres. 2011 , 22, 1706-13	22
1386	The ongoing history of thermal therapy for cancer. 2011 , 20, 229-35, vii	38
1385	Principles of Anticancer Drug Development. 2011 ,	
1384	HCC and angiogenesis: possible targets and future directions. 2011 , 8, 292-301	360
1383	Hepatocellular Carcinoma:. 2011 ,	3
1382	Management of treatment-related toxicity with targeted therapies for renal cell carcinoma: evidence-based practice and best practices. 2011 , 25, 893-915	18
1381	Chronic Liver Failure. 2011 ,	2

1380	Somatostatin receptors in non-neuroendocrine malignancies: the potential role of somatostatin analogs in solid tumors. 2011 , 7, 895-913	27
1379	Cancer Stem Cells in Solid Tumors. 2011 ,	5
1378	Venous Embolization of the Liver. 2011 ,	1
1377	Gastrointestinal Oncology. 2011 ,	
1376	Ultrasonography, computed tomography and magnetic resonance imaging of hepatocellular carcinoma: toward improved treatment decisions. 2011 , 81 Suppl 1, 86-99	43
1375	New targeted therapies for gastric cancer. 2011 , 20, 595-604	19
1374	Hepatoprotective versus oncogenic functions of STAT3 in liver tumorigenesis. 2011 , 179, 714-24	44
1373	Novel angiogenesis inhibitors: addressing the issue of redundancy in the angiogenic signaling pathway. 2011 , 37, 344-52	31
1372	Role of Wnt/β-catenin signaling in liver metabolism and cancer. 2011 , 43, 1021-9	125
1371	Identification of the bleomycin hydrolase gene as a methylated tumor suppressor gene in hepatocellular carcinoma using a novel triple-combination array method. 2011 , 312, 150-7	22
1370	Stereotactic radiation therapy and selective internal radiation therapy for hepatocellular carcinoma. 2011 , 15, 54-63	28
1369	[New perspectives for radiosensitization in hepatocellular carcinoma: a review of mechanisms involved in liver oncogenesis]. 2011 , 15, 32-8	2
1368	[Sorafenib and radiotherapy association for hepatocellular carcinoma]. 2011 , 15, 77-80	13
1367	[Radioembolisation for hepatocellular carcinoma]. 2011 , 15, 64-8	2
1366	[Medical therapies for hepatocellular carcinoma]. 2011 , 15, 28-31	7
1365	Experience Using Doxorubicin-Loaded DC Beads During Hepatic Chemoembolisation. 2011 , 35, 172-179	
1364	Molecular classification of hepatocellular carcinoma anno 2011. 2011 , 47, 1789-97	64
1363	Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. 2011 , 47, 2117-27	399

1362	Noncontrast chest computed tomography immediately after transarterial chemoembolization in patients with hepatocellular carcinoma: clinical benefits and effect of radiation reduction on image quality in low-dose scanning. 2011 , 80, e188-94	1
1361	Signaling pathways in hepatocellular carcinoma. 2011 , 81 Suppl 1, 18-23	31
1360	Transcatheter arterial infusion chemotherapy with a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma refractory to transcatheter arterial chemoembolization. 2011 , 41, 770-5	19
1359	Hepatic arterial infusion therapy with a fine powder formulation of cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis. 2011 , 41, 69-75	23
1358	Dual antitumour effect of 5-azacytidine by inducing a breakdown of resistance-mediating factors and epigenetic modulation. 2011 , 60, 156-65	16
1357	Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. 2011 , 29, 3960-7	246
1356	Erythema marginatum hemorrhagicum: a unique cutaneous side effect of sorafenib. 2011 , 64, 1194-6	5
1355	Antiviral therapy for hepatitis B virus-associated hepatocellular carcinoma: potential to reduce the tumor recurrence rates and/or improve overall survival. 2011 , 76, 457-9	1
1354	VEGF and angiotensin signaling in tumor angiogenesis and metastasis. 2011 , 17, 347-62	336
1353	Hepatocellular carcinoma survival in uninsured and underinsured patients. 2011 , 166, 189-93	10
1352	Pharmacological inhibition of Frizzled-7 displays anti-tumor properties in hepatocellular carcinoma. 2011 , 54, 288-99	65
1351	mTOR inhibitors and sorafenib for recurrent hepatocellular carcinoma after orthotopic liver transplantation. 2011 , 54, 396-8	30
1350	Magnetic resonance spectroscopy of bile in the detection of cholangiocarcinoma. 2011 , 54, 398-9; author reply 399-400	
1349	Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. 2011 , 54, 695-704	129
1348	Potential of immunotherapy for hepatocellular carcinoma. 2011 , 54, 830-4	91
1347	Epithelial-to-mesenchymal transition and acquired resistance to sunitinib in a patient with hepatocellular carcinoma. 2011 , 54, 1073-8	38
1346	Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil. 2011 , 55, 858-65	102
1345	Neuropilin-1 is upregulated in hepatocellular carcinoma and contributes to tumour growth and vascular remodelling. 2011 , 55, 866-75	63

1344	Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. 2011 , 55, 1041-8	135
1343	Validation of preclinical multiparametric imaging for prediction of necrosis in hepatocellular carcinoma after embolization. 2011 , 55, 1034-40	32
1342	Gene-expression signature of vascular invasion in hepatocellular carcinoma. 2011 , 55, 1325-31	110
1341	Fighting the bushfire in HCC trials. 2011 , 55, 276-7	20
1340	EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. 2011 , 55, 1309-16	254
1339	Hepatocellular carcinoma. <i>New England Journal of Medicine</i> , 2011 , 365, 1118-27	57.2 3015
1338	Iodine-131-lipiodol therapy in hepatic tumours. 2011 , 55, 246-52	16
1337	Selective internal radiation therapy (SIRT) in primary or secondary liver cancer. 2011 , 55, 253-7	17
1336	19-Nor-2[3-hydroxypropyl]-1[5-dihydroxyvitamin D3 (MART-10) is a potent cell growth regulator with enhanced chemotherapeutic potency in liver cancer cells. 2011 , 76, 1513-9	30
1335	Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse. 2011 , 9, 13-23	33
1334	Pharmacogenomics and cancer stem cells: a changing landscape?. 2011 , 32, 487-94	18
1333	Using sorafenib for recurrent hepatocellular carcinoma after liver transplantation—interactions between calcineurin inhibitor: two case reports. 2011 , 43, 2800-5	11
1332	Liver transplantation for hepatocellular carcinoma: an update. 2011 , 10, 234-42	25
1331	GALNT14 SNP as a potential predictor of response to combination chemotherapy using 5-FU, mitoxantrone and cisplatin in advanced HCC. 2011 , 12, 1061-73	22
1330	Clinical outcome of esophageal varices after hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with major portal vein tumor thrombus. 2011 , 41, 1046-56	3
1329	Combining sorafenib with chemoembolization for hepatocellular cancer. 2011 , 8, 216-219	
1328	Carcinoma hepatocelular. 2011 , 15, 1-9	
1327	Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. 2011 , 7, 1149-67	161

1326	Targeting integrins in hepatocellular carcinoma. 2011 , 15, 421-37	20
1325	Development and validation of a new prognostic score of death for patients with hepatocellular carcinoma in palliative setting. 2011 , 54, 108-14	25
1324	From liver cirrhosis to HCC. 2011 , 6 Suppl 1, 93-8	18
1323	Sorafenib and the medical treatment of hepatocellular carcinoma. 2011 , 1,	
1322	Targeting receptor tyrosine kinase pathways in hepatocellular carcinoma. 2011 , 11, 560-75	19
1321	Targeting EGFR in bilio-pancreatic and liver carcinoma. 2011 , 3, 16-22	5
1320	Advanced hepatocellular carcinoma. Review of targeted molecular drugs. 2011 , 10, 21-27	86
1319	Colon Perforation during Sorafenib Therapy for Advanced Hepatocellular Carcinoma. A Case Report. 2011 , 97, 794-799	5
1318	Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma. 2011 , 18, 228-40	43
1317	Patterns of presentation, referral, and treatment of hepatocellular carcinoma in a pre-sorafenib era: experience of a Canadian provincial cancer agency. 2011 , 18, e297-303	1
1316	Biological agents â€”hope and caution. 2011 , 1,	
1315	Non-invasive radiofrequency-induced targeted hyperthermia for the treatment of hepatocellular carcinoma. 2011 , 2011, 676957	38
1314	RNA interference as therapeutics for hepatocellular carcinoma. 2011 , 6, 106-15	27
1313	Survival of patients with primary liver cancer in central and northern Denmark, 1998-2009. 2011 , 3 Suppl 1, 3-10	13
1312	Terpenoids as potential chemopreventive and therapeutic agents in liver cancer. 2011 , 3, 228-49	172
1311	Characteristics of human Ewing/PNET sarcoma models. 2011 , 31, 174-82	23
1310	Critical reappraisal of risk factors for occurrence of hepatocellular carcinoma in patients with hepatitis C virus. 2011 , 3, 21-8	4
1309	Could HBx protein expression affect signal pathway inhibition by gefitinib or selumetinib, a MEK inhibitor, in hepatocellular carcinoma cell lines?. 2011 , 26, 214-21	2

1308	Prognostic index for portal vein tumor thrombosis in patients with hepatocellular carcinoma treated with radiation therapy. 2011 , 26, 1014-22	48
1307	Diagnostic and Prognostic Molecular Markers in Hepatocellular Carcinoma. 2011 , 31, 181-190	62
1306	Sorafenib-induced liver failure: a case report and review of the literature. 2011 , 2011, 941395	18
1305	Type 1 interferon receptor in peripheral blood mononuclear cells may predict response to intra-arterial 5-fluorouracil + interferon therapy for advanced hepatocellular carcinoma. 2011 , 3, 45-52	
1304	[Contribution of microCT structural imaging to preclinical evaluation of hepatocellular carcinoma chemotherapeutics on orthotopic graft in ACI rats]. 2011 , 98, 120-32	3
1303	Coexpression of PDGFR-alpha, PDGFR-beta and VEGF as a prognostic factor in patients with hepatocellular carcinoma. 2011 , 26, 108-16	20
1302	Rapid progression of combined hepatocellular carcinoma and cholangiocarcinoma. 2011 , 11, 37-41	6
1301	Toxic epidermal necrolysis associated with sorafenib and tosufloxacin in a patient with hepatocellular carcinoma. 2011 , 23, S404-7	5
1300	Lipid nanocapsules loaded with rhenium-188 reduce tumor progression in a rat hepatocellular carcinoma model. 2011 , 6, e16926	31
1299	Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib. 2011 , 6, e16978	48
1298	Recurrent hepatocellular carcinoma in liver transplant recipients: Parameters affecting time to recurrence, treatment options and survival in the sorafenib era. 2011 , 97, 436-441	9
1297	Glypican-3 Targeting of Liver Cancer Cells Using Multifunctional Nanoparticles. 2011 , 10, 7290.2010.00048	32
1296	A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors. 2011 , 23, 1233-8	37
1295	FLT3 inhibitors: a story of the old and the new. 2011 , 18, 71-6	40
1294	Molecular predictors of response to antiangiogenesis therapies. 2011 , 17, 134-41	46
1293	Prediction of posthepatectomy recurrence of hepatocellular carcinoma by circulating cancer stem cells: a prospective study. 2011 , 254, 569-76	101
1292	Radioembolization for hepatocellular carcinoma: a review of the evidence and treatment recommendations. 2011 , 34, 422-31	82
1291	Hepatocellular carcinoma: current management and perspectives for the future. 2011 , 253, 453-69	327

1290	Personalized medicine in hepatocellular carcinoma: rationale and clinical data. 2011 , 1, 1403-1411	1
1289	Clinical management and case reports for the treatment of hepatocellular carcinoma with sorafenib. 2011 , 45, 733-7	3
1288	High aromatase activity and overexpression of epidermal growth factor receptor in fibrolamellar hepatocellular carcinoma in a child. 2011 , 33, e195-7	16
1287	Selective targeting of genetically engineered mesenchymal stem cells to tumor stroma microenvironments using tissue-specific suicide gene expression suppresses growth of hepatocellular carcinoma. 2011 , 254, 767-74; discussion 774-5	86
1286	Molecular targeted therapy of gastrointestinal cancer. 2011 , 11, 670-80	1
1285	Use of protein array technology to investigate receptor tyrosine kinases activated in hepatocellular carcinoma. 2011 , 2, 399-403	6
1284	Arsenic trioxide plus cisplatin/interferon β /doxorubicin/capecitabine combination chemotherapy for unresectable hepatocellular carcinoma. 2011 , 4, 60-6	19
1283	Inhibition of glypican-3 expression via RNA interference influences the growth and invasive ability of the MHCC97-H human hepatocellular carcinoma cell line. 2011 , 28, 497-503	24
1282	Soluble VEGF receptor-2 may be a predictive marker of anti-angiogenic therapy with clinically available safe agents. 2011 , 2, 69-73	4
1281	Carcinome h�patocellulaire. 2011 , 6, 1-9	
1280	Treatment options in hepatocellular carcinoma today. 2011 , 100, 22-9	83
1279	Primary Malignant Neoplasms of the Liver. 2011 , 681-703	4
1278	Emerging treatments for small-cell lung cancer: Phase II and III trials. 2011 , 1, 255-263	
1277	Na ⁺ /K ⁺ -ATPase β mediates sensitivity of hepatocellular carcinoma cells to bufalin. 2011 , 25, 825-30	25
1276	Sorafenib and hepatic arterial infusion chemotherapy for unresectable advanced hepatocellular carcinoma: A comparative study. 2011 , 2, 433-441	19
1275	Why, when, and how to prevent hepatitis B virus reactivation in cancer patients undergoing chemotherapy. 2011 , 9, 465-77	20
1274	Cost-effectiveness of screening for recurrent hepatocellular carcinoma after liver transplantation. 2011 , 25, 283-91	13
1273	Hepatocellular carcinoma with persistent hepatitis B virus infection shows unusual downregulation of Ras expression and differential response to Ras mediated signaling. 2011 , 26, 135-44	10

1272	Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population. 2011 , 26, 340-7	66
1271	Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: does transarterial chemoembolization improve survival in these patients?. 2011 , 26, 145-54	86
1270	Future role of gastroenterologists in digestive oncology in the Asia Pacific region: Panir Chelvam Memorial Lecture, Asian Pacific Digestive Week 2010. 2011 , 26, 432-6	3
1269	Angiogenesis blockade as therapy for hepatocellular carcinoma: progress and challenges. 2011 , 26, 4-6	7
1268	Clinical significance and implication of neoangiogenesis in hepatocellular carcinoma. 2011 , 26, 792-3	3
1267	Computed tomography findings of sorafenib-treated hepatic tumors in patients with advanced hepatocellular carcinoma. 2011 , 26, 1201-6	12
1266	Survival of patients with advanced hepatocellular carcinoma: sorafenib versus other treatments. 2011 , 26, 1612-8	25
1265	Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma. 2011 , 26, 1604-11	65
1264	Hepatocellular carcinoma and vitamin D: a review. 2011 , 26, 1597-603	49
1263	Sorafenib, doesn't it have any competitor in advanced hepatocellular carcinoma?. 2011 , 26, 1585-6	
1262	MicroRNA, hypoxic stress and hepatocellular carcinoma: future directions. 2011 , 26, 1586-8	3
1261	Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant. 2011 , 24, 991-8	28
1260	Sorafenib before liver transplantation for hepatocellular carcinoma: risk or give up. 2011 , 24, e97; author reply e98-9	3
1259	Sorafenib-associated hand-foot syndrome in Japanese patients. 2011 , 38, 261-6	18
1258	YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. 2011 , 102, 1374-80	322
1257	Tumor stroma reaction-related gene signature predicts clinical outcome in human hepatocellular carcinoma. 2011 , 102, 1522-31	39
1256	Skin delivery of short hairpin RNA of indoleamine 2,3 dioxygenase induces antitumor immunity against orthotopic and metastatic liver cancer. 2011 , 102, 2214-20	24
1255	The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma. 2011 , 34, 205-13	81

1254	Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. 2011 , 34, 949-59	61
1253	Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score. 2011 , 34, 1193-201	84
1252	Hepatocellular carcinoma treated with sorafenib: authors' reply. 2011 , 34, 1348-1349	
1251	Anti-tumour and anti-angiogenic effects of zoledronic acid on human non-small-cell lung cancer cell line. 2011 , 44, 139-46	45
1250	Meta-analysis of dermatological toxicities associated with sorafenib. 2011 , 36, 344-50	42
1249	Fetoprotein impairs activation of natural killer cells by inhibiting the function of dendritic cells. 2011 , 165, 211-9	33
1248	Recurrent hepatocellular carcinoma after liver transplant: identifying the high-risk patient. 2011 , 13, 626-32	16
1247	Presentation and outcomes of hepatocellular carcinoma patients at a western centre. 2011 , 13, 712-22	22
1246	Clinical and molecular insights into the hepatocellular carcinoma tumour marker des- β -carboxyprothrombin. 2011 , 31, 22-35	77
1245	Early Fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma. 2011 , 31, 369-76	47
1244	How I manage my patients with hepatocellular carcinoma. 2011 , 31 Suppl 1, 145-50	1
1243	Novel molecular therapies in hepatocellular carcinoma. 2011 , 31 Suppl 1, 151-60	34
1242	Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection. 2011 , 31, 740-3	58
1241	General overview of neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: necessity or option?. 2011 , 31, 1081-9	18
1240	Non-invasive in vivo imaging for liver tumour progression using an orthotopic hepatocellular carcinoma model in immunocompetent mice. 2011 , 31, 1200-8	15
1239	Prognostic value of ^{18}F -FDG PET for hepatocellular carcinoma patients treated with sorafenib. 2011 , 31, 1144-9	50
1238	Molecular pathogenesis of hepatocellular carcinoma. 2011 , 35, 821-5	35
1237	Emerging strategies in the treatment of advanced hepatocellular carcinoma: the role of targeted therapies. 2011 , 65, 182-8	19

1236	Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction. 2011 , 278, 3494-507	42
1235	Bevacizumab in combination with oxaliplatin and doxorubicin or liposomal doxorubicin for hepatocellular cancer: a case series. 2011 , 7, 174-9	1
1234	Treatment of recurrent hepatocellular carcinoma after liver transplantation. 2011 , 7, 258-69	9
1233	Therapeutic cancer vaccines: are we there yet?. 2011 , 239, 27-44	217
1232	Harnessing synthetic lethal interactions in anticancer drug discovery. 2011 , 10, 351-64	202
1231	Molecular targeting of CSN5 in human hepatocellular carcinoma: a mechanism of therapeutic response. 2011 , 30, 4175-84	57
1230	Hepatic and HSC-specific sorafenib effects in rats with established secondary biliary cirrhosis. 2011 , 91, 241-51	48
1229	Metal-free imidazolium salts inhibit the growth of hepatocellular carcinoma in a mouse model. 2011 , 91, 744-51	11
1228	Major challenges limiting liver transplantation in the United States. 2011 , 11, 1773-84	124
1227	Liver transplantation for hepatocellular carcinoma: five steps to prevent recurrence. 2011 , 11, 2031-5	79
1226	Hepatobiliary tumours. 2011 , 39, 630-633	0
1225	Poster 40: A Rare Occurrence of Hepatocellular Carcinoma Metastasis to the Mandible: Report of a Case and Review of the Literature. 2011 , 69, e75-e76	1
1224	Gene signatures in hepatocellular carcinoma (HCC). 2011 , 21, 4-9	40
1223	Mitogen-activated protein kinases in hepatocellular carcinoma development. 2011 , 21, 10-20	137
1222	Diffusion magnetic resonance imaging in cancer patient management. 2011 , 21, 119-40	39
1221	Radiation therapy for hepatocellular carcinoma. 2011 , 21, 271-7	78
1220	Hepatic radiation toxicity: avoidance and amelioration. 2011 , 21, 256-63	145
1219	Radiosensitizers in hepatocellular carcinoma. 2011 , 21, 303-11	14

1218	Overview: Where does radiation therapy fit in the spectrum of liver cancer local-regional therapies?. 2011 , 21, 241-6	65
1217	Chemoembolization for hepatocellular carcinoma. 2011 , 46, 105-14	4
1216	The role of microRNAs in human liver cancers. 2011 , 38, 752-63	97
1215	Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study. 2011 , 123, 33-6	42
1214	Antiangiogenic effects of pazopanib in xenograft hepatocellular carcinoma models: evaluation by quantitative contrast-enhanced ultrasonography. 2011 , 11, 28	18
1213	Clinical response to Auroon Misheil Therapy in a man with advanced multifocal hepatocellular carcinoma: A case report. 2011 , 5, 478	1
1212	Heart failure caused by molecularly targeted therapies for cancer. 2011 , 31, 62-75	2
1211	Major liver resection in elderly patients: a multi-institutional analysis. 2011 , 212, 787-95	85
1210	Treatment strategy for hepatocellular carcinoma with major portal vein or inferior vena cava invasion: a single institution experience. 2011 , 212, 796-803	34
1209	Long-term safety and tolerability of sorafenib in patients with advanced non-small-cell lung cancer: a case-based review. 2011 , 12, 212-7	7
1208	VEGF targeted therapy in acute myeloid leukemia. 2011 , 80, 241-56	19
1207	Trans-arterial chemoembolization as a therapy for liver tumours: New clinical developments and suggestions for combination with angiogenesis inhibitors. 2011 , 80, 40-53	54
1206	Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: a meta-analysis of clinical trials. 2011 , 80, 291-300	47
1205	Advanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ): focus on targeted therapies. 2012 , 81, 38-48	23
1204	Anti-hepatocellular carcinoma activity using human HepG2 cells and hepatotoxicity of 6-substituted methyl 3-aminothieno[3,2-b]pyridine-2-carboxylate derivatives: in vitro evaluation, cell cycle analysis and QSAR studies. 2011 , 46, 5800-6	124
1203	Effect of sorafenib on the energy metabolism of hepatocellular carcinoma cells. 2011 , 670, 39-43	28
1202	[Experience using doxorubicin-loaded DC Beads] during hepatic chemoembolisation]. 2011 , 35, 172-9	3
1201	microRNA-1274a, a modulator of sorafenib induced a disintegrin and metalloproteinase 9 (ADAM9) down-regulation in hepatocellular carcinoma. 2011 , 585, 1828-34	47

1200	Inhibiting TGF- β signaling in hepatocellular carcinoma. 2011 , 1815, 214-23	49
1199	Antiangiogenic agents and targets: A perspective. 2011 , 81, 6-12	37
1198	The NADPH oxidase inhibitor VAS2870 impairs cell growth and enhances TGF- β -induced apoptosis of liver tumor cells. 2011 , 81, 917-24	38
1197	Targeting liver cancer: first steps toward a miRacle?. 2011 , 20, 698-9	30
1196	mTOR signaling in disease. 2011 , 23, 744-55	352
1195	Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma. 2011 , 13, 1324-30	31
1194	Anti-tumour effects of transcatheter arterial embolisation administered in combination with thalidomide in a rabbit VX2 liver tumour model. 2011 , 84, 179-83	3
1193	MicroRNA122 is a key regulator of β -fetoprotein expression and influences the aggressiveness of hepatocellular carcinoma. 2011 , 2, 338	82
1192	CXCL12 (SDF1 α)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?. 2011 , 17, 2074-80	332
1191	The diffusion-weighted imaging perfusion fraction f is a potential marker of sorafenib treatment in advanced hepatocellular carcinoma: a pilot study. 2011 , 21, 281-90	109
1190	Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled. 2011 , 44, 183-9	24
1189	NF- κ B in the liver--linking injury, fibrosis and hepatocellular carcinoma. 2011 , 8, 108-18	799
1188	Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer. 2011 , 32, 88-111	149
1187	Improved diagnostic imaging and interventional therapies prolong survival after resection for hepatocellular carcinoma in cirrhosis: the university of bologna experience over 10 years. 2011 , 18, 1630-7	40
1186	Risk factors, prognosis, and management of early and late intrahepatic recurrence after resection of primary clear cell carcinoma of the liver. 2011 , 18, 1955-63	81
1185	Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response. 2011 , 18, 2192-9	65
1184	Glucose-regulated protein 78 (GRP78) mediated the efficacy to curcumin treatment on hepatocellular carcinoma. 2011 , 18, 2395-403	37
1183	Clinically relevant biomarkers to select patients for targeted inhibitor therapy after resection of hepatocellular carcinoma. 2011 , 18, 3384-90	17

1182	Signaling pathways governing tumor angiogenesis. 2011 , 81 Suppl 1, 24-9	132
1181	Knowledge of hepatocellular carcinoma screening guidelines and clinical practices among gastroenterologists. 2011 , 56, 569-77	24
1180	Differential effects of vitamin K1 on AFP and DCP levels in patients with unresectable HCC and in HCC cell lines. 2011 , 56, 1876-83	13
1179	Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial. 2011 , 29, 481-8	42
1178	A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium. 2011 , 29, 1045-9	66
1177	Inhibition of Akt signaling in hepatoma cells induces apoptotic cell death independent of Akt activation status. 2011 , 29, 1303-13	33
1176	Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. 2011 , 29, 1511-4	28
1175	Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer. 2011 , 125, 137-43	31
1174	Angiotensin converting enzyme inhibitors and hepatocellular carcinoma incidence in the General Practice Research Database. 2011 , 22, 1743-7	4
1173	Functional and clinical evidence of the influence of sorafenib binding to albumin on sorafenib disposition in adult cancer patients. 2011 , 28, 3199-207	33
1172	Kinase gene expression and subcellular protein expression pattern of protein kinase C isoforms in curcumin-treated human hepatocellular carcinoma Hep 3B cells. 2011 , 66, 136-42	14
1171	Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. 2011 , 101, 57-66	103
1170	Sorafenib in unresectable intrahepatic cholangiocellular carcinoma: a case report. 2011 , 123, 61-4	7
1169	Surgical treatment of lymph node metastases from hepatocellular carcinoma. 2011 , 18, 559-66	29
1168	The cancer stem cell marker CD133 is a predictor of the effectiveness of S1+ pegylated interferon α 2b therapy against advanced hepatocellular carcinoma. 2011 , 46, 212-21	13
1167	A novel transcatheter arterial infusion chemotherapy using iodized oil and degradable starch microspheres for hepatocellular carcinoma: a prospective randomized trial. 2011 , 46, 359-66	26
1166	Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells. 2011 , 46, 779-89	42
1165	Molecular targeted therapy for hepatocellular carcinoma in the current and potential next strategies. 2011 , 46, 289-96	34

1164	Triple expression of B7-1, B7-2 and 4-1BBL enhanced antitumor immune response against mouse H22 hepatocellular carcinoma. 2011 , 137, 695-703	15
1163	Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma. 2011 , 137, 659-67	42
1162	A new staging system for resectable hepatocellular carcinoma: comparison with six existing staging systems in a large Chinese cohort. 2011 , 137, 739-50	40
1161	Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies. 2011 , 44, 117-24	17
1160	Tumorangiogenese und aktuelle therapeutische Möglichkeiten der Inhibition. 2011 , 17, 513-519	2
1159	Tyrosinkinaseinhibitoren. 2011 , 17, 641-650	
1158	A signature of six genes highlights defects on cell growth and specific metabolic pathways in murine and human hepatocellular carcinoma. 2011 , 11, 419-29	13
1157	Hepatic resection with or without adjuvant iodine-131-lipiodol for hepatocellular carcinoma: a comparative analysis. 2011 , 16, 125-32	14
1156	Combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon β for advanced hepatocellular carcinoma. 2011 , 16, 221-9	13
1155	Prise en charge des carcinomes oesogastriques, pancréatiques et hépatocellulaires du sujet âgé. 2011 , 13, 90-96	
1154	Angiogenesis as a therapeutic target in arthritis in 2011: learning the lessons of the colorectal cancer experience. 2011 , 14, 223-34	52
1153	Intra-arterial treatment with α 92 microspheres for hepatocellular carcinoma: 4 years experience at the Ghent University Hospital. 2011 , 38, 2117-24	24
1152	Hepatocellular nodules in liver cirrhosis: state of the art CT evaluation (perfusion CT/volume helical shuttle scan/dual-energy CT, etc.). 2011 , 36, 273-81	45
1151	Combination therapy of transcatheter arterial chemoembolization and arterial administration of antiangiogenesis on VX2 liver tumor. 2011 , 34, 824-32	20
1150	Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations. 2011 , 90, 473-5	8
1149	A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma. 2011 , 67, 315-24	76
1148	A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. 2011 , 67, 751-64	59
1147	Kinase activation profile associated with TGF- β -dependent migration of HCC cells: a preclinical study. 2011 , 68, 79-86	38

1146	High-performance liquid chromatographic method for the determination of sorafenib in human serum and peritoneal fluid. 2011 , 68, 239-45	26
1145	Lack of food effect on single-dose pharmacokinetics of brivanib, and safety and efficacy following multiple doses in subjects with advanced or metastatic solid tumors. 2011 , 68, 1377-85	1
1144	Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function. 2011 , 68, 1285-90	60
1143	PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma. 2011 , 68, 539-45	27
1142	Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function. 2011 , 68, 1639-40; author reply 1641-2	1
1141	Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function. 2011 , 68, 1641-1642	1
1140	Sorafenib-associated multivessel coronary artery vasospasm. 2011 , 36, 348-51	33
1139	Drug therapy of cancer. 2011 , 67, 437-47	17
1138	Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines. 2011 , 49, 235-47	4
1137	Radiologic complete response with sirolimus and sorafenib in a hepatocellular carcinoma patient who relapsed after orthotopic liver transplantation. 2011 , 42, 50-3	25
1136	A woman with remotely treated pancreas cancer and new abdominal pain: a discussion of evaluation and management. 2011 , 42, 236-40	0
1135	Safe use of sorafenib in a patient undergoing salvage liver transplantation for recurrent hepatocellular carcinoma after hepatic resection. 2011 , 28, 1044-7	9
1134	Diabetes mellitus impairs the response to intra-arterial chemotherapy in hepatocellular carcinoma. 2011 , 28, 1080-8	19
1133	Complete response after sorafenib therapy for hepatocellular carcinoma in an HIV-HBV co infected patient: Possible synergy with HAART ? A case report. 2011 , 28 Suppl 1, S165-8	29
1132	Impressive efficacy of sorafenib in a patient with an hepatocellular carcinoma and a portal vein thrombosis associated with a metastatic ENT cancer. 2011 , 28 Suppl 1, S246-9	0
1131	Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma. 2011 , 5, 850-6	34
1130	Hepatocellular and biliary tract carcinomas: SEOM clinical guidelines. 2011 , 13, 536-44	5
1129	Can we develop effective combination antiangiogenic therapy for patients with hepatocellular carcinoma?. 2011 , 5, 177-184	10

1128	Recent advances and future challenges in the treatment of hepatocellular and biliary tract carcinomas. 2011 , 4, 94-97	1
1127	Whither hepatocellular carcinoma in sub-Saharan Africa?. 2011 , 3, 153-154	
1126	Hematologic toxicities of small molecule tyrosine kinase inhibitors. 2011 , 6, 203-15	10
1125	Infiltrating hepatocellular carcinoma: seeing the tree through the forest. 2011 , 15, 2089-97	56
1124	Sorafenib combined with cryoablation to treat unresectable hepatocellular carcinoma. 2011 , 23, 188-93	3
1123	Hepatocellular carcinoma: prevention and therapy. 2011 , 13, 186-94	7
1122	Stopping rules employing response rates, time to progression, and early progressive disease for phase II oncology trials. 2011 , 11, 164	1
1121	Complete response for advanced liver cancer during sorafenib therapy: case report. 2011 , 11, 4	36
1120	Design and rationale of the HCC BRIDGE study in China: a longitudinal, multicenter cohort trial in hepatocellular carcinoma. 2011 , 11, 53	18
1119	Retrospective comparison between a regular and a split-dose protocol of 5-fluorouracil, cisplatin, and mitoxantrone for the treatment of far advanced hepatocellular carcinoma. 2011 , 11, 117	15
1118	Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1. 2011 , 11, 464	26
1117	Phase I study evaluating the treatment of patients with hepatocellular carcinoma (HCC) with carbon ion radiotherapy: the PROMETHEUS-01 trial. 2011 , 11, 67	29
1116	A hepatoprotective <i>Lindera obtusiloba</i> extract suppresses growth and attenuates insulin like growth factor-1 receptor signaling and NF-kappaB activity in human liver cancer cell lines. 2011 , 11, 39	20
1115	Soluble Frizzled-7 receptor inhibits Wnt signaling and sensitizes hepatocellular carcinoma cells towards doxorubicin. 2011 , 10, 16	68
1114	Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib. 2011 , 9, 120	22
1113	Targeting insulin-like growth factor axis in hepatocellular carcinoma. 2011 , 4, 30	70
1112	A Baf1-ER-inducible oncogenic zebrafish liver cell model identifies hepatocellular carcinoma signatures. 2011 , 225, 19-28	16
1111	Critical review of controversial issues in the management of advanced pediatric liver tumors. 2011 , 56, 1013-8	43

1110	Which matters most: number of tumors, size of the largest tumor, or total tumor volume?. 2011 , 17 Suppl 2, S58-66	48
1109	Tissue biomarkers as predictors of outcome and selection of transplant candidates with hepatocellular carcinoma. 2011 , 17 Suppl 2, S67-71	19
1108	Treatment of recurrent hepatocellular carcinoma after liver transplantation. 2011 , 17 Suppl 2, S162-6	40
1107	What is the role of adjuvant therapy after liver transplantation for hepatocellular carcinoma?. 2011 , 17 Suppl 2, S147-58	13
1106	Imaging diagnosis and staging of hepatocellular carcinoma. 2011 , 17 Suppl 2, S34-43	34
1105	Priority of candidates with hepatocellular carcinoma awaiting liver transplantation can be reduced after successful bridge therapy. 2011 , 17, 1344-54	76
1104	Targeting the growth factors and angiogenesis pathways: small molecules in solid tumors. 2011 , 103, 574-86	18
1103	Outcomes of hepatic resection for huge hepatocellular carcinoma (≥10 cm in diameter). 2011 , 104, 292-8	60
1102	Hepatic tumor response evaluation by MRI. 2011 , 24, 721-33	18
1101	Effect of sorafenib on murine liver regeneration. 2011 , 53, 577-86	27
1100	Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model. 2011 , 53, 483-92	83
1099	Development of molecularly targeted therapies in biliary tract cancers: reassessing the challenges and opportunities. 2011 , 53, 695-704	55
1098	Management of hepatocellular carcinoma: an update. 2011 , 53, 1020-2	6054
1097	Sorafenib inhibits transforming growth factor β -mediated epithelial-mesenchymal transition and apoptosis in mouse hepatocytes. 2011 , 53, 1708-18	77
1096	RN181 suppresses hepatocellular carcinoma growth by inhibition of the ERK/MAPK pathway. 2011 , 53, 1932-42	31
1095	Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma. 2011 , 53, 1943-58	66
1094	Strategies for hepatocellular carcinoma therapy and diagnostics: lessons learned from high throughput and profiling approaches. 2011 , 53, 2112-21	44
1093	Outcome of patients suffering from a spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure and treated with antivirals. 2011 , 54, 1108-9	2

- 1092 Lack of an association between an apolipoprotein C3 genetic variant and the liver fat content in patients with type 2 diabetes. **2011**, 54, 1109-10 2
- 1091 Vitamin D deficiency may link diabetes and liver neoplasms. **2011**, 54, 1111-2
- 1090 Carnitine palmitoyltransferase as a potential target for treating diabetes: is inhibition or activation preferable?. **2011**, 54, 1110-1
- 1089 Profound differences of microRNA expression patterns in hepatocytes and hepatoma cell lines commonly used in hepatitis C virus studies. **2011**, 54, 1112-3 9
- 1088 Updated management of hepatocellular carcinoma. **2011**, 54, 1113 8
- 1087 Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis. **2011**, 54, 573-85 73
- 1086 Stem cells or macrophages: which contribute to bone marrow cell therapy for liver cirrhosis?. **2011**, 54, 1103; author reply 1104 3
- 1085 Association of the cannabinoid receptor 2 (CB2) Gln63Arg polymorphism with indices of liver damage in obese children: an alternative way to highlight the CB2 hepatoprotective properties. **2011**, 54, 1102; author reply 1102-3 16
- 1084 Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. **2011**, 54, 868-78 458
- 1083 Human hepatic cancer stem cells are characterized by common stemness traits and diverse oncogenic pathways. **2011**, 54, 1031-42 65
- 1082 Reply:. **2011**, 54, 1104-1104
- 1081 Reply:. **2011**, 54, 1102-1103
- 1080 Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. **2011**, 54, 1104-5; author reply 1105 4
- 1079 Human hepatic stellate cells are liver-resident antigen-presenting cells. **2011**, 54, 1107 4
- 1078 Reply:. **2011**, 54, 1105-1105
- 1077 Clinical correlation of miR-375 and alpha-fetoprotein in hepatocellular carcinoma: comparison in mice and humans. **2011**, 54, 1105-6; author reply 1106 5
- 1076 Reply. **2011**, 54, 1106-1106
- 1075 Prominent regulatory but weak antigen-presenting cell function of hepatic stellate cells. **2011**, 54, 1108 8

1074	Prevention of recurrence after resection of hepatocellular carcinoma: a daunting challenge. 2011 , 54, 757-9	99
1073	Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. 2011 , 54, 2055-63	270
1072	Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques. 2011 , 54, 2238-44	83
1071	Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma: results of a phase 2 study. 2011 , 117, 125-33	32
1070	V-CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials. 2011 , 117, 2478-88	34
1069	Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma. 2011 , 117, 3187-92	65
1068	FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era?. 2011 , 117, 3293-304	40
1067	Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors. 2011 , 117, 4475-83	262
1066	¹⁸ F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma. 2011 , 117, 4779-87	45
1065	Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. 2011 , 117, 5094-102	150
1064	Liver specific overexpression of platelet-derived growth factor-B accelerates liver cancer development in chemically induced liver carcinogenesis. 2011 , 128, 1259-68	50
1063	Expression and prognostic significance of placental growth factor in hepatocellular carcinoma and peritumoral liver tissue. 2011 , 128, 1559-69	23
1062	Identification of a secretory protein c19orf10 activated in hepatocellular carcinoma. 2011 , 129, 1576-85	13
1061	Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma. 2011 , 129, 1963-9	85
1060	Loss of runt-related transcription factor 3 causes development and progression of hepatocellular carcinoma. 2011 , 112, 745-9	28
1059	Pushing the limits of surgical management in patients with hepatocellular carcinoma. 2011 , 98, 1183-4	1
1058	Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization. 2011 , 79, 163-71	160
1057	Sonic hedgehog signaling protects human hepatocellular carcinoma cells against ionizing radiation in an autocrine manner. 2011 , 80, 851-9	51

1056	Targeting immune suppressing myeloid-derived suppressor cells in oncology. 2011 , 77, 12-9	119
1055	Pazopanib: Clinical development of a potent anti-angiogenic drug. 2011 , 77, 163-71	107
1054	Experience with sorafenib and adverse event management. 2011 , 78, 24-32	48
1053	Targeted anti-cancer therapy in the elderly. 2011 , 78, 227-42	26
1052	Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins. 2011 , 10, 1241-51	47
1051	c-Met-Akt pathway-mediated enhancement of inhibitory c-Raf phosphorylation is involved in vitamin K1 and sorafenib synergy on HCC growth inhibition. 2011 , 12, 531-8	19
1050	Subtle hepatocellular carcinoma: a persisting role for alpha-fetoprotein monitoring in high-risk patients with cirrhosis. 2011 , 5, 565-8	
1049	Combination therapy for renal cell cancer: what are possible options?. 2011 , 81, 220-9	18
1048	Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors. 2011 , 22, 2508-2515	18
1047	Randomized, phase II study comparing interferon combined with hepatic arterial infusion of fluorouracil plus cisplatin and fluorouracil alone in patients with advanced hepatocellular carcinoma. 2011 , 81, 281-90	57
1046	Perfusion CT findings in patients with metastatic carcinoid tumors undergoing bevacizumab and interferon therapy. 2011 , 196, 569-76	46
1045	Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy. 2011 , 19, 1170-9	101
1044	Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. 2011 , 258, 627-34	208
1043	Transarterial therapies for hepatocellular carcinoma. 2011 , 12, 1057-73	28
1042	Therapeutic potential of targeting glypican-3 in hepatocellular carcinoma. 2011 , 11, 543-8	20
1041	Small-molecule protein kinase inhibitors and their effects on the immune system: implications for cancer treatment. 2011 , 3, 213-27	43
1040	Changing pathology with changing drugs: tumors of the gastrointestinal tract. 2011 , 78, 76-89	12
1039	Genetics of hepatobiliary carcinogenesis. 2011 , 31, 173-87	131

1038	Points of therapeutic intervention along the Wnt signaling pathway in hepatocellular carcinoma. 2011 , 11, 549-59	16
1037	microRNA involvement in hepatocellular carcinoma. 2011 , 11, 500-21	79
1036	Arterially directed therapies for hepatocellular carcinoma. 2011 , 197, W590-602	16
1035	[Increasing number and improved survival of patients with hepatocellular carcinoma from 1988 to 2007: data of a German university clinic]. 2011 , 49, 720-7	6
1034	[Radiological evaluation of tumor response in oncological studies (tumor response evaluation)]. 2011 , 183, 695-703	7
1033	Inhibition of tumor angiogenesis by antibodies, synthetic small molecules and natural products. 2011 , 18, 3136-55	56
1032	Fibrolamellar carcinoma: a review with focus on genetics and comparison to other malignant primary liver tumors. 2011 , 31, 61-70	63
1031	Evolving molecular mechanism-based strategies for control of hepatocellular carcinoma. 2011 , 18, 4375-88	6
1030	The metabolic and toxicological considerations for mTOR inhibitors in the treatment of hepatocarcinoma. 2011 , 7, 1535-46	5
1029	Antiangiogenic therapies: is VEGF-A inhibition alone enough?. 2011 , 11, 485-96	4
1028	Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma. 2011 , 21, 197-202	27
1027	Adjuvant therapy after curative treatment for hepatocellular carcinoma. 2011 , 81 Suppl 1, 50-5	37
1026	A new rapid and sensitive LC-MS assay for the determination of sorafenib in plasma: application to a patient undergoing hemodialysis. 2011 , 33, 705-10	12
1025	Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma. 2011 , 10, 169-77	100
1024	Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies. 2011 , 17, 1956-63	36
1023	Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. 2011 , 17, 1973-83	130
1022	Increasing incidence of brain metastasis in patients with advanced hepatocellular carcinoma in the era of antiangiogenic targeted therapy. 2011 , 16, 82-6	27
1021	The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib. 2011 , 16, 1270-9	80

1020	Complete histologic response induced by sorafenib in advanced hepatocellular carcinoma: a case report. 2011 , 29, e330-2	36
1019	An uphill battle downstream of RAF. 2011 , 29, 2298-300	1
1018	Role of tyrosine kinase inhibitors in tumor immunology. 2011 , 3, 107-16	11
1017	Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin. 2011 , 17, 363-71	72
1016	Sorafenib: activity and clinical application in patients with hepatocellular carcinoma. 2011 , 12, 303-13	21
1015	Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib. 2011 , 17, 4504-12	77
1014	miR-221 silencing blocks hepatocellular carcinoma and promotes survival. 2011 , 71, 7608-16	181
1013	Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer. 2011 , 16, 1508-19	46
1012	"And what other medications are you taking?". 2011 , 29, e288-91	5
1011	Bortezomib sensitizes HCC cells to CS-1008, an antihuman death receptor 5 antibody, through the inhibition of CIP2A. 2011 , 10, 892-901	33
1010	FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations. 2011 , 16, 1162-74	41
1009	Antitumor activity of BIBF 1120, a triple angiokinase inhibitor, and use of VEGFR2+pTyr+ peripheral blood leukocytes as a pharmacodynamic biomarker in vivo. 2011 , 17, 1373-81	32
1008	Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. 2011 , 165, 315-22	162
1007	[Targeting the RAS signalling pathway in cancer]. 2011 , 98, 1019-28	8
1006	A human model of epithelial to mesenchymal transition to monitor drug efficacy in hepatocellular carcinoma progression. 2011 , 10, 850-60	52
1005	Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. 2011 , 29, 2350-6	122
1004	Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. 2011 , 337, 155-61	229
1003	Enhancing the clinical activity of sorafenib through dose escalation: rationale and current experience. 2011 , 3, 95-100	11

1002	Targeting angiogenesis in esophagogastric adenocarcinoma. 2011 , 16, 844-58	42
1001	Thérapeutiques ciblées dans le traitement des tumeurs solides. 2011 , 55-89	1
1000	A phase I/II study of combined chemotherapy with mitoxantrone and uracil/tegafur for advanced hepatocellular carcinoma. 2011 , 41, 328-33	1
999	An overview of evidence-based management of hepatocellular carcinoma: a meta-analysis. 2011 , 7, 463-75	82
998	Targeted therapy in hepatocellular carcinoma. 2011 , 2011, 348297	18
997	Hepatocellular carcinoma: current management and future development-improved outcomes with surgical resection. 2011 , 2011, 728103	42
996	Liver resection after downstaging hepatocellular carcinoma with sorafenib. 2011 , 2011, 791013	28
995	The molecular pathogenesis and clinical implications of hepatocellular carcinoma. 2011 , 2011, 818672	17
994	Radioembolization for hepatocellular carcinoma using TheraSphere® . 2011 , 17, 215-7	3
993	Treatment of Advanced Hepatocellular Carcinoma: Sorafenib and Beyond. 2011 , 3, 39-47	
992	Intra-atrial tumor thrombi secondary to hepatocellular carcinoma responding to chemotherapy. 2011 , 3, 435-7	13
991	Acalculous cholecystitis in a patient with hepatocellular carcinoma on sorafenib. 2011 , 2011, 201529	10
990	Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: kinetics and potential biomarker value. 2011 , 17, 918-27	26
989	Sorafenib therapy in patients with advanced hepatocellular carcinoma in advanced liver cirrhosis. 2011 , 83, 275-82	13
988	When are "positive" clinical trials in oncology truly positive?. 2011 , 103, 16-20	90
987	Deferoxamine for advanced hepatocellular carcinoma. <i>New England Journal of Medicine</i> , 2011 , 365, 576-87.2	103
986	Systemic treatment and targeted therapy in patients with advanced hepatocellular carcinoma. 2011 , 3, 167-75	23
985	Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results?. 2011 , 80, 153-9	49

984	Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma. 2011 , 29, 289-302	30
983	Future treatment option for hepatocellular carcinoma: a focus on brivanib. 2011 , 29, 316-20	9
982	Des-Ecarboxyprothrombin may be a promising biomarker to determine the therapeutic efficacy of sorafenib for hepatocellular carcinoma. 2011 , 29, 321-5	43
981	Management of patients with hepatocellular carcinoma and extrahepatic metastasis. 2011 , 29, 333-8	28
980	Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models. 2011 , 80, 167-74	39
979	[Gastrointestinal tumors--interdisciplinary discussion over new data]. 2011 , 34 Suppl 3, 1-31	4
978	Long-term outcome of combined interferon- α and 5-fluorouracil treatment for advanced hepatocellular carcinoma with major portal vein thrombosis. 2011 , 80, 63-9	33
977	High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy. 2011 , 81, 98-103	16
976	AFP measurement in monitoring treatment response of advanced hepatocellular carcinoma to sorafenib: case report and review of the literature. 2011 , 34, 538-42	4
975	Superselective transarterial chemoembolization for hepatocellular carcinoma: recent progression and perspective. 2011 , 81 Suppl 1, 105-10	7
974	Treatment algorithm for intermediate and advanced stage hepatocellular carcinoma: Korea. 2011 , 81 Suppl 1, 141-7	23
973	Complete response of advanced hepatocellular carcinoma with multiple lung metastases treated with sorafenib: a case report. 2011 , 81 Suppl 1, 152-7	35
972	Adjuvant hepatic arterial infusional chemotherapy with 5-fluorouracil and cisplatin after curative resection of hepatocellular carcinoma. 2011 , 81, 184-91	16
971	Cholangiocarcinoma--current treatment options. 2011 , 100, 30-4	54
970	Molecularly targeted therapies for hepatocellular carcinoma: sorafenib as a stepping stone. 2011 , 29, 303-9	19
969	Early decrease in β -fetoprotein, but not des-Ecarboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma. 2011 , 81, 251-8	70
968	Targeted-therapy and imaging response: a new paradigm for clinical evaluation?. 2011 , 6, 259-65	17
967	Differential inhibition of transmembrane 4 L six family member 5 (TM4SF5)-mediated tumorigenesis by TSAHC and sorafenib. 2011 , 11, 330-6	12

966	Host response to short-term, single-agent chemotherapy induces matrix metalloproteinase-9 expression and accelerates metastasis in mice. 2011 , 71, 6986-96	84
965	Mucin glycosylating enzyme GALNT2 regulates the malignant character of hepatocellular carcinoma by modifying the EGF receptor. 2011 , 71, 7270-9	77
964	Impact of renin-angiotensin system in hepatocellular carcinoma. 2011 , 11, 431-41	18
963	Cardiotoxicity associated with targeting kinase pathways in cancer. 2011 , 120, 14-32	127
962	Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation. 2011 , 11, 944-53	18
961	Resveratrol interferes with N-nitrosodiethylamine-induced hepatocellular carcinoma at early and advanced stages in male Wistar rats. 2011 , 4, 1211-7	34
960	TACE and sorafenib: a good marriage?. 2011 , 29, 3949-52	50
959	Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma. 2011 , 10, 1007-17	68
958	The outcomes and safety of single-agent sorafenib in the treatment of elderly patients with advanced hepatocellular carcinoma (HCC). 2011 , 16, 1721-8	53
957	Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition. 2011 , 17, 5299-310	110
956	Kinase inhibitors in the treatment of chronic hepatitis C virus. 2011 , 60, 879-80	13
955	Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs. 2011 , 29, 2543-9	57
954	Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics. 2011 , 17, 6914-23	66
953	Sorafenib and sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CYP3A5-mediated midazolam 1'-hydroxylation. 2011 , 39, 757-62	36
952	Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies. 2011 , 105, 353-9	39
951	Randomised double-blind trial of megestrol acetate vs placebo in treatment-naive advanced hepatocellular carcinoma. 2011 , 105, 945-52	28
950	Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition. 2011 , 131, 2087-95	55
949	Suppression of hepatic tumor growth and metastasis by metronomic therapy in a rat model of hepatocellular carcinoma. 2011 , 43, 305-12	9

948	Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib. 2011 , 11, 1807-16	20
947	Clinical Cancer Prevention. 2011 ,	3
946	ShRNA-targeted MAP4K4 inhibits hepatocellular carcinoma growth. 2011 , 17, 710-20	69
945	Cerebrovascular accidents associated with sorafenib in hepatocellular carcinoma. 2011 , 2011, 616080	3
944	DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. 2011 , 71, 6073-83	180
943	Summary of the 2010 AHPBA/SSO/SSAT Consensus Conference on HCC. 2011 , 2011, 565060	12
942	Vascular endothelial growth factor receptors and the therapeutic targeting of angiogenesis in cancer: where do we go from here?. 2011 , 18, 85-103	21
941	Targeted therapy for biliary tract cancer. 2011 , 3, 2243-54	12
940	New targets and targeted drugs for the treatment of cancer: an outlook to pediatric oncology. 2011 , 28, 539-55	9
939	Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in <i>Caenorhabditis elegans</i> and <i>Drosophila</i> Parkinson's disease models. 2011 , 20, 3933-42	103
938	A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors. 2011 , 22, 1413-1419	62
937	Angiogenesis: a target in solid tumors, also in leukemia?. 2011 , 2011, 1-8	55
936	Clinical course of sorafenib treatment in patients with hepatocellular carcinoma. 2012 , 47, 809-19	11
935	Efficacy of sorafenib after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria: a preliminary study. 2012 , 5, 457-62	12
934	Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in Japan. 2012 , 4, 165-83	19
933	Potentiality and boundaries of use of sorafenib in patients with hepatocellular carcinoma: awaiting the results of ongoing clinical trials. 2012 , 4, 549-65	1
932	Results of en bloc resection for hepatocellular carcinoma extending to adjacent organs. 2012 , 55, 222-6	9
931	Hepatitis B- and hepatitis C-related hepatocellular carcinomas in the United States: similarities and differences. 2012 , 12, e7635	39

930 Pretransplant Evaluation and Care. **2012**, 837-852

929 Malignant Liver Tumors. **2012**, 463-482 2

928 Sorafenib prevents escape from host immunity in liver cirrhosis patients with advanced hepatocellular carcinoma. **2012**, 2012, 607851 21

927 Approach of the patient with a liver mass. **2012**, 3, 252-262 3

926 Effects of the combined administration of propranolol plus sorafenib on portal hypertension in cirrhotic rats. **2012**, 302, G1191-8 28

925 Hepatitis B Virus Reactivation during Treatment with Multi-Tyrosine Kinase Inhibitor for Hepatocellular Carcinoma. **2012**, 5, 515-9 6

924 Independent factors and predictive score for extrahepatic metastasis of hepatocellular carcinoma following curative hepatectomy. **2012**, 17, 963-9 27

923 Recent advances in radiofrequency ablation for the management of hepatocellular carcinoma. **2012**, 12, e5945 11

922 Gemcitabine and cisplatin-based combination chemotherapy in advanced hepatocellular carcinoma: An Indian experience. **2012**, 33, 42-7 8

921 Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib. **2012**, 23, 2103-2108 32

920 Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial. **2012**, 82, 67-74 70

919 A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer. **2012**, 18, 4820-9 141

918 Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review. **2012**, 17, 135-44 74

917 Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. **2012**, 18, 3686-96 202

916 Combining antiangiogenics to overcome resistance: rationale and clinical experience. **2012**, 18, 3750-61 58

915 FEATURES. **2012**, 16, 27-59

914 Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma. **2012**, 17, 1063-72 81

913 Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: a phase II North Central Cancer Treatment Group Clinical Trial. **2012**, 35, 329-33 48

912	Activity of thalidomide and capecitabine in patients with advanced hepatocellular carcinoma. 2012 , 35, 222-7	13
911	TGF-beta inhibitor-loaded polyelectrolyte multilayers capsules for sustained targeting of hepatocarcinoma cells. 2012 , 18, 4155-64	16
910	Gastrointestinal oncology--what you need to know. 2012 , 12, 575-9	
909	Biomarkers in hepatocellular carcinoma--letter. 2012 , 18, 4861	4
908	Guardian and selective killer: the versatile functions of TLR3 in hepatocellular carcinoma. 2012 , 104, 1780-2	2
907	Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. 2012 , 30, 871-7	146
906	Interventional Oncology. 2012 ,	3
905	Transarterial chemoembolization for hepatocellular carcinoma over three decades: current progress and perspective. 2012 , 42, 247-55	37
904	Sorafenib-mediated targeting of the AAA+ ATPase p97/VCP leads to disruption of the secretory pathway, endoplasmic reticulum stress, and hepatocellular cancer cell death. 2012 , 11, 2610-20	54
903	Acyclic retinoid targets platelet-derived growth factor signaling in the prevention of hepatic fibrosis and hepatocellular carcinoma development. 2012 , 72, 4459-71	44
902	The challenge of choosing appropriate end points in single-arm phase II studies of rare diseases. 2012 , 30, 896-8	19
901	Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. 2012 , 17, 359-66	129
900	RAS/RAF/MEK inhibitors in oncology. 2012 , 19, 1164-76	50
899	Role of angiogenesis inhibitors in colorectal cancer: sensitive and insensitive tumors. 2012 , 12, 303-15	14
898	[Personalised hepatology - current concepts, developments and expectations in the post-genome era]. 2012 , 50, 41-6	2
897	Possible involvement of angiogenesis in chronic liver diseases: interaction among renin-angiotensin-aldosterone system, insulin resistance and oxidative stress. 2012 , 19, 1889-98	22
896	Zunahme und verbessertes Überleben des hepatozellulären Karzinoms im Zeitraum von 1988 bis 2007: Daten einer deutschen Universitätsklinik. 2012 , 33, 34-41	
895	Radiologische Evaluation des Tumoransprechens in onkologischen Therapiestudien (Tumor Response Evaluation). 2012 , 33, 103-111	

894	Small molecule kinase inhibitors as anti-cancer therapeutics. 2012 , 12, 399-411	40
893	Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis. 2012 , 4, 600-13	37
892	Local-regional treatment of hepatocellular carcinoma. 2012 , 262, 43-58	265
891	Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy. 2012 , 18, 3992-7	37
890	The inhibitory effect of MSCs expressing TRAIL as a cellular delivery vehicle in combination with cisplatin on hepatocellular carcinoma. 2012 , 13, 1175-84	21
889	IBD in 2011: Advances in IBD management--towards a tailored approach. 2012 , 9, 70-2	7
888	Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3. 2012 , 11, 452-63	100
887	New drugs—how much are they worth? The Italian registries: a model to evaluate appropriateness and effectiveness. 2012 , 19, 398-403	7
886	Combination of local transcatheter arterial chemoembolization and systemic anti-angiogenic therapy for unresectable hepatocellular carcinoma. 2012 , 1, 201-15	15
885	Appropriate management of cutaneous adverse events maximizes compliance with sorafenib treatment: a single-center experience. 2012 , 8, 609-15	11
884	IGF-II Producing Hepatocellular Carcinoma Treated with Sorafenib: Metabolic Complications and a Foresight to Molecular Targeting Therapy to the IGF Signal. 2012 , 6, 784-9	7
883	The effect of sorafenib treatment on the diabetic status of patients with renal cell or hepatocellular carcinoma. 2012 , 8, 1051-7	10
882	Treatment of hepatocellular carcinoma: a systematic review. 2012 , 1, 144-58	214
881	Angiogenic activity of hepatitis B and C viruses. 2012 , 22, 159-70	21
880	Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia. 2012 , 53, 1062-7	21
879	Treatment of hepatocellular carcinoma with sorafenib - focus on special populations and adverse event management. 2012 , 50, 1018-27	10
878	How I do it: triaging patients with hepatocellular carcinoma. 2012 , 29, 64-8	1
877	[Hepatocellular carcinoma - from immunobiology to immunotherapy]. 2012 , 50, 47-56	9

876	Exploring the efficacy and safety of single-agent sorafenib in a cohort of Italian patients with hepatocellular carcinoma. 2012 , 12, 1283-8	7
875	Long-term results of sorafenib in advanced-stage hepatocellular carcinoma: what can we learn from routine clinical practice?. 2012 , 12, 869-75	20
874	Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities. 2012 , 1, 48-55	122
873	Sorafenib (BAY 43-9006) in hepatocellular carcinoma patients: from discovery to clinical development. 2012 , 19, 938-44	60
872	Molecular determinants of gastrointestinal and liver cancers: role of bile acid activated nuclear receptors. 2012 , 12, 625-36	2
871	Rational drug design for identifying novel multi-target inhibitors for hepatocellular carcinoma. 2012 , 12, 1088-97	9
870	Targeted therapy at the end of life in advanced cancer patients. 2012 , 15, 991-7	18
869	Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2012 , 23 Suppl 7, vii41-8	262
868	Phase I trial of sorafenib in combination with 5-fluorouracil/leucovorin in advanced solid tumors. 2012 , 52, 656-69	7
867	Food increased the bioavailability of BMS-690514, an orally active EGFR/HER2/VEGF receptor kinase inhibitor, in healthy subjects. 2012 , 52, 1350-6	3
866	Molecular biology of liver carcinogenesis and hepatitis. 2012 , 142-152.e3	1
865	Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma. 2012 , 6, 173-85	48
864	Sorafenib in locally advanced or metastatic breast cancer. 2012 , 21, 1177-91	18
863	Lack of effect of brivanib on the pharmacokinetics of midazolam, a CYP3A4 substrate, administered intravenously and orally in healthy participants. 2012 , 52, 914-21	3
862	Cellular immune responses to hepatocellular carcinoma: lessons for immunotherapy. 2012 , 30, 483-91	28
861	Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems. 2012 , 107, 1672-7	18
860	Severe toxicity caused by sorafenib in hepatocellular carcinoma match the data from renal cell carcinoma. 2012 , 106, 1246	5
859	Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3 β and NF- κ B to suppress tumor cell growth. 2012 , 31, 4848-58	52

858	Arresting the Culprit: Targeted Antagomir Delivery to Sequester Oncogenic miR-221 in HCC. 2012 , 1, e12	9
857	Quantification of variability in breath-hold perfusion CT of hepatocellular carcinoma: a step toward clinical use. 2012 , 265, 448-56	21
856	Tumour growth kinetics assessment: added value to RECIST in cancer patients treated with molecularly targeted agents. 2012 , 106, 854-7	27
855	A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: the prognostic nutritional index (PNI). 2012 , 106, 1439-45	244
854	BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy. 2012 , 3, e259	65
853	Inhibiting angiogenesis in breast cancer: the beginning of the end or the end of the beginning?. 2012 , 30, 898-901	28
852	BEAM trial: lighting the way ahead?. 2012 , 30, 6-7	4
851	Phase II studies in soft tissue sarcoma: time for reappraisal. 2012 , 17, 154-6	5
850	Factors impacting prognosis prediction in BCLC stage C and Child-Pugh class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy. 2012 , 17, 970-7	9
849	Anti-VEGF therapies in the clinic. 2012 , 2,	152
848	Concentration and volume effects in thermochemical ablation in vivo: results in a porcine model. 2012 , 28, 113-21	13
847	Analysis of possible mechanisms accounting for raf-1 kinase inhibitor protein downregulation in hepatocellular carcinoma. 2012 , 16, 579-88	17
846	Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis. 2012 , 17, 1204-12	73
845	Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo. 2012 , 11, 2284-93	120
844	A novel anticancer agent, SKLB70359, inhibits human hepatic carcinoma cells proliferation via G0/G1 cell cycle arrest and apoptosis induction. 2012 , 29, 281-90	16
843	Effectiveness of high-dose three-dimensional conformal radiotherapy in hepatocellular carcinoma with portal vein thrombosis. 2012 , 42, 721-9	46
842	Malignant epithelioid hemangioendothelioma of the liver successfully treated with Sorafenib. 2012 , 4, e34	35
841	Aflibercept in the treatment of metastatic colorectal cancer. 2012 , 6, 19-30	33

840	Molecular Biomarkers of Response to Antiangiogenic Therapy for Cancer. 2012 , 2012,	18
839	Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics. 2012 , 4, 19-37	151
838	Contemporary strategies in the management of hepatocellular carcinoma. 2012 , 2012, 154056	4
837	Molecular mechanisms of liver injury and hepatocarcinogenesis: focusing on the role of stress-activated MAPK. 2012 , 2012, 172894	50
836	Implications of the Use of Eukaryotic Translation Initiation Factor 5A (eIF5A) for Prognosis and Treatment of Hepatocellular Carcinoma. 2012 , 2012, 760928	21
835	Watch the GAP: Emerging Roles for IQ Motif-Containing GTPase-Activating Proteins IQGAPs in Hepatocellular Carcinoma. 2012 , 2012, 958673	16
834	Do imaging biomarkers relate to outcome in patients treated with VEGF inhibitors?. 2012 , 18, 6588-98	46
833	Hepatocellular carcinoma: natural history, current management, and emerging tools. 2012 , 6, 207-19	45
832	Gemcitabine Plus Carboplatin in Patients with Advanced Hepatocellular Carcinoma: Results of a Phase II Study. 2012 , 2012, 420931	0
831	Conditional survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients. 2012 , 18, 4397-405	61
830	A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report. 2012 , 18, 6011-22	88
829	Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. 2012 , 7, 1086-90	126
828	TGF- β in epithelial to mesenchymal transition and metastasis of liver carcinoma. 2012 , 18, 4135-47	84
827	Anti-VEGF strategies - from antibodies to tyrosine kinase inhibitors: background and clinical development in human cancer. 2012 , 18, 2680-701	18
826	Sorafenib dose escalation in the treatment of advanced hepatocellular carcinoma. 2012 , 82, 119-25	23
825	Prolonged Complete Response after GEMOX Chemotherapy in a Patient with Advanced Fibrolamellar Hepatocellular Carcinoma. 2012 , 5, 169-72	29
824	Chemoembolization in patients with hepatocellular carcinoma. 2012 , 1, 41-50	69
823	Complete response after short-term sorafenib treatment in a patient with lymph node metastasis of hepatocellular carcinoma. 2012 , 5, 380-4	13

822	Evaluation of the mRECIST and α -fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib. 2012 , 83, 192-200	55
821	Therapeutic monitoring of gastroenteropancreatic neuroendocrine tumors: the challenges ahead. 2012 , 96, 261-71	46
820	Why does every hepatocellular carcinoma clinical trial using molecular targeted agents fail?. 2012 , 1, 59-60	7
819	Hepatic artery chemoembolization for hepatocellular carcinoma recurrence confined to the transplanted liver. 2012 , 5, 506-10	5
818	How to improve treatment outcomes for hepatocellular carcinoma of intermediate and advanced stage. 2012 , 30, 598-602	16
817	Application of Radiotherapeutic Strategies in the BCLC-Defined Stages of Hepatocellular Carcinoma. 2012 , 1, 216-25	26
816	Immunotherapeutic approaches to hepatocellular carcinoma treatment. 2012 , 1, 226-37	43
815	Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition. 2012 , 1, 247-56	58
814	Real-life clinical practice with sorafenib in advanced hepatocellular carcinoma: a single-center experience. 2012 , 30, 609-16	21
813	Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. 2012 , 18, 2090-8	126
812	Therapeutically targeting microRNAs in liver cancer. 2013 , 19, 1180-91	23
811	Imaging Findings of Cirrhotic Liver. 2012 , 47-83	
810	Primary Liver Cancer. 2012 , 163-182	1
809	Contrast-enhanced ultrasound for liver imaging: recent advances. 2012 , 18, 2236-52	38
808	mTor as a potential target for the prevention and treatment of hepatocellular carcinoma. 2012 , 12, 1045-61	19
807	Role of Acyclic Retinoid in the Chemoprevention of Hepatocellular Carcinoma: Basic Aspects, Clinical Applications, and Future Prospects. 2012 , 12, 1119-1128	5
806	Targeted Therapy for Liver Cancer: Updated Review in 2012. 2012 , 12, 1062-1072	3
805	Hepatocellular Carcinoma Diagnostics, Treatments and Potential Theragnostics in the Asia-Pacific. 2012 , 10, 159-169	

804	The expression levels of CD44v6 are correlated with the invasiveness of hepatocellular carcinoma in vitro, but do not appear to be clinically significant. 2012 , 3, 1047-1051	7
803	Tailored Angiogenesis Inhibition in Cancer Therapy: Respecting the Heart to Improve the Net Outcome. 2012 , 7, 265-288	4
802	Recent Developments in Targeted Therapies of the RAF-MEK and PI3KAKT Pathways in Cancer Treatment. 2012 , 8, 205-217	
801	The role of microRNAs in liver cancer. 2012 , 24, 223-8	28
800	The TGF- β signaling pathway as a pharmacological target in a hepatocellular carcinoma. 2012 , 18, 4148-54	15
799	Conformationally constrained peptides as protein tyrosine kinase inhibitors. 2012 , 18, 2852-66	6
798	Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma. 2012 , 24, 563-74	15
797	Rezidiv des hepatozellulösen Karzinoms nach orthotoper Lebertransplantation: Nachsorge und therapeutische Optionen. 2012 , 28, 338-343	2
796	Elaborate designs with artisan spirit to treat liver cancer in Japan. 2012 , 53, 463-485	
795	Radiation therapy for tumor thrombus in the portal vein or inferior vena cava in unresectable hepatocellular carcinoma. 2012 , 53, 486-493	2
794	PWE-273 Enhanced liver fibrosis test accurately identifies liver fibrosis and predicts clinical outcomes in alcoholic liver disease. 2012 , 61, A408.3-A409	1
793	PWE-275 Multiple organ dysfunction syndrome (MODS), rather than the need for renal replacement therapy per se, dictates poor prognosis in patients with cirrhosis admitted to ICU. 2012 , 61, A409.2-A410	
792	Role of DLC1 tumor suppressor gene and MYC oncogene in pathogenesis of human hepatocellular carcinoma: potential prospects for combined targeted therapeutics (review). 2012 , 41, 393-406	43
791	Cancer stem cell as a potential therapeutic target in hepatocellular carcinoma. 2012 , 12, 1081-94	29
790	Non-Coding RNAs as Therapeutic Targets in Hepatocellular Cancer. 2012 , 12, 1073-1080	5
789	Inhibition of corneal neovascularization in rats by systemic administration of sorafenib. 2012 , 31, 907-12	17
788	Sorafenib for advanced-stage hepatocellular carcinoma. 2012 , 24, 346-7	4
787	Weight loss induced by tyrosine kinase inhibitors of the vascular endothelial growth factor pathway. 2012 , 23, 149-54	3

786	Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection. 2012 , 255, 8-17	85
785	Inhibition of the placental growth factor decreases burden of cholangiocarcinoma and hepatocellular carcinoma in a transgenic mouse model. 2012 , 24, 1020-32	12
784	Sorafenib in combination with ionizing radiation has a greater anti-tumour activity in a breast cancer model. 2012 , 23, 525-33	14
783	New sorafenib derivatives: synthesis, antiproliferative activity against tumour cell lines and antimetabolic evaluation. 2012 , 17, 1124-37	13
782	Unexpected remission of hepatocellular carcinoma (HCC) with lung metastasis to the combination therapy of thalidomide and cyproheptadine: report of two cases and a preliminary HCC cell line study. 2012 , 2012,	14
781	Uncommon Hepatobiliary Tumors. 2012 , 423-440	
780	Sarcomatous hepatocellular carcinoma with remittent fever. 2012 , 51, 3025-9	5
779	Chemoembolization of unresectable hepatocellular carcinoma: Decreased toxicity with slow-release doxorubicin-eluting beads compared with lipiodol. 2012 , 27, 1377-83	32
778	Overexpression of the RD RNA binding protein in hepatitis C virus-related hepatocellular carcinoma. 2012 , 28, 728-34	8
777	Comparison of the efficacy of transcatheter arterial chemoembolization and sorafenib for advanced hepatocellular carcinoma. 2012 , 4, 381-386	11
776	Caffeine increases the antitumor effect of Cisplatin in human hepatocellular carcinoma cells. 2012 , 35, 400-7	15
775	Hepatocarcinoma. 2012 , 11, 693-703	
774	Management of HCC. 2012 , 56 Suppl 1, S75-87	431
773	Hepatocellular carcinoma. 2012 , 379, 1245-55	3409
772	Molecular targeted therapies in hepatocellular carcinoma. 2012 , 39, 486-92	83
771	BND-12, a novel nonhaematotoxic naphthalimide derivative, inhibits tumour growth and metastasis of hepatocellular carcinoma. 2012 , 64, 1483-90	2
770	Pharmacokinetic evaluation of axitinib. 2012 , 8, 259-70	19
769	Sorafenib in treatment of patients with advanced hepatocellular carcinoma: a systematic review. 2012 , 11, 458-66	25

768	RET fusion genes in non-small-cell lung cancer. 2012 , 30, 4439-41	32
767	High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation. 2012 , 25, 1158-64	46
766	Des-Carboxyl prothrombin is associated with tumor angiogenesis in hepatocellular carcinoma. 2012 , 27, 1602-8	23
765	Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma. 2012 , 106, 1997-2003	76
764	Clinical trial design in the age of molecular profiling. 2012 , 823, 19-34	2
763	Exploiting the cancer genome: strategies for the discovery and clinical development of targeted molecular therapeutics. 2012 , 52, 549-73	83
762	Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study. 2012 , 23, 3137-3143	78
761	Active home-based cancer treatment. 2012 , 5, 137-43	13
760	Expression of serotonin receptors in human hepatocellular cancer. 2012 , 18, 5902-10	48
759	Hepatobiliary Surgery: Indications, Evaluation, and Outcomes. 2012 , 285-297	2
758	Sorafenib in liver cancer. 2012 , 13, 1059-67	39
757	Antifibrotic activity of sorafenib in experimental hepatic fibrosis: refinement of inhibitory targets, dosing, and window of efficacy in vivo. 2013 , 58, 257-64	39
756	Saturable absorption of sorafenib in patients with solid tumors: a population model. 2012 , 30, 1991-2000	35
755	Feasibility study of intra-patient sorafenib dose-escalation or re-escalation in patients with previously treated advanced solid tumors. 2012 , 30, 2001-7	3
754	(+)-Episesamin exerts anti-neoplastic effects in human hepatocellular carcinoma cell lines via suppression of nuclear factor-kappa B and inhibition of MMP-9. 2012 , 30, 2087-95	11
753	Sorafenib exposure decreases over time in patients with hepatocellular carcinoma. 2012 , 30, 2046-9	81
752	Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group. 2012 , 30, 2377-83	87
751	Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities. 2012 , 30, 2066-79	74

750	Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease. 2012 , 30, 2384-90	49
749	Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. 2012 , 13, e11-22	708
748	VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AVITA and AVOREN randomised trials. 2012 , 13, 724-33	157
747	Prognostic significance and clinical relevance of Sprouty 2 protein expression in human hepatocellular carcinoma. 2012 , 11, 177-84	14
746	Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma according to Child-Pugh classification. 2012 , 27, 1850-7	35
745	Some new approaches to the management of hepatocellular carcinoma. 2012 , 39, 369-73	5
744	TNF-dependent signaling pathways in liver cancer: promising targets for therapeutic strategies?. 2012 , 30, 500-7	14
743	Impact of targeted neoadjuvant therapies in the treatment of solid organ tumours. 2013 , 100, 5-14	5
742	Systemic targeted therapy beyond sorafenib. 2012 , 1, 212-216	6
741	Natural history and staging for hepatocellular carcinoma. 2012 , 1, 183-185	3
740	Impact of intra-individual molecular heterogeneity in personalized treatment of hepatocellular carcinoma. 2012 , 56, 2416-9	14
739	Antiangiogenic therapy for cancer: an update. 2012 , 32, 1095-111	124
738	B7-H3 is expressed in human hepatocellular carcinoma and is associated with tumor aggressiveness and postoperative recurrence. 2012 , 61, 2171-82	69
737	Portal hemodynamic effects of sorafenib in patients with advanced hepatocellular carcinoma: a prospective cohort study. 2012 , 47, 1030-5	19
736	Systemic combination therapy of intravenous continuous 5-fluorouracil and subcutaneous pegylated interferon alfa-2a for advanced hepatocellular carcinoma. 2012 , 47, 1152-9	8
735	Epidemiologie und molekulare Pathogenese des hepatozellulären Karzinoms. 2012 , 7, 382-389	
734	Systemische Therapie des hepatozellulären Karzinoms. 2012 , 7, 413-418	
733	Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes. 2012 , 82, 2004-11	170

732	PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation. 2012 , 176, 542-8	65
731	The effects of sorafenib on liver regeneration in a model of partial hepatectomy. 2012 , 178, 242-7	10
730	Treatment of primary liver cancer using highly-conformal radiotherapy with kV-image guidance and respiratory control. 2012 , 102, 56-61	26
729	ADAM10 overexpression confers resistance to doxorubicin-induced apoptosis in hepatocellular carcinoma. 2012 , 33, 1535-41	18
728	Complete clinical response of a patient with lymph node and pulmonary metastatic hepatocellular carcinoma to very low-dose sorafenib (Nexavar®) therapy. 2012 , 1, 224-229	0
727	Selective internal radiation therapy of hepatocellular carcinoma: potential hepatopulmonary shunt reduction after sorafenib administration. 2012 , 23, 949-52	33
726	Multidisciplinary management of hepatocellular carcinoma. 2012 , 10, 354-62	39
725	Does Fibrosis Influence Survival after Liver Transplantation? Evidence from the SEER Database. 2021 , 11, 5594-5605	
724	Strategies to improve sorafenib efficacy during image-guided treatment of hepatocellular carcinoma.. 2021 , 9, 1745	
723	Anti-cancer effects of 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives on hepatocellular carcinoma harboring FGFR4 activation. 2021 , 24, 34-49	
722	Hepatozelluläres Karzinom. 2022 , 283-290	
721	Effect of SMMC-7721-derived exosomes on hepatocytes studied by AFM. 2021 ,	
720	CRISPR/Cas9 in Gastrointestinal Malignancies.. 2021 , 9, 727217	0
719	Mitochondrial Plasticity Promotes Resistance to Sorafenib and Vulnerability to STAT3 Inhibition in Human Hepatocellular Carcinoma. 2021 , 13,	0
718	Alnustone inhibits the growth of hepatocellular carcinoma via ROS- mediated PI3K/Akt/mTOR/p70S6K axis. 2021 ,	1
717	Dysregulation of RalA signaling through dual regulatory mechanisms exerts its oncogenic functions in hepatocellular carcinoma. 2021 ,	1
716	The Efficacy of Radiotherapy in the Treatment of Hepatocellular Carcinoma with Distant Organ Metastasis. 2021 , 2021, 5190611	0
715	Downstaging Conversion Therapy in Patients With Initially Unresectable Advanced Hepatocellular Carcinoma: An Overview. 2021 , 11, 772195	1

714	Kinase Inhibitors' Effects on Innate Immunity in Solid Cancers. 2021 , 13,	0
713	Proposal for new sleep disorder criteria in patients with chronic liver disease: Influence of liver-related complications. 2021 ,	2
712	Pattern of progression of intrahepatic cholangiocarcinoma: Implications for second-line clinical trials. 2021 ,	1
711	Bioinformatics Analysis Identifies Precision Treatment with Paclitaxel for Hepatocellular Carcinoma Patients Harboring Mutant or Wild-Type Gene. 2021 , 11,	
710	Hepatocellular carcinoma locoregional therapies: Outcomes and future horizons. 2021 , 27, 7462-7479	1
709	Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma. 2021 ,	4
708	Changes in therapeutic options for hepatocellular carcinoma in Asia. 2021 ,	0
707	Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.. 2021 , 12, 783236	0
706	Elevated expression of RIT1 hyperactivates RAS/MAPK signal and sensitizes hepatocellular carcinoma to combined treatment with sorafenib and AKT inhibitor. 2021 ,	0
705	Artemisinin Mediates Its Tumor-Suppressive Activity in Hepatocellular Carcinoma Through Targeted Inhibition of FoxM1.. 2021 , 11, 751271	1
704	Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis. 2021 ,	0
703	Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial. 2021 , 15, 1402-1412	0
702	First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials.. 2022 , 11, 75-84	2
701	A case of conversion hepatectomy for huge ruptured hepatocellular carcinoma after transarterial embolization and lenvatinib therapy. 2021 , 1	0
700	Combination of psoas muscle mass index and neutrophil/lymphocyte ratio as a prognostic predictor for patients undergoing nonsurgical hepatocellular carcinoma therapy.. 2021 , 5, 1335-1343	1
699	Role of Biobanks for Cancer Research and Precision Medicine in Hepatocellular Carcinoma. 2021 , 1	
698	Checkpoint inhibitors: literature review of new treatments for hepatocellular carcinoma.. 2021 , 8, 22	1
697	Combination therapies plus transarterial chemoembolization in hepatocellular carcinoma: a snapshot of clinical trial progress. 2021 , 1-13	1

696	Aldehyde dehydrogenase expression may be a prognostic biomarker and associated with liver cirrhosis in patients resected for hepatocellular carcinoma.. 2021 , 40, 101677	
695	BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. 2021 ,	51
694	GOLM1 exacerbates CD8 T cell suppression in hepatocellular carcinoma by promoting exosomal PD-L1 transport into tumor-associated macrophages. 2021 , 6, 397	1
693	Revisiting Hepatic Artery Infusion Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma. 2021 , 22,	1
692	Drug-Eluting Bead Transarterial Chemoembolization Combined with FOLFOX-Based Hepatic Arterial Infusion Chemotherapy for Large or Huge Hepatocellular Carcinoma. 2021 , 8, 1445-1458	0
691	A Ferroptosis and Pyroptosis Molecular Subtype-Related Signature Applicable for Prognosis and Immune Microenvironment Estimation in Hepatocellular Carcinoma. 2021 , 9, 761839	6
690	A paradoxical role for sestrin 2 protein in tumor suppression and tumorigenesis. 2021 , 21, 606	1
689	RABL2A-CCDC34 Axis Promotes Sorafenib Resistance in Hepatocellular Carcinoma. 2021 , 40, 1418-1427	0
688	The Efficacy of Transarterial Chemoembolization plus Apatinib or Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma. 2021 , 2021, 8169012	
687	Genome-scale CRISPR-Cas9 knockout screening in hepatocellular carcinoma with lenvatinib resistance. 2021 , 7, 359	1
686	Acquired Resistance to Antiangiogenic Therapies in Hepatocellular Carcinoma Is Mediated by Yes-Associated Protein 1 Activation and Transient Expansion of Stem-Like Cancer Cells. 2021 ,	1
685	Clusterin and Related Scoring Index as Potential Early Predictors of Response to Sorafenib in Hepatocellular Carcinoma. 2021 ,	
684	The Fellowship of Privileged Scaffolds-One Structure to Inhibit Them All. 2021 , 14,	2
683	Phytochemicals as an Alternative or Integrative Option, in Conjunction with Conventional Treatments for Hepatocellular Carcinoma. 2021 , 13,	0
682	Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha-fetoprotein levels. 2021 ,	1
681	Current Status and Future Perspective of the Treatment for Radioiodine Refractory Differentiated Thyroid Cancer. 2021 , 14, 98-111	
680	Pharmacological Targeting of Ferroptosis in Cancer Treatment. 2021 ,	1
679	The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer.. 2021 , 12, 792691	0

- 678 Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma. **2021**, 2
- 677 Novel Nanocrystal Injection of Insoluble Drug Anlotinib and Its Antitumor Effects on Hepatocellular Carcinoma.. **2021**, 11, 777356 0
- 676 Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib. **2021**, 6, 100330 0
- 675 Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials. **2021**, 1-9 3
- 674 Hepatic Interventional Oncology. **2022**, 415-441
- 673 Personalized Medicine for Patients with Liver, Biliary Tract, and Pancreatic Cancer. **2021**, 1-17
- 672 Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma.. **2021**, 20, 15330338211063848 2
- 671 A combination of portal vein stent insertion and endovascular iodine-125 seed-strip implantation, followed by transcatheter arterial chemoembolization with sorafenib for treatment of hepatocellular carcinoma-associated portal vein tumor thrombus.. **2021**, 13, 670-679
- 670 Hepatocellular carcinoma with complete response to the immunotherapy: the oncologist's dilemma.. **2022**, 11, 119-122
- 669 Editorial comment on: "".. **2022**, 11, 112-114
- 668 Success is not final, failure is not fatal: The changing landscape of systemic therapy for advanced hepatocellular carcinoma. **2021**, 8, 127
- 667 A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab. **2021**, 9, 23247096211058489 0
- 666 Multidisciplinary approach to the treatment of advanced hepatocellular carcinoma in the era of new biologic agents. **2021**,
- 665 A meta-analysis comparing hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma.. **2022**, 11, 99-112 0
- 664 A narrative review of systemic treatment options for hepatocellular carcinoma: state of the art review.. **2022**, 13, 426-437 0
- 663 Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma.. **2022**, 14, 0
- 662 Comprehensive kinomic study via a chemical proteomic approach reveals kinome reprogramming in hepatocellular carcinoma tissues.. **2021**, e2100141
- 661 MiRNA-124-3p.1 sensitizes hepatocellular carcinoma cells to sorafenib by regulating FOXO3a by targeting AKT2 and SIRT1.. **2022**, 13, 35 1

660	Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study.. 2022 , 22, 55	0
659	Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma.. 2022 , 14,	1
658	The Pyroptosis-Related Gene Signature Predicts the Prognosis of Hepatocellular Carcinoma.. 2021 , 8, 781427	1
657	The role of BCL9 genetic variation as a biomarker for hepatitis C-related hepatocellular carcinoma in Egyptian patients.. 2022 , 20, 4	
656	Intracellular Reduction-Responsive Molecular Targeted Nanomedicine for Hepatocellular Carcinoma Therapy.. 2021 , 12, 809125	
655	The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab.. 2022 , 14,	1
654	Immunotherapy in older patients with hepatocellular carcinoma.. 2021 , 162, 76-98	1
653	Inhibiting VEGF in cancer immunotherapy. 2022 , 2, 12-16	
652	Towards a tailored systemic therapy for liver cancer. 2020 , 8, 1327-1327	
651	Selecting patients for treatment with immunotherapy: Our experience in a resource-deprived economy. 2020 , 025-027	
650	Lenvatinib in elderly hepatocellular carcinoma patients, a new therapeutic option in first line. 2020 , 8, 1335-1335	
649	Silencing <i>KIF14</i> ; reverses acquired resistance to sorafenib in hepatocellular carcinoma. 2020 , 12, 22975-23003	1
648	Predictive factors for long-term survival in patients with advanced hepatocellular carcinoma treated with sorafenib. 2020 , 33,	1
647	Combining immune checkpoint inhibitor with lenvatinib prolongs survival than lenvatinib alone in sorafenib-experienced hepatocellular carcinoma patients. 2020 , 34,	4
646	Tivozanib for hepatocellular carcinoma: not likely a new option. 2020 , 8, 1337-1337	
645	Time to stop using hepatic arterial infusion chemotherapy (HAIC) for advanced hepatocellular carcinoma?âthe SCOOP-2 trial experience. 2020 , 8, 1340-1340	0
644	The Evolving Treatment Landscape of Hepatocellular Carcinoma: More Choices, More Responsibility. 2020 , 27, 136-137	0
643	Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner. 2020 , 8, 1532-1532	0

- 642 Transplantation in hepatocellular carcinoma - controversies and recommendations: A review of current literature. **2021**, 8, 49
- 641 B-RAF PROTEIN IMMUNOEXPRESSION IN HEPATOCELLULAR CARCINOMA DUE TO HEPATITIS C VIRUS RELATED CIRRHOSIS.. **2021**, 58, 419-423
- 640 Simple Scoring System for Predicting TACE Unsuitable among Intermediate-Stage Hepatocellular Carcinoma Patients in the Multiple Systemic Treatment Era. **2021**, 1-9
- 639 Dynamics of endothelial progenitor cells in patients with advanced hepatocellular carcinoma. **2021**,
- 638 Transarterial Radioembolization for Unresectable Hepatocellular Carcinoma: Real-Life Efficacy and Safety Analysis of Korean Patients.. **2022**, 14, 0
- 637 Hepatectomy Versus Sorafenib in Advanced Non-Metastatic Hepatocellular Carcinoma: A Real-Life Multicentric Weighted Comparison.. **2022**, 275, 0
- 636 Genetic Landscape of Multistep Hepatocarcinogenesis.. **2022**, 14, 1
- 635 Role of Pretransplant Treatments for Patients with Hepatocellular Carcinoma Waiting for Liver Transplantation.. **2022**, 14, 0
- 634 Fasting improves therapeutic response in hepatocellular carcinoma through p53-dependent metabolic synergism.. **2022**, 8, eabh2635 2
- 633 Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: Shedding light on the preclinical rationale and clinical trials.. **2022**, 0
- 632 Ago-RIP Sequencing Identifies New MicroRNA-449a-5p Target Genes Increasing Sorafenib Efficacy in Hepatocellular Carcinoma.. **2022**, 13, 62-75 1
- 631 Tumor-Associated Macrophages in Hepatocellular Carcinoma Pathogenesis, Prognosis and Therapy.. **2022**, 14, 2
- 630 Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis.. **2022**, 0
- 629 Hepatocellular Carcinoma: Molecular Pathogenesis and Therapeutic Advances.. **2022**, 14, 1
- 628 CD26/DPP4 as a Therapeutic Target in Nonalcoholic Steatohepatitis Associated Hepatocellular Carcinoma.. **2022**, 14, 0
- 627 Fibroblast-derived prolargin is a tumor suppressor in hepatocellular carcinoma.. **2022**, 0
- 626 Synthesis and Anti-Hepatoma Activities of U12 Derivatives Arresting G0/G1 Phase and Inducing Apoptosis by PI3K/AKT/mTOR Pathway.. **2022**, 15,
- 625 Overexpression of PD-L1 is an Independent Predictor for Recurrence in HCC Patients Who Receive Sorafenib Treatment After Surgical Resection.. **2021**, 11, 783335

- 624 circKCNN2 suppresses the recurrence of hepatocellular carcinoma at least partially via regulating miR-520c-3p/methyl-DNA-binding domain protein 2 axis.. **2022**, 12, e662 3
- 623 FOXM1-induced TYMS upregulation promotes the progression of hepatocellular carcinoma.. **2022**, 22, 47
- 622 The Landscape Of Alpha Fetoprotein In Hepatocellular Carcinoma: Where Are We?. **2022**, 18, 536-551 1
- 621 Epigenetic regulation of ferroptosis via ETS1/miR-23a-3p/ACSL4 axis mediates sorafenib resistance in human hepatocellular carcinoma.. **2022**, 41, 3 3
- 620 Effectiveness of Lenvatinib Versus Sorafenib for Unresectable Hepatocellular Carcinoma in Patients with Hepatic Decompensation.. **2022**, 1
- 619 The hsa_circRNA_102049 mediates the sorafenib sensitivity of hepatocellular carcinoma cells by regulating gene expression.. **2022**, 13, 2272-2284
- 618 Neutrophils as potential therapeutic targets in hepatocellular carcinoma.. **2022**, 1
- 617 A Novel Angiogenesis-Related Prognostic Signature Associated with the Hepatocellular Carcinoma Immune Microenvironment and Survival Outcome.. **2022**, 15, 311-323
- 616 Drug-Specific Orofacial Complications of Novel Anti-cancer Therapies. **2022**, 153-169
- 615 Signaling by the tyrosine kinase Yes promotes liver cancer development.. **2022**, 15, eabj4743 1
- 614 Conventional Therapies Do Not Prolong the Prognosis of Hepatocellular Carcinoma Patients with Extrahepatic Metastases under Receiving of Tyrosine Kinase Inhibitors.. **2022**, 14,
- 613 Impact of psoas muscle index assessed by a simple measurement method on tolerability and duration of continued treatment with sorafenib in hepatocellular carcinoma patients.. **2022**,
- 612 Oral Mucositis. **2022**, 49-97
- 611 Immune checkpoint inhibitors in HCC: cellular, molecular and systemic data.. **2022**, 0
- 610 Golgi phosphoprotein 3 promotes angiogenesis and sorafenib resistance in hepatocellular carcinoma via upregulating exosomal miR-494-3p.. **2022**, 22, 35 0
- 609 Ribavirin inhibits the growth and ascites formation of hepatocellular carcinoma through downregulation of type I CARM1 and type II PRMT5.. **2021**, 435, 115829 0
- 608 Loco-Regional Treatments for Hepatocellular Carcinoma in People Living with HIV.. **2022**, 14, 43-55 2
- 607 Recent advances in systemic therapy for hepatocellular carcinoma.. **2022**, 10, 3 3

- 606 ZCCHC17 Served as a Predictive Biomarker for Prognosis and Immunotherapy in Hepatocellular Carcinoma.. **2021**, 11, 799566
- 605 Response Evaluation Criteria in Cancer of the Liver version 6 (RECICL 2021 Revised Version).. **2022**, 0
- 604 Management of hepatocellular carcinoma recurrence after liver transplantation.. **2021**, 27, 100654 0
- 603 Sarcopenia in hepatocellular carcinoma: Current knowledge and future directions.. **2022**, 28, 432-448 0
- 602 Antiangiogenic drugs: Chemosensitizers for combination cancer therapy. **2022**, 29-66
- 601 A Review of Potential Role of Capsule Endoscopy in the Work-Up for Chemotherapy-Induced Diarrhea.. **2022**, 10,
- 600 Implications of Stemness Features in 1059 Hepatocellular Carcinoma Patients from Five Cohorts: Prognosis, Treatment Response, and Identification of Potential Compounds.. **2022**, 14, 0
- 599 Progress of HOTAIR-microRNA in hepatocellular carcinoma.. **2022**, 20, 4 0
- 598 H1-Antihistamines Reduce the Risk of Hepatocellular Carcinoma in Patients With Hepatitis B Virus, Hepatitis C Virus, or Dual Hepatitis B Virus-Hepatitis C Virus Infection.. **2022**, JCO2101802 4
- 597 Evaluation of staging systems to predict prognosis in hepatocellular carcinoma patients treated with radioembolization.. **2022**, 8, e08770
- 596 Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.. **2022**, 23, 77-90 19
- 595 Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment.. **2022**, 12, 822507
- 594 Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib.. **2022**, 22, 1 0
- 593 Novel Cellular Therapies for Hepatocellular Carcinoma.. **2022**, 14, 1
- 592 Durvalumab: an investigational agent for unresectable hepatocellular carcinoma.. **2022**, 0
- 591 MiR-25 enhances autophagy and promotes sorafenib resistance of hepatocellular carcinoma via targeting FBXW7.. **2022**, 19, 257-266 0
- 590 S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms. **2022**, 60, e56-e130 0
- 589 S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms âKurzversion 2.00 âJuni 2021, AWMF-Registernummer: 032-053OL. **2022**, 60, 81-107

588	Key Genes Associated with Tumor-Infiltrating Non-regulatory CD4- and CD8-Positive T Cells in Microenvironment of Hepatocellular Carcinoma.. 2022 , 1	
587	Precision Medicine for Hepatocellular Carcinoma: Clinical Perspective.. 2022 , 12,	1
586	CHRNA5 Contributes to Hepatocellular Carcinoma Progression by Regulating YAP Activity.. 2022 , 14,	1
585	Terapias sistmicas en carcinoma hepatocelular: secuencia de tratamientos. 2022 , 57-71	
584	Phase I Study Evaluating Dose De-escalation of Sorafenib with Metformin and Atorvastatin in Hepatocellular Carcinoma (SMASH).. 2022 , 27, 165-e222	0
583	Ferroptosis Regulator Modification Patterns and Tumor Microenvironment Immune Infiltration Characterization in Hepatocellular Carcinoma.. 2022 , 9, 807502	1
582	Sorafenib Plus Hepatic Arterial Infusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized Trial.. 2022 , 211545	1
581	Efficacy and safety of endovascular brachytherapy combined with transarterial chemoembolization for the treatment of hepatocellular carcinoma patients with type III or IV portal vein tumor thrombosis.. 2022 , 20, 30	0
580	Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?. 2022 ,	0
579	NAFLD indirectly impairs antigen-specific CD8 T'cell immunity against liver cancer in mice.. 2022 , 25, 103847	
578	Equal Efficacy and Safety Profile in Elderly Patients with Hepatocellular Carcinoma Receiving Palliative Treatment.. 2022 , 14,	
577	XSSJS inhibits hepatic fibrosis by promoting the mir29b-3p/VEGFA axis in vitro and in vivo.. 2022 ,	0
576	Jianpi Huayu Decoction enhances the effect of sorafenib and alleviates adverse events in hepatocellular carcinoma by remodeling the gut microbiota. 2022 , 2, 100057	
575	Combination treatment with sorafenib and wh-4 additively suppresses the proliferation of liver cancer cells.. 2022 , 23, 232	
574	Effectiveness of fourth-line dual immunotherapy in hepatocellular carcinoma with simultaneous steroid administration for immune-related hepatitis.. 2022 , 15, 17562848211051026	0
573	Efficacy of Local-regional Treatment Plus Sorafenib in Intermediate-stage Hepatocellular Carcinoma Patients Refractory to Transarterial Chemoembolization.	
572	Disrupting CANCER angiogenesis and immune checkpoint networks for improved tumor immunity.. 2022 ,	2
571	Theranostics in primary and secondary liver tumors: the need for a personalized approach. 2021 ,	1

- 570 PBLD inhibits angiogenesis via impeding VEGF/VEGFR2-mediated microenvironmental cross-talk between HCC cells and endothelial cells.. **2022,** 0
- 569 Advanced Hepatocellular Cancer Treated with Sorafenib and Novel Inflammatory Markers.. **2022,** 1 0
- 568 TARE in Hepatocellular Carcinoma: From the Right to the Left of BCLC.. **2022,** 0
- 567 A step toward a better understanding of hepatocellular progression after transarterial embolization.. **2022,**
- 566 [Clinical relevance of the new S3 guideline on hepatocellular carcinoma and biliary tract cancer for practitioners].. **2022,** 62, 200
- 565 High-Molecular-Weight Fractions of Spruce and Eucalyptus Lignin as a Perspective Nanoparticle-Based Platform for a Therapy Delivery in Liver Cancer.. **2021,** 9, 817768 0
- 564 Augmented efficacy of utrosidine B over sorafenib in a murine model of human hepatocellular carcinoma.
- 563 Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).. **2021,** JCO2101963 5
- 562 C-Reactive Protein Levels Predict Responses to PD-1 Inhibitors in Hepatocellular Carcinoma Patients.. **2022,** 13, 808101 1
- 561 Hemostatic alterations in patients with cirrhosis and hepatocellular carcinoma: laboratory evidence and clinical implications.. **2022,** 2
- 560 Potentials of Non-Invasive F-FDG PET/CT in Immunotherapy Prediction for Non-Small Cell Lung Cancer.. **2021,** 12, 810011
- 559 Modulation of the tumour microenvironment in hepatocellular carcinoma by tyrosine kinase inhibitors: from modulation to combination therapy targeting the microenvironment.. **2022,** 22, 73 1
- 558 Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function.. **2022,** 2
- 557 Case Report: One-Year Delay in the Effect of Conversion Surgery Therapy for Advanced Hepatocellular Carcinoma After Systemic Therapy.. **2021,** 8, 810251 1
- 556 Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.. **2022,** 13, 778505
- 555 Design, synthesis, and biological evaluation of quinazoline derivatives with covalent reversible warheads as potential FGFR4 inhibitors.. **2022,** 121, 105673 0
- 554 Ethoxy-erianin phosphate and afatinib synergistically inhibit liver tumor growth and angiogenesis via regulating VEGF and EGFR signaling pathways.. **2022,** 438, 115911 0
- 553 Efficacy of the immune checkpoint inhibitor nivolumab in the treatment of advanced hepatocellular carcinoma with the exhausted possibilities of therapy with tyrosine kinase inhibitors. **2021,** 84-93

552	Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy.. 2021 , 13, 9379-9389	0
551	The prominence of potential biomarkers in the diagnosis and management of hepatocellular carcinoma: Current scenario and future anticipation.. 2021 ,	1
550	Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.. 2021 ,	15
549	Case Report: Durable Response to Very Low Dose Tyrosine Kinase Inhibitors in Advanced Hepatocellular Carcinoma.. 2021 , 11, 780798	0
548	Chemotherapeutic Drug-Regulated Cytokines Might Influence Therapeutic Efficacy in HCC.. 2021 , 22,	2
547	Indication of Surgical Hepatectomy for the Patients of Hepatocellular Carcinoma with Inferior Vena Cava Tumor Thrombosis. 2021 , 67, E10-E17	
546	Telomerase in hepatocellular carcinoma. 2022 , 181-197	
545	Investigating the Association between COMMD3 Expression and the Prognosis of Hepatocellular Carcinoma.. 2022 , 13, 1871-1881	0
544	Immunotherapies for hepatocellular carcinoma and intrahepatic cholangiocarcinoma: Current and developing strategies. 2022 ,	
543	Hepatocellular carcinoma—An updated review. 2022 , 11-31	
542	Implications of genetic heterogeneity in hepatocellular cancer. 2022 ,	
541	Perspectives for yttrium-90 radioembolization as therapeutic option for hepatocellular carcinoma.. 2022 , 114,	
540	Combination of ShuangDan Capsule and Sorafenib Inhibits Tumor Growth and Angiogenesis in Hepatocellular Carcinoma Via PI3K/Akt/mTORC1 Pathway.. 2022 , 21, 15347354221078888	0
539	Updates on the staging and treatment of hepatocellular carcinoma. 2022 , 307-319	
538	Role of microRNAs in hepatocellular cancer pathogenesis and prognosis. 2022 , 311-325	
537	Patient-derived functional organoids as a personalized approach for drug screening against hepatobiliary cancers. 2022 ,	
536	Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience.. 2022 , 14, 17588359221080298	0
535	Ginsenoside Rk1 regulates glutamine metabolism in hepatocellular carcinoma through inhibition of the ERK/c-Myc pathway.. 2022 , 13, 3793-3811	

- 534 Hepatopancreaticobiliary Cancer in Older Adults with Frailty. **2022**, 421-445
- 533 The Relationship between albumin-Bilirubin grade and survival in hepatocellular carcinoma patients treated with sorafenib.. **2022**, 25, 173-177
- 532 Highly Potent Immunotoxins Targeting the Membrane-distal N-lobe of GPC3 for Immunotherapy of Hepatocellular Carcinoma.. **2022**, 13, 1370-1384 ○
- 531 Neurological complications of GI cancers. **2022**, 365-386
- 530 Chirurgische Onkologie. **2022**, 369-381
- 529 Long-term remission by nivolumab monotherapy for sorafenib-refractory hepatocellular carcinoma. **2022**, 9, 41 ○
- 528 Impurity Free and Scalable Process of Sorafenib Tosylate: Hepatocellular Carcinoma. **2022**, 34, 711-714
- 527 Nuclear Medicine Therapy in primary liver cancers. **2022**,
- 526 Tyrosine kinases: their role in hepatocellular carcinoma. **2022**, 133-148
- 525 Target therapy in cancer treatment. **2022**,
- 524 Small Molecule Inhibitors That Target Signal Transduction Pathways Involved In Oxidative Stress-Induced Cancer. **2022**, 1-14
- 523 Tumor lysates cancer vaccine. **2022**, 21-49
- 522 Safety and efficacy of prophylactic and therapeutic vaccine based on live-attenuated Listeria monocytogenes in hepatobiliary cancers.. **2022**,
- 521 Rescuing SLAMF3 Expression Restores Sorafenib Response in Hepatocellular Carcinoma Cells through the Induction of Mesenchymal-to-Epithelial Transition.. **2022**, 14, ○
- 520 Two cases of rapid progression of esophageal varices after atezolizumab-bevacizumab treatment for hepatocellular carcinoma.. **2022**, 15, 451 ○
- 519 Tryptophan-sorbitol based carbon quantum dots for theranostics against hepatocellular carcinoma.. **2022**, 20, 78 ○
- 518 ECM Depletion Is Required to Improve the Intratumoral Uptake of Iron Oxide Nanoparticles in Poorly Perfused Hepatocellular Carcinoma.. **2022**, 12, 837234 ○
- 517 PD-1 targeted immunotherapy for advanced hepatocellular carcinoma: current utilization and outcomes in the USA.. **2022**, ○

- 516 Broad Transcriptomic Impact of Sorafenib and Its Relation to the Antitumoral Properties in Liver Cancer Cells.. **2022**, 14,
- 515 Hepatocellular carcinoma after a sustained virological response by direct-acting antivirals harbors TP53 inactivation.. **2022**,
- 514 Glypican-3: A Novel and Promising Target for the Treatment of Hepatocellular Carcinoma.. **2022**, 12, 824208 ○
- 513 Combination therapy of sorafenib and drug-eluting bead transarterial chemoembolization for advanced hepatocellular carcinoma with and without hepatic arteriovenous shunt.. **2022**, 85, ○
- 512 Establishment of a Novel Mouse Hepatocellular Carcinoma Model for Dynamic Monitoring of Tumor Development by Bioluminescence Imaging.. **2022**, 12, 794101 ○
- 511 Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study.. **2022**, 12, 809709 ○
- 510 Sorafenib-Induced Autophagy Promotes Glycolysis by Upregulating the p62/HDAC6/HSP90 Axis in Hepatocellular Carcinoma Cells.. **2021**, 12, 788667 ○
- 509 The clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines: 2022 update.. **2022**, 16, 1
- 508 The Bright and the Dark Side of TGF-β Signaling in Hepatocellular Carcinoma: Mechanisms, Dysregulation, and Therapeutic Implications.. **2022**, 14, ○
- 507 Hypoxia-induced macropinocytosis represents a metabolic route for liver cancer.. **2022**, 13, 954 ○
- 506 Features of modified response evaluation criteria use in solid tumors in patients with hepatocellular carcinoma. **2022**, 27, 33-39
- 505 The dual checkpoint blockade in unresectable hepatocellular carcinoma: Opportunities emerging in clinical trials.. **2022**, ○
- 504 Expression of Podoplanin in Hepatocellular Carcinoma in a Sample of Egyptian Population â Immunohistopathological Study. **2022**, 10, 366-375
- 503 Comparison of External Beam Radiation Therapy Modalities for Hepatocellular Carcinoma With Macrovascular Invasion: A Meta-Analysis and Systematic Review.. **2022**, 12, 829708 ○
- 502 Use of chemotherapy to treat hepatocellular carcinoma.. **2022**, 16, ○
- 501 Therapeutic Vaccines against Hepatocellular Carcinoma in the Immune Checkpoint Inhibitor Era: Time for Neoantigens?. **2022**, 23, ○
- 500 Genome-wide CRISPR screen identifies synthetic lethality between DOCK1 inhibition and metformin in liver cancer.. **2022**, 1
- 499 Ferroptosis in Cancer ImmunotherapyâImplications for Hepatocellular Carcinoma. **2022**, 2, 185-217 ○

- 498 Regorafenib Combined with PD-1 Blockade Immunotherapy versus Regorafenib as Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Study.. **2022**, 9, 157-170 1
- 497 Inhibition of the PINK1-Parkin Pathway Enhances the Lethality of Sorafenib and Regorafenib in Hepatocellular Carcinoma.. **2022**, 13, 851832 0
- 496 Neoadjuvant approaches in hepatocellular carcinoma: There's no time like the present.. **2022**,
- 495 Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook.. **2022**, 9, 233-263 1
- 494 Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma.. **2022**, 1 0
- 493 Knockdown of AKR1C3 Promoted Sorafenib Sensitivity Through Inhibiting the Phosphorylation of AKT in Hepatocellular Carcinoma.. **2022**, 12, 823491 0
- 492 Conversion surgery after preoperative therapy for advanced hepatocellular carcinoma in the era of molecular targeted therapy and immune checkpoint inhibitors.. **2022**, 1 1
- 491 Exosome-Mediated Therapeutic Strategies for Management of Solid and Hematological Malignancies.. **2022**, 11, 0
- 490 Drug delivery strategy in hepatocellular carcinoma therapy.. **2022**, 20, 26 0
- 489 Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indications.. **2022**, 22, 293 0
- 488 FNDC5 Causes Resistance to Sorafenib by Activating the PI3K/Akt/Nrf2 Pathway in Hepatocellular Carcinoma Cells.. **2022**, 12, 852095 0
- 487 Aktuelle Diagnostik und systemische Therapie des hepatozellulären Karzinoms. **2022**, 28, 269-277
- 486 Piperlongumine synergistically enhances the antitumour activity of sorafenib by mediating ROS-AMPK activation and targeting CPSF7 in liver cancer.. **2022**, 177, 106140 0
- 485 Proteomic Analyses Identify Therapeutic Targets in Hepatocellular Carcinoma.. **2022**, 12, 814120 0
- 484 Design, Green Synthesis and Tailoring of Vitamin E TPGS Augmented Niosomal Nano-Carrier of Pyrazolopyrimidines as Potential Anti-Liver and Breast Cancer Agents with Accentuated Oral Bioavailability.. **2022**, 15, 2
- 483 Anti-Cancer Activity of Venom on Hepatocellular Carcinoma in 3D Cell Culture.. **2022**, 27,
- 482 Microvascular Invasion in Hepatocellular Carcinoma: A Review of Its Definition, Clinical Significance, and Comprehensive Management.. **2022**, 2022, 9567041 0
- 481 Efficacy of Lenvatinib and Sorafenib in the Real-World First-Line Treatment of Advanced-Stage Hepatocellular Carcinoma in a Taiwanese Population.. **2022**, 11,

- 480 Breaking the Child-Pugh Dogma in Hepatocellular Carcinoma.. **2022**, JCO2102373 ○
- 479 Cell Differentiation Trajectory in Liver Cirrhosis Predicts Hepatocellular Carcinoma Prognosis and Reveals Potential Biomarkers for Progression of Liver Cirrhosis to Hepatocellular Carcinoma.. **2022**, 13, 858905 ○
- 478 Optimization of the Clinical Effectiveness of Radioembolization in Hepatocellular Carcinoma with Dosimetry and Patient-Selection Criteria.. **2022**, 29, 2422-2434
- 477 Cytoskeletal dynamics regulates stromal invasion behavior of distinct liver cancer subtypes.. **2022**, 5, 202 ○
- 476 The role of long non-coding RNAs in angiogenesis and anti-angiogenic therapy resistance in cancer.. **2022**, 28, 397-407 ○
- 475 GPX2 is a potential therapeutic target to induce cell apoptosis in lenvatinib against hepatocellular carcinoma. **2022**,
- 474 Screening and Validation of a Carvacrol-Targeting Viability-Regulating Protein, SLC6A3, in Liver Hepatocellular Carcinoma.. **2022**, 2022, 3736104
- 473 Predicting Genomic Alterations of Phosphatidylinositol-3 Kinase Signaling in Hepatocellular Carcinoma: A Radiogenomics Study Based on Next-Generation Sequencing and Contrast-Enhanced CT.. **2022**, 1 1
- 472 Circulating Cell-Free DNA Captures the Intratumor Heterogeneity in Multinodular Hepatocellular Carcinoma.. **2022**, 6, e2100335 1
- 471 Diabetes Medications and Risk of Hepatocellular Carcinoma.. **2022**, ○
- 470 Immune Checkpoint Blockade in Chinese Patients With Hepatocellular Carcinoma: Characteristics and Particularity.. **2022**, 12, 764923
- 469 Successful treatment with laparoscopic surgery and sequential multikinase inhibitor therapy for hepatocellular carcinoma: A case report.. **2022**, 14, 260-267
- 468 Which FLT3 Inhibitor for Treatment of AML?. **2022**, 23, 359 ○
- 467 Transarterial Chemoembolization Combined With Tyrosine Kinase Inhibitors for Intermediate-Stage Hepatocellular Carcinoma, What Else Can We Do?. **2022**, 12, 824799 ○
- 466 Context dependent isoform specific PI3K inhibition confers drug resistance in hepatocellular carcinoma cells.. **2022**, 22, 320 ○
- 465 Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study.. **2022**, 13, 848387 ○
- 464 Cardiotoxicity Induced by Protein Kinase Inhibitors in Patients with Cancer.. **2022**, 23, ○
- 463 Increased CD8+ T-Cell Infiltration and Efficacy for Multikinase Inhibitors after PD-1 Blockade in Hepatocellular Carcinoma.. **2022**, ○

- 462 AGA Technical Review on Systemic Therapies for Hepatocellular Carcinoma.. **2022**, 162, 937-951 2
- 461 Contrast-enhanced MRI could predict response of systemic therapy in advanced intrahepatic cholangiocarcinoma.. **2022**, 1
- 460 Effectiveness of TKI Inhibitors Combined With PD-1 in Patients With Postoperative Early Recurrence of HCC: A Real-World Study.. **2022**, 12, 833884
- 459 Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis.. **2022**, 22, 135
- 458 Safety and Efficacy of Sorafenib and Lenvatinib in Patients Who Underwent Surgery or Whole-Brain Radiotherapy for Brain Metastasis of Hepatocellular Carcinoma.. **2022**, 11,
- 457 Clinical usefulness of geriatric assessment in elderly patients with unresectable hepatocellular carcinoma receiving sorafenib or lenvatinib therapy.. **2022**, e1613 ○
- 456 Anti-angiogenic effect of the combination low-dose sorafenib and EGCG in HCC-induced Wistar rats. 11, 289
- 455 A novel AMPK activator shows therapeutic potential in hepatocellular carcinoma by suppressing HIF1 β -mediated aerobic glycolysis.. **2022**, ○
- 454 Inflammatory Response-Related Long Non-Coding RNA Signature Predicts the Prognosis of Hepatocellular Carcinoma.. **2022**, 2022, 9917244 ○
- 453 Expanding the immunotherapy roadmap for hepatocellular carcinoma.. **2022**, 40, 252-254
- 452 Novel Perspectives in Immune Checkpoint Inhibitors and the Management of Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma.. **2022**, 14, ○
- 451 Why does survival of hepatocellular carcinoma patients remain so low? Key stumbling blocks and questions in preclinical and clinical development.. **2022**, ○
- 450 Integrin subunit beta 8 contributes to lenvatinib resistance in HCC.. **2022**,
- 449 Repurposing Live Attenuated Trivalent MMR Vaccine as Cost-effective Cancer Immunotherapy.
- 448 AGA Clinical Practice Guideline on Systemic Therapy for Hepatocellular Carcinoma.. **2022**, 162, 920-934 2
- 447 Consensus subtypes of hepatocellular carcinoma associated with clinical outcomes and genomic phenotypes.. **2022**,
- 446 microRNA-106b-5p Promotes Cell Growth and Sensitizes Chemosensitivity to Sorafenib by Targeting the BTG3/Bcl-xL/p27 Signaling Pathway in Hepatocellular Carcinoma.. **2022**, 2022, 1971559 ○
- 445 Synthesis, and docking studies of novel heterocycles incorporating the indazolylthiazole moiety as antimicrobial and anticancer agents.. **2022**, 12, 3424 1

- 444 A clinical and pathological update on hepatocellular carcinoma. **2022**, 22, 14-22
- 443 Changes in Body Composition Predict the Time to Treatment Failure of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma: A Pilot Retrospective Study.. **2022**, 1-10
- 442 A Gene Co-Expression Network-Based Drug Repositioning Approach Identifies Candidates for Treatment of Hepatocellular Carcinoma.. **2022**, 14, 1
- 441 Tumor Treating Fields Concomitant with Sorafenib in Advanced Hepatocellular Cancer: Results of the HEPANOVA Phase II Study.. **2022**, 14, 0
- 440 Rapidly Evolving Landscape and Future Horizons in Hepatocellular Carcinoma in the Era of Immuno-Oncology.. **2022**, 12, 821903 0
- 439 Phase II clinical trial of cabozantinib for the treatment of recurrent hepatocellular carcinoma after liver transplantation.. **2022**,
- 438 Transcriptome Analysis of Liver Cancer Cell Huh-7 Treated With Metformin.. **2022**, 13, 822023 0
- 437 Transcriptional suppression of Dicer by HOXB-AS3/EZH2 complex dictates Sorafenib resistance and cancer stemness.. **2022**, 0
- 436 Cholesterol sensor SCAP contributes to sorafenib resistance by regulating autophagy in hepatocellular carcinoma.. **2022**, 41, 116 0
- 435 Early Predictive Value of Circulating Biomarkers for Sorafenib in Advanced Hepatocellular Carcinoma.. **2022**, 0
- 434 The Treatment Landscape of Advanced Hepatocellular Carcinoma.. **2022**, 1 1
- 433 Deciphering the heterogeneous niche in the tumor progression of hepatocellular carcinoma: a Spatial single-cell landscape and multi-omics atlas analysis.
- 432 The Role of Ferroptosis in the Treatment and Drug Resistance of Hepatocellular Carcinoma.. **2022**, 10, 845232 0
- 431 SPC25 promotes hepatocellular carcinoma metastasis via activating the FAK/PI3K/AKT signaling pathway through ITGB4.. **2022**, 47, 1
- 430 The impact of VEGF on cancer metastasis and systemic disease.. **2022**, 1
- 429 Clinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinoma.. **2022**, 17, e0265235
- 428 DUB3/KLF4 combats tumor growth and chemoresistance in hepatocellular carcinoma.. **2022**, 8, 166
- 427 Cabozantinib enhances anti-PD1 activity and elicits a neutrophil-based immune response in hepatocellular carcinoma.. **2022**, 0

- 426 Combined Hepatocellular-Cholangiocarcinoma: What the Multidisciplinary Team Should Know.. **2022**, 12, 1
- 425 Is hepatocellular carcinoma complicated with portal vein tumor thrombosis potentially curable by radiotherapy in the form of stereotactic body radiation therapy?. **2022**, 1-54
- 424 Metformin treatment rescues CD8 T cell response to immune checkpoint inhibitor therapy in mice with NAFLD.. **2022**, 1
- 423 Aryl Hydrocarbon Receptor: From Homeostasis to Tumor Progression.. **2022**, 10, 884004 0
- 422 Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study.. **2022**, 6
- 421 Prognostic comparative genes predict targets for sorafenib combination therapies in hepatocellular carcinoma.. **2022**, 20, 1752-1763
- 420 Predictors of mortality within the first year post-hepatectomy for hepatocellular carcinoma.. **2022**, 34, 14
- 419 Prognostic value of PD-L1 expression combined with hypoxia-associated immunosuppression in hepatocellular carcinoma.. **2022**,
- 418 Radiomics signature: A potential biomarker for Errestin1 phosphorylation prediction in hepatocellular carcinoma.. **2022**, 28, 1479-1493 0
- 417 Ferroptosis in Hepatocellular Carcinoma: Mechanisms, Drug Targets and Approaches to Clinical Translation.. **2022**, 14, 0
- 416 Combined Targeting of AKT and mTOR Inhibits Tumor Formation of EpCAM and CD90 Human Hepatocellular Carcinoma Cells in an Orthotopic Mouse Model.. **2022**, 14, 1
- 415 Letter to the Editor: Prognostic prediction for patients with hepatocellular carcinoma receiving immunotherapy: Are we there yet? - authors' reply.. **2021**,
- 414 Immune checkpoint inhibitors for hepatocellular carcinoma - A game changer in treatment landscape.. **2022**,
- 413 Hepatitis B Virus-Associated Hepatocellular Carcinoma and Chronic Stress.. **2022**, 23, 0
- 412 Physical activity improves outcomes of combined lenvatinib plus anti-PD-1 therapy in unresectable hepatocellular carcinoma: a retrospective study and mouse model.. **2022**, 11, 20
- 411 Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trial.. **2022**, 12, e059779
- 410 Activation of YAP1 by STK25 contributes to the progression of hepatocellular carcinoma.. **2022**, 76, 101797
- 409 Circumsporozoite Protein of - and George Baker Virus A-Derived Peptides Trigger Efficient Cell Internalization of Bioconjugates and Functionalized Poly(ethylene glycol)--poly(benzyl malate)-Based Nanoparticles in Human Hepatoma Cells.. **2022**, 14, 0

- 408 Emerging Immunotherapy for Hepatocellular Carcinoma: A Guide for Hepatologists.. **2022**, 2
- 407 Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.. **2022**, 167, 1-12 ○
- 406 Design, synthesis, antitumor, and VEGFR-2 inhibition activities of novel 4-anilino-2-vinyl-quinazolines: Molecular modeling studies.. **2022**, 122, 105710 ○
- 405 SMYD5 acts as a potential biomarker for hepatocellular carcinoma.. **2022**, 113076
- 404 Myeloid-derived suppressor cells promote tumor growth and sorafenib resistance by inducing FGF1 upregulation and fibrosis.. **2022**, 28, 100788 ○
- 403 Safety, efficacy, and tolerability of immune checkpoint inhibitors in the treatment of hepatocellular carcinoma.. **2022**, 42, 101748 ○
- 402 Integrated Analysis of Angiogenesis-Mediated Tumor Immune Microenvironment Pattern in Hepatocellular Carcinoma (HCC) and a Novel Prognostic Model Construction to Predict Patient Outcome.. **2021**, 27, e934937
- 401 Validation of the prophylactic efficacy of urea-based creams on sorafenib-induced hand-foot skin reaction in patients with advanced hepatocellular carcinoma: A randomised experiment study.. **2021**, e1532
- 400 Three-Dimensional Cell Culture Models of Hepatocellular Carcinoma - a Review.. **2021**, 52, 1294 ○
- 399 Data Centric Molecular Analysis and Evaluation of Hepatocellular Carcinoma Therapeutics Using Machine Intelligence-Based Tools.. **2021**, 52, 1266
- 398 Growth differentiation factor 1-induced tumour plasticity provides a therapeutic window for immunotherapy in hepatocellular carcinoma. **2021**, 12, 7142 ○
- 397 Significant response to atezolizumab plus bevacizumab treatment in unresectable hepatocellular carcinoma with major portal vein tumor thrombus: a case report.. **2021**, 21, 470 ○
- 396 Programmed Cell Death 1 and Hepatocellular Carcinoma: An Epochal Story.. **2021**, 52, 1217
- 395 Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy.. **2021**, 3
- 394 Treatment of hepatocellular carcinoma with autologous platelets encapsulating sorafenib or lenvatinib: A novel therapy exploiting tumor-platelet interactions.. **2021**, ○
- 393 Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma.. **2022**, 11, 48-60 ○
- 392 Patients' Experience of Systemic Treatment of Hepatocellular Carcinoma: A Review of the Impact on Quality of Life.. **2021**, 14,
- 391 Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors.. **2021**, 12, 794099 ○

- 390 FGFR4 inhibitors for the treatment of hepatocellular carcinoma: a synopsis of therapeutic potential.. **2021**, 1-8 1
- 389 Trends of Clinical Outcomes of Patients with Advanced Hepatocellular Carcinoma Treated with First-Line Sorafenib in Randomized Controlled Trials.. **2022**, 9, 19-26
- 388 Comparative assessment of standard and immune response criteria for evaluation of response to PD-1 monotherapy in unresectable HCC.. **2021**, 47, 969 1
- 387 First-Line Systemic Treatment Strategies for Unresectable Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials.. **2021**, 11, 771045 1
- 386 Response Evaluation and Survival Prediction Following PD-1 Inhibitor in Patients With Advanced Hepatocellular Carcinoma: Comparison of the RECIST 1.1, iRECIST, and mRECIST Criteria.. **2021**, 11, 764189 1
- 385 Cell Death in Hepatocellular Carcinoma: Pathogenesis and Therapeutic Opportunities.. **2021**, 14, 1
- 384 Liver Transplantation for Hepatocellular Carcinoma after Downstaging or Bridging Therapy with Immune Checkpoint Inhibitors.. **2021**, 13, 1
- 383 Upper Limits of Downstaging for Hepatocellular Carcinoma in Liver Transplantation.. **2021**, 13,
- 382 Comparative study between sorafenib and lenvatinib as the first-line therapy in the sequential treatment of unresectable hepatocellular carcinoma in a real-world setting.. **2022**, 6, 29-35
- 381 Identification of seven-gene marker to predict the survival of patients with lung adenocarcinoma using integrated multi-omics data analysis.. **2021**, e24190 3
- 380 Demystifying Lysosomal α -Fucosidase in Liver Cancer-Bearing Mice by Specific Two-Photon Fluorescence Imaging.. **2021**, 0
- 379 A targetable LIFR-NF- κ B-LCN2 axis controls liver tumorigenesis and vulnerability to ferroptosis.. **2021**, 12, 7333 7
- 378 Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Meta-analysis. **2021**, 4, e2136128 1
- 377 HBV-HCC treatment with mRNA electroporated HBV-TCR T cells. **2022**, 2,
- 376 Wavelength Independent Photo-Chemo Tri-Modal Combinatorial Renal Cell Carcinoma Therapy with Biocompatible Gold-Titania Nanostars. **2022**, 5, 2100204
- 375 Unique situation of hepatocellular carcinoma in Egypt: A review of epidemiology and control measures.. **2021**, 13, 1919-1938 0
- 374 Low Inorganic Phosphate Stress Inhibits Liver Cancer Progression: from In Vivo to In Vitro. **2022**, 5, 2100224 2
- 373 Transarterial Chemoembolization (TACE) Combined With Sorafenib versus TACE in Patients With BCLC Stage C Hepatocellular Carcinoma â A Retrospective Study. **2021**,

372	Surgery for hepatocellular carcinoma with tumor thrombosis in inferior vena cava: A case report.. 2021 , 9, 11495-11503	
371	A Retrospective Study of Lenvatinib Monotherapy or Combined With Programmed Cell Death Protein 1 Antibody in the Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma in China.. 2021 , 11, 788635	0
370	Systematic characterization of the tumor microenvironment in Chinese patients with hepatocellular carcinoma highlights intratumoral B´cells as a potential immunotherapy target.. 2022 , 47,	1
369	Body Composition as a Novel Prognostic Biomarker for the Patients with Advanced Hepatocellular Carcinoma. 2021 , 70, 157-164	
368	Prospect of lenvatinib for unresectable hepatocellular carcinoma in the new era of systemic chemotherapy.. 2021 , 13, 2076-2087	
367	Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib.. 2021 , 27, 8166-8181	0
366	Favorable response to multimodal treatment in hepatocellular carcinoma with inferior vena cava and right atrial tumor thrombus and left adrenal gland metastasis: A case report and literature review. 2021 , 100, e27987	1
365	Is There Still a Place for Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma at the Time of Immunotherapies? A Focus on Lenvatinib.. 2021 , 13,	0
364	Current status of first-line therapy, anti-angiogenic therapy and its combinations of other agents for unresectable hepatocellular carcinoma.. 2021 , 13, 2038-2049	1
363	Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC-B stage patients classified as beyond up to seven criteria - Multicenter analysis. 2021 ,	0
362	Immuno-Metabolic Modulation of Liver Oncogenesis by the Tryptophan Metabolism.. 2021 , 10,	0
361	Comprehensive analysis of spatial architecture in primary liver cancer.. 2021 , 7, eabg3750	2
360	Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment.. 2021 , 14,	1
359	Oncogenic Activation of YAP Signaling Sensitizes Ferroptosis of Hepatocellular Carcinoma ALOXE3-Mediated Lipid Peroxidation Accumulation.. 2021 , 9, 751593	0
358	Biological therapies in patients with liver disease: are they really lifesavers?. 2021 ,	
357	Mouse characteristics that affect establishing xenografts from hepatocellular carcinoma patient biopsies in the United States.. 2021 ,	1
356	Clinical Significance of Sarcopenia in Patients with Advanced Hepatocellular Carcinoma Undergoing Sorafenib Treatment. 2021 , 13, 62-67	
355	Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells. 2021 , 22,	1

- 354 Targeting chromatin: Transcriptional gene activation (saRNA). **2022**, 3-16
- 353 Survival Outcomes and Safety of Programmed Cell Death/Programmed Cell Death Ligand 1 Inhibitors for Unresectable Hepatocellular Carcinoma: Result From Phase III Trials.. **2022**, 29, 10732748221092924
- 352 Designing of nanocarriers for liver targeted drug delivery and diagnosis. **2022**, 45-75
- 351 Frontline therapy for advanced hepatocellular carcinoma: an update.. **2022**, 15, 17562848221086126 ○
- 350 The Use of Transcatheter Arterial Embolization and Systemic Therapy for the Treatment of Hepatocellular Carcinoma. **2022**, 81, 11-17
- 349 Different Radiological Criteria for Early Tumor Response Evaluation in Patients With Unresectable Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody Plus Bevacizumab.. **2022**, 12, 848129
- 348 Prognosis of hepatocellular carcinoma and its association with immune cells using systemic inflammatory response index.. **2022**,
- 347 Racial and ethnic disparities in early treatment with immunotherapy for advanced hepatocellular carcinoma in the United States.. **2022**, ○
- 346 Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment.. **2022**, 1
- 345 MicroRNA-146a promotes proliferation, migration, and invasion of HepG2 via regulating FLAP.. **2022**, 22, 149
- 344 Sorafenib Versus Lenvatinib-Based Sequential Systemic Therapy for Advanced Hepatocellular Carcinoma: A Real-World Analysis.. **2022**, 14,
- 343 EGFR/MET promotes hepatocellular carcinoma metastasis by stabilizing tumor cells and resisting to RTKs inhibitors in circulating tumor microemboli.. **2022**, 13, 351 ○
- 342 Pembrolizumab monotherapy for previously untreated advanced hepatocellular carcinoma: data from the open-label, phase 2 KEYNOTE-224 trial.. **2022**, ○
- 341 Immune Checkpoint Inhibitors as Therapy to Down-Stage Hepatocellular Carcinoma Prior to Liver Transplantation.. **2022**, 14, ○
- 340 Development and Validation of TACE Refractoriness-Related Diagnostic and Prognostic Scores and Characterization of Tumor Microenvironment Infiltration in Hepatocellular Carcinoma.. **2022**, 13, 869993 ○
- 339 Determinants of Survival and Post-Progression Outcomes by Sorafenib-Regorafenib Sequencing for Unresectable Hepatocellular Carcinoma.. **2022**, 14, ○
- 338 MBP-11901 Inhibits Tumor Growth of Hepatocellular Carcinoma through Multitargeted Inhibition of Receptor Tyrosine Kinases.. **2022**, 14,
- 337 TIPS plus sequential systemic therapy of advanced HCC patients with tumour thrombus-related symptomatic portal hypertension.. **2022**, 1

- 336 CT-707 overcomes hypoxia-mediated sorafenib resistance in Hepatocellular carcinoma by inhibiting YAP signaling.. **2022**, 22, 425
- 335 Clinical efficacy and safety of external radiotherapy combined with sorafenib in the treatment of hepatocellular carcinoma: A systematic review and meta-analysis.. **2022**, 100710
- 334 Efficacy of Nanofiber Sheets Incorporating Lenvatinib in a Hepatocellular Carcinoma Xenograft Model.. **2022**, 12,
- 333 Safety and Long-Term Survival Outcome in Patients With Unresectable Barcelona Clinic Liver Cancer (BCLC) Stages C and D Advanced Hepatocellular Carcinoma Treated With 40 Gh Drug-Eluting Bead Transcatheter Arterial Chemoembolization.. **2022**, 14, e24047
- 332 Influence of skeletal muscle volume loss during lenvatinib treatment on prognosis in unresectable hepatocellular carcinoma: a multicenter study in Tohoku, Japan.. **2022**, 12, 6479 ○
- 331 Outcomes and Toxicities of Modern Combined Modality Therapy with Atezolizumab Plus Bevacizumab and Radiation Therapy for Hepatocellular Carcinoma.. **2022**, 14, ○
- 330 In Vitro Angiogenesis Inhibition and Endothelial Cell Growth and Morphology.. **2022**, 23,
- 329 Design, synthesis and biological evaluation of 3-arylisoquinoline derivatives as topoisomerase I and II dual inhibitors for the therapy of liver cancer.. **2022**, 237, 114376
- 328 Association between Hepatic Oxidative Stress Related Factors and Activation of Wnt/ β Catenin Signaling in NAFLD-Induced Hepatocellular Carcinoma.. **2022**, 14, ○
- 327 Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma.. **2022**, 14, ○
- 326 Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis.. **2022**, ○
- 325 Conversion surgery for hepatocellular carcinoma after tyrosine kinase inhibitor treatment. ○
- 324 CCDC88A Post-Transcriptionally Regulates VEGF miR-101 and Subsequently Regulates Hepatocellular Carcinoma.. **2022**, 13, 859331 ○
- 323 Efficacy and safety of PD-1 inhibitor combined with antiangiogenic therapy for unresectable hepatocellular carcinoma: A multicenter retrospective study.. **2022**, ○
- 322 Metastatic hepatocellular carcinoma to the bone diagnosed by fine needle aspiration in a veteran population.. **2022**,
- 321 HSPB11 is a Prognostic Biomarker Associated with Immune Infiltrates in Hepatocellular Carcinoma.. **2022**, 15, 4017-4027
- 320 Examination of factors contributing to the prognosis in TACE treatment of hepatocellular carcinoma. **2022**, 63, 187-195
- 319 Quantitative proteomic profiling of hepatocellular carcinoma at different serum alpha-fetoprotein level.. **2022**, 20, 101422

318 Data_Sheet_1.pdf. **2020**,

317 Image_1.pdf. **2018**,

316 Image_1.TIF. **2019**,

315 Image_2.TIF. **2019**,

314 Image_3.TIF. **2019**,

313 Image_4.TIF. **2019**,

312 Table_1.docx. **2019**,

311 Table_1.DOCX. **2019**,

310 Table_1.docx. **2020**,

309 Table_2.docx. **2020**,

308 Table_3.docx. **2020**,

307 Data_Sheet_1.pdf. **2019**,

306 Data_Sheet_1.DOCX. **2020**,

305 DataSheet_1.pdf. **2020**,

304 Data_Sheet_1.docx. **2018**,

303 Table_1.xls. **2019**,

302 Data_Sheet_1.PDF. **2019**,

301 Data_Sheet_1.doc. **2019**,

300 Presentation_1.PPTX. 2019,

299 Presentation_2.PPTX. 2019,

298 Presentation_3.PPTX. 2019,

297 Presentation_4.PPTX. 2019,

296 Presentation_1.pdf. 2019,

295 Image_1.TIF. 2018,

294 Image_2.TIF. 2018,

293 Image_3.TIF. 2018,

292 Presentation_1.PDF. 2018,

291 Table_1.DOCX. 2018,

290 Image_1.TIF. 2020,

289 Table_1.pdf. 2020,

288 Image_1.TIF. 2019,

287 Image_2.tif. 2019,

286 Image_3.TIF. 2019,

285 Data_Sheet_1.docx. 2020,

284 Image_1.TIFF. 2018,

283 Table_1.XLSX. 2018,

282 Table_2.xlsx. **2018,**

281 Data_Sheet_1.docx. **2019,**

280 Fluorescence-Reporting-Guided Tumor Acidic Environment-Activated Triple Photodynamic, Chemodynamic, and Chemotherapeutic Reactions for Efficient Hepatocellular Carcinoma Cell Ablation.. **2022,**

279 Galectin-1 orchestrates an inflammatory tumor-stroma crosstalk in hepatoma by enhancing TNFR1 protein stability and signaling in carcinoma-associated fibroblasts.. **2022,** ○

278 A multidisciplinary approach to peritoneal metastasis from hepatocellular carcinoma: clinical features, management and outcomes.. **2022,** 8, 42-48

277 Updates on clinical trials for the management of hepatocellular carcinoma. **2022,** 259-273

276 Pharmacogenomics and outcomes for hepatocellular cancer treatment. **2022,** 401-414

275 Recent advances in medical treatment of hepatocellular cancer. **2022,** 365-375

274 Immunotherapy for hepatocellular cancer: a review of current status. **2022,** 245-258

273 mTOR regulates aerobic glycolysis through NEAT1 and nuclear paraspeckle-mediated mechanism in hepatocellular carcinoma.. **2022,** 12, 3518-3533 ○

272 Liver Tumors. **2022,** 279-289

271 Precision medicine approaches for treating hepatocellular carcinoma. **2022,** 287-299

270 Sorafenib-Induced Liver Failure in a Hepatocellular Carcinoma Patient: Letter to the editor.. **2022,** 46, 101931 ○

269 The Prognostic Significance and Potential Mechanism of Ferroptosis-Related Genes in Hepatocellular Carcinoma.. **2022,** 13, 844624

268 Consideration of Management Techniques for Advanced Hepatocellular Carcinoma With Metastasis to the Right Atrium: A Case Report. **2022,**

267 The AGH score is a predictor of disease-free survival and targeted therapy efficacy after liver transplantation in patients with hepatocellular carcinoma.. **2022,**

266 An Overview of Hepatocellular Carcinoma After Insufficient Radiofrequency Ablation.. **2022,** 9, 343-355

265 Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience.. **2022,** ○

- 264 Apparent Diffusion Coefficient MRI Shows Association With Early Progression of Unresectable Intrahepatic Cholangiocarcinoma With Combined Targeted-Immunotherapy.. **2022,**
- 263 Predictive significance of circulating histones in hepatocellular carcinoma patients treated with sorafenib.. **2022,**
- 262 Advanced hepatocellular carcinoma: Impact of systemic treatments on health-related quality of life and patient-reported outcomes.
- 261 An Insight into the Novel Immunotherapy and Targeted Therapeutic Strategies for Hepatocellular Carcinoma and Cholangiocarcinoma. **2022, 12, 665** ○
- 260 Own Experience of Using Lenvatinib in Patients with Advanced Hepatocellular Carcinoma in Real Clinical Practice based on Moscow City Oncological Hospital. **2022, 24, 106-109**
- 259 Modulation of the Gut Microbiome to Improve Clinical Outcomes in Hepatocellular Carcinoma.. **2022, 14,**
- 258 Neoadjuvant Therapy With Cabozantinib as a Bridge to Liver Transplantation in Patients With Hepatocellular Carcinoma (HCC): A Case Report. **2022, 1,**
- 257 Child-Pugh Score and -rs2231142 Genotype Independently Predict Survival in Advanced Hepatoma Patients Treated with Sorafenib.. **2022, 11,**
- 256 Hepatocellular Carcinoma: The Role of MicroRNAs. **2022, 12, 645** ○
- 255 Hepatitis B Virus-Associated Hepatocellular Carcinoma. **2022, 14, 986** ○
- 254 HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy.. **2022, 132,** ○
- 253 Activity and Tissue Distribution of Antisense Oligonucleotide CT102 Encapsulated with Cytidiny/Cationic Lipid against Hepatocellular Carcinoma.. **2022,** ○
- 252 New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma.. **2022, 1**
- 251 Therapeutic Management of Advanced Hepatocellular Carcinoma: An Updated Review. **2022, 14, 2357** ○
- 250 Immunotherapy-Based Treatments of Hepatocellular Carcinoma: Expert Panel Narrative Review.. **2022,**
- 249 Immunotherapy and Microbiota for Targeting of Liver Tumor-Initiating Stem-like Cells. **2022, 14, 2381**
- 248 A Novel and Robust Prognostic Model for Hepatocellular Carcinoma Based on Enhancer RNAs-Regulated Genes. **2022, 12,**
- 247 Circulating tumor cells: A step toward precision medicine in hepatocellular carcinoma.. **2022,** ○

- 246 Checkpoint inhibition in hepatocellular carcinoma: Outsmarting the Squid Game. **2022**, 5, 165-168
- 245 Hepatitis C virus eradication ameliorates the prognosis of advanced hepatocellular carcinoma treated with sorafenib.. **2022**, ○
- 244 Lipolysis-Stimulated Lipoprotein Receptor Impairs Hepatocellular Carcinoma and Inhibits the Oncogenic Activity of YAP1 PPPY Motif.. **2022**, 12, 896412
- 243 Artemyrianosins A-J, cytotoxic germacrane-type sesquiterpene lactones from *Artemisia myriantha*.. **2022**, 12, 16
- 242 Zn Mediated Urea Bond Formation: A Novel and Convenient Method. **2022**, 7, ○
- 241 Case Report: Radiotherapy Plus Immunotherapy and Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma With a Right Atrium and Inferior Vena Cava Tumor Thrombus. **2022**, 12, ○
- 240 Rejuvenating hepatic tumor microenvironment immunity with a phosphatidylserine-targeting small molecule drug conjugate.. **2022**, 151, 113084
- 239 Molecular docking analysis of piperlongumine with different apoptotic proteins involved in Hepatocellular Carcinoma.. **2021**, 17, 829-833
- 238 Molecular pathogenesis and systemic therapies for hepatocellular carcinoma.. **2022**, 3, 386-401 ○
- 237 Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC.. **2022**,
- 236 Identification of Context-Specific Fitness Genes Associated With Metabolic Rearrangements for Prognosis and Potential Treatment Targets for Liver Cancer. **2022**, 13,
- 235 EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells.. **2022**, 12, 8007
- 234 Liver (Hepatocellular) Cancer. **2022**, 247-257
- 233 Right hepatic vein reconstruction in middle hepatectomy: A case report.. **2022**, 95, 107188
- 232 Molecular imaging: The convergence of form and function. 14-24
- 231 Immune cell infiltration and immunotherapy in hepatocellular carcinoma. **2022**, 19, 7178-7200
- 230 The Efficacy and Safety of Transarterial Chemoembolization Plus Iodine 125 Seed Implantation in the Treatment of Hepatocellular Carcinoma With Oligometastases: A Case Series Reports. **2022**, 12,
- 229 Efficacy and Safety of Apatinib in Advanced Hepatocellular Carcinoma: A Multicenter Real World Retrospective Study. **2022**, 13,

- 228 MiR-129-5p exerts Wnt signaling-dependent tumor-suppressive functions in hepatocellular carcinoma by directly targeting hepatoma-derived growth factor HDGF.. **2022**, 22, 192 ○
- 227 Real-World Assessment of Cancer Drugs Using Local Data Uploaded to the Systemic Anti-Cancer Therapy Dataset in England.. **2022**,
- 226 A case of conversion hepatectomy for huge hepatocellular carcinoma with adrenal metastasis and vascular invasion after atezolizumab-bevacizumab treatment.. **2022**, ○
- 225 C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib.. **2022**, 12, 8421
- 224 Experimental drug treatments for hepatocellular carcinoma: Clinical trial failures 2015 to 2021.. **2022**,
- 223 Hepatic arterial infusion chemotherapy versus transarterial chemoembolization for patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis.. **2022**, 1-9 ○
- 222 Impact of lenvatinib on renal function compared to sorafenib for unresectable hepatocellular carcinoma.. **2022**, 101, e29289
- 221 Predicting Clinical Trial Outcomes Using Drug Bioactivities through Graph Database Integration and Machine Learning.. **2022**,
- 220 Proton beam radiotherapy combined with anti-PD1/PDL1 immune checkpoint inhibitors for advanced hepatocellular carcinoma.. **2022**, 12, 1606-1620
- 219 Targeting the altered tyrosine kinases in colorectal cancer: From inhibitors to drugs. **2022**, 361-391
- 218 Real-world efficacy and safety of cabozantinib in Korean patients with advanced hepatocellular carcinoma: a multicenter retrospective analysis. **2022**, 14, 175883592210979
- 217 Protein kinase inhibitors and cancer targeted therapy. **2022**, 23-70
- 216 Durable objective response to sorafenib and role of sequential treatment in unresectable hepatocellular carcinoma. **2022**, 14, 175883592210994
- 215 Effectiveness and Safety of Anlotinib with or without PD-1 Blockades in the Treatment of Patients with Advanced Primary Hepatocellular Carcinoma: A Retrospective, Real-World Study in China. Volume 16, 1483-1493
- 214 Significance of post-progression therapy after tyrosine kinase inhibitors for advanced hepatocellular carcinoma.
- 213 In Vitro Cell Density Determines the Sensitivity of Hepatocarcinoma Cells to Ascorbate. **2022**, 12,
- 212 II Consenso mexicano de carcinoma hepatocelular. Parte II: tratamiento. **2022**,
- 211 Combination TACE and SBRT for Unresectable Single Large HCC: Results from a Prospective Phase II Trial. **2022**,

- 210 Effect of CRISPR Knockout of AXIN1 or ARID1A on Proliferation and Migration of Porcine Hepatocellular Carcinoma. **2022**, 12,
- 209 Members of the Chromobox Family Have Prognostic Value in Hepatocellular Carcinoma. **2022**, 13,
- 208 Hepatobiliary Cancers. **2022**, 311-355
- 207 Apigenin alleviates cancer drug Sorafenib induced multiple toxic effects in Swiss albino mice via anti-oxidative stress. **2022**, 447, 116072 ○
- 206 Development and Validation of a Novel Nomogram for Predicting Vessels that Encapsulate Tumor Cluster in Hepatocellular Carcinoma. **2022**, 29, 107327482211028
- 205 Multifocal Hepatocellular Carcinoma: Genomic and Transcriptional Heterogeneity. **2022**, 71-75
- 204 Immune-Checkpoint Inhibitors in Hepatocellular Carcinoma. **2022**, 177-183
- 203 An exploratory clinical trial of apatinib combined with intensity-modulated radiation therapy for patients with unresectable hepatocellular carcinoma. ○
- 202 Indonesian consensus on systemic therapies for hepatocellular carcinoma.
- 201 Safety and Efficacy of Sintilimab and Anlotinib as First Line Treatment for Advanced Hepatocellular Carcinoma (KEEP-G04): A Single-Arm Phase 2 Study. 12, ○
- 200 Ferroptosis at the crossroads of tumor-host interactions, metastasis, and therapy response.
- 199 Bevacizumab, With Sorafenib and Cyclophosphamide Provides Clinical Benefit for Recurrent or Refractory Osseous Sarcomas in Children and Young Adults. 12,
- 198 Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy. **2022**, 11, ○
- 197 Molecular targeted drugs, comprehensive classification and preclinical models for the implementation of precision immune oncology in hepatocellular carcinoma. ○
- 196 Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice. ○
- 195 Augmented Efficacy of Uttroside B over Sorafenib in a Murine Model of Human Hepatocellular Carcinoma. **2022**, 15, 636
- 194 Myricetin Induces Apoptosis and Protective Autophagy through Endoplasmic Reticulum Stress in Hepatocellular Carcinoma. **2022**, 2022, 1-13
- 193 Hepatocellular Carcinoma: Pick the Winner—Tyrosine Kinase Inhibitor Versus Immuno-oncology Agent—Based Combinations.

- 192 Durable complete response is achieved by balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma. ○
- 191 A Phase I Study of Locoregional High-Dose Autologous Natural Killer Cell Therapy With Hepatic Arterial Infusion Chemotherapy in Patients With Locally Advanced Hepatocellular Carcinoma. **2022**, 13,
- 190 Emerging drugs for the treatment of hepatocellular carcinoma. 1-9
- 189 RECIST 1.1 versus mRECIST for assessment of tumour response to molecular targeted therapies and disease outcomes in patients with hepatocellular carcinoma: a systematic review and meta-analysis. **2022**, 12, e052294
- 188 Comparison of nivolumab and sorafenib for first systemic therapy in patients with hepatocellular carcinoma and Child-Pugh B cirrhosis.
- 187 First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination. **2022**, 10, 1304 ○
- 186 A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors. **2022**, 41,
- 185 Does first-line treatment have prognostic impact for unresectable HCC ?âAtezolizumab plus bevacizumab versus lenvatinib.
- 184 Hepatobiliary carcinomas. **2023**, 358-365
- 183 Treatment of biliary tract carcinoma over the last 30 years. **2022**,
- 182 The Research Progress in Bone Metastasis of Hepatocellular Carcinoma. **2022**, 12, 5434-5440
- 181 Imaging response assessment for oncology: An algorithmic approach. **2022**, 9, 100426 ○
- 180 CLIC1 Drives Angiogenesis in Hepatocellular Carcinoma by Modulating VEGFA. **2022**, 21, 153303382211068
- 179 Application of Serum Biomarkers in Early Diagnosis and Prognosis of Hepatocellular Carcinoma. **2022**, 12, 5446-5453
- 178 Hepatocarcinoma: experiencia de la vida real en un centro especializado de Bogot Colombia. **2022**, 37, 163-173
- 177 Design, Synthesis, and Biological Evaluation of Novel Evodiamine Derivatives as Potential Antihepatocellular Carcinoma Agents. **2022**, 65, 7975-7992
- 176 Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. ○
- 175 Liver cancer heterogeneity modeled by in situ genome editing of hepatocytes. **2022**, 8,

- 174 Tissue factor promotes HCC carcinogenesis by inhibiting BCL2-dependent autophagy. **2022**,
- 173 N7-Methylguanosine Genes Related Prognostic Biomarker in Hepatocellular Carcinoma. 13,
- 172 Enhanced oral bioavailability and antitumor therapeutic efficacy of sorafenib administered in core-shell protein nanoparticle.
- 171 Mechanisms of chronic alcohol exposure-induced aggressiveness in cellular model of HCC and recovery after alcohol withdrawal. **2022**, 79,
- 170 Real-World Data on Ramucirumab Therapy including Patients Who Experienced Two or More Systemic Treatments: A Multicenter Study. **2022**, 14, 2975 ○
- 169 Hepatotropic Peptides Grafted onto Maleimide-Decorated Nanoparticles: Preparation, Characterization and In Vitro Uptake by Human HepaRG Hepatoma Cells. **2022**, 14, 2447
- 168 Immunotherapy of advanced hepatocellular carcinoma: case report and literature review. **2022**, 31-39
- 167 Immunotherapy as a Therapeutic Strategy for Gastrointestinal Cancer—Current Treatment Options and Future Perspectives. **2022**, 23, 6664 ○
- 166 Association of Increased Programmed Death Ligand 1 Expression and Regulatory T Cells Infiltration with Higher Hepatocellular Carcinoma Recurrence in Patients with Hepatitis B Virus Pre-S2 Mutant after Curative Surgical Resection. **2022**, 14, 1346
- 165 The combination treatment strategy of lenvatinib for hepatocellular carcinoma: a real-world study. ○
- 164 Second Generation Small Molecule Inhibitors of Gankyrin for the Treatment of Pediatric Liver Cancer. **2022**, 14, 3068
- 163 Selection of Systemic Treatment Regimen for Unresectable Hepatocellular Carcinoma: Does Etiology Matter?.
- 162 Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma In Vitro and In Vivo. **2022**, 14, 2959
- 161 The Critical Role of Ferroptosis in Hepatocellular Carcinoma. 10, ○
- 160 Imaging for better responses to immunotherapy in HCC.
- 159 Prognostic Advantages of Individual Additional Interventions After Lenvatinib Therapy in Patients with Advanced Hepatocellular Carcinoma.
- 158 Application of Tivantinib for Hepatocellular Carcinoma: A Meta-Analysis Study. **2022**, 2022, 1-6
- 157 A Multifunctional Vanadium-Iron-Oxide Nanoparticle Eradicates Hepatocellular Carcinoma via Targeting Tumor and Endothelial Cells.

- 156 Real-world treatment patterns, clinical outcomes, and health care resource utilization in advanced unresectable hepatocellular carcinoma.
- 155 Changing Epidemiological Trends of Hepatobiliary Carcinomas in Austria 2010–2018. **2022**, 14, 3093
- 154 Deletion of Lactate Dehydrogenase-A Impairs Oncogene-Induced Mouse Hepatocellular Carcinoma Development. **2022**, ○
- 153 Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies. 12, ○
- 152 The Therapeutic Role of PNU-74654 in Hepatocellular Carcinoma May Involve Suppression of NF- κ B Signaling. **2022**, 58, 798 ○
- 151 METTL1 is required for non-homologous end joining repair and renders hepatocellular carcinoma resistant to radiotherapy. ○
- 150 Second-line treatment of advanced hepatocellular carcinoma: Time for more individualized treatment options?. **2022**, 14, 1074-1086
- 149 Aggregation-induced Emission (AIE) and Magnetic Resonance Imaging Characteristics for Targeted and Image-guided siRNA Therapy of Hepatocellular Carcinoma. 2200579
- 148 Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances. **2022**, 13, 448-472
- 147 Adjuvant Sorafenib Following Radiofrequency Ablation for Early-Stage Recurrent Hepatocellular Carcinoma With Microvascular Invasion at the Initial Hepatectomy. 12,
- 146 Iron Oxide Nanoparticles Functionalized with Fucoïdan: a Potential Theranostic Nanotool for Hepatocellular Carcinoma.
- 145 DJ-1/FGFR-1 Signaling Pathway Contributes to Sorafenib Resistance in Hepatocellular Carcinoma. **2022**, 2022, 1-20 ○
- 144 MAEL Augments Cancer Stemness Properties and Resistance to Sorafenib in Hepatocellular Carcinoma through the PTGS2/AKT/STAT3 Axis. **2022**, 14, 2880
- 143 Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma. 13, ○
- 142 Ursolic acid enhances the antitumor effects of sorafenib associated with Mcl-1-related apoptosis and SLC7A11-dependent ferroptosis in human cancer. **2022**, 182, 106306 ○
- 141 Deciphering key regulators of *Inonotus hispidus* petroleum ether extract involved in anti-tumor through whole transcriptome and proteome analysis in H22 tumor-bearing mice model. **2022**, 296, 115468 ○
- 140 Research Progress of Apatinib in the Treatment of Advanced Liver Cancer. **2022**, 12, 131-135
- 139 Bioinformatics-based analysis of SUMOylation-related genes in hepatocellular carcinoma reveals a role of upregulated SAE1 in promoting cell proliferation. **2022**, 17, 1183-1202

- 138 TKIs beyond immunotherapy predict improved survival in advanced HCC.
- 137 Hepatocellular Carcinoma Down-Staging for Liver Transplantation in the Era of Systemic Combined Therapy with Anti-VEGF / TKI and Immunotherapy. ○
- 136 Radiotherapy for bone metastases of hepatocellular carcinoma: a hybrid systematic review with meta-analyses. 1-30 ○
- 135 Emerging insights on immunotherapy in liver cancer.
- 134 Targeting Ferroptosis Pathway to Combat Therapy Resistance and Metastasis of Cancer. 13, ○
- 133 Hepatocellular Carcinoma.
- 132 Glasgow prognostic score predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter analysis. **2022**, 34, 857-864
- 131 Long-term survival with sorafenib-based multidisciplinary treatment for Vp4 hepatocellular carcinoma: a case report.
- 130 Transarterial chemoembolization failure/refractoriness: A scientific concept or pseudo-proposition. **2022**, 14, 528-537
- 129 The second Mexican consensus on hepatocellular carcinoma. Part II: Treatment. **2022**,
- 128 Role of N6-Methyladenosine Methylation Regulators in the Drug Therapy of Digestive System Tumours. 13,
- 127 Response of Scalp and Skull Metastasis to Anti-PD-1 Antibody Combined with Regorafenib Treatment in a Sorafenib-Resistant Hepatocellular Carcinoma Patient and a Literature Review. Volume 15, 703-716
- 126 Rapid progression to death after hepatocellular carcinoma diagnosis particularly among persons with advanced HIV disease in Kampala, Uganda.
- 125 Neoadjuvant Immunotherapy for Hepatocellular Carcinoma. Volume 9, 571-581
- 124 Preoperative tumor embolization prolongs time to recurrence of meningiomas: a retrospective propensity-matched analysis. neurintsurg-2022-019080
- 123 Pretreatment Modified AlbuminâBilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma. **2022**, 29, 4799-4810 ○
- 122 Impact and Novel Perspective of Immune Checkpoint Inhibitors in Patients with Early and Intermediate Stage HCC. **2022**, 14, 3332
- 121 Intraarterial Therapies for the Management of Hepatocellular Carcinoma. **2022**, 14, 3351

- 120 Conversion surgery for hepatocellular carcinoma with portal vein tumor thrombus after successful atezolizumab plus bevacizumab therapy: a case report. **2022**, 20, ○
- 119 Cold Atmospheric Plasma Conveys Selectivity Against Hepatocellular Carcinoma Cells via Triggering EGFR(Tyr1068)-Mediated Autophagy. 12,
- 118 Reduced Rates of Post-Transplant Recurrent Hepatocellular Carcinoma in Non-Alcoholic Steatohepatitis: A Propensity Score Matched Analysis. 35,
- 117 Cuproptosis-Related Risk Score Predicts Prognosis and Characterizes the Tumor Microenvironment in Hepatocellular Carcinoma. 13, ○
- 116 Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysis.
- 115 Ficolin-3 may act as a tumour suppressor by recognising O-GlcNAcylation site in hepatocellular carcinoma. **2022**, 110899
- 114 Comprehensive characterization of enhancer RNA in hepatocellular carcinoma reveals three immune subtypes with implications for immunotherapy. **2022**,
- 113 Embolization therapy with microspheres for the treatment of liver cancer: State-of-the-art of clinical translation. **2022**, ○
- 112 Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. **2022**, ○
- 111 Ranking of transarterial and targeted therapies for advanced hepatocellular carcinoma in the era of immuno-oncology: A network meta-analysis of randomized sorafenib-controlled trials.
- 110 Growth hormone receptor antagonism downregulates ATP-binding cassette transporters contributing to improved drug efficacy against melanoma and hepatocarcinoma in vivo. 12, ○
- 109 Boric acid exert anti-cancer effect in poorly differentiated hepatocellular carcinoma cells via inhibition of AKT signaling pathway. **2022**, 127043
- 108 A generational comparison for unfavorable cancer of unknown primary in a single institute over 20 years.
- 107 Efficacy and Safety of Lenvatinib Combined With PD-1 Inhibitors Plus TACE for Unresectable Hepatocellular Carcinoma Patients in China Real-World. 12,
- 106 Ets1 mediates sorafenib resistance by regulating mitochondrial ROS pathway in hepatocellular carcinoma. **2022**, 13,
- 105 Improving the Therapeutic Efficacy of Sorafenib for Hepatocellular Carcinoma by Repurposing Disulfiram. 12,
- 104 Cellular Prion Protein Is Closely Associated with Early Recurrence and Poor Survival in Patients with Hepatocellular Carcinoma. **2022**, 12, 1635
- 103 The Potential Predictive Biomarkers for Advanced Hepatocellular Carcinoma Treated With Anti-Angiogenic Drugs in Combination With PD-1 Antibody. 13,

- 102 Current status of primary liver cancer and decompensated cirrhosis in Japan: launch of a nationwide registry for advanced liver diseases (REAL).
- 101 Bioinformatics Analysis for Constructing a Six-Immune-Related Long Noncoding RNA Signature as a Prognostic Model of Hepatocellular Carcinoma. **2022**, 2022, 1-15
- 100 Low Baseline Plasma L-Glutamine Concentration Identifies Hepatocellular Carcinoma Patients at High Risk of Developing Early Gastrointestinal Adverse Events during Sorafenib Treatment. **2022**, 4, 141-152
- 99 Mechanisms of resistance to tyrosine kinase inhibitors in liver cancer stem cells and potential therapeutic approaches. ○
- 98 Real-world effectiveness of lenvatinib monotherapy in previously treated unresectable hepatocellular carcinoma in US clinical practice.
- 97 Treatment of hepatocellular carcinoma in sub-Saharan Africa: challenges and solutions. **2022**,
- 96 Comparative Response of HCC Cells to TKIs: Modified in vitro Testing and Descriptive Expression Analysis. Volume 9, 595-607
- 95 MicroRNAs at the Crossroad between Immunoediting and Oncogenic Drivers in Hepatocellular Carcinoma. **2022**, 12, 930
- 94 Iridium photosensitizer constructed liposomes with hypoxia-activated prodrug to destrust hepatocellular carcinoma. **2022**,
- 93 Cross-regulation between microRNAs and key proteins of signaling pathways in hepatocellular carcinoma.
- 92 Dose Individualization of Oral Multi-Kinase Inhibitors for the Implementation of Therapeutic Drug Monitoring. **2022**, 45, 814-823
- 91 Efficacy and feasibility of surgery and external radiotherapy for hepatocellular carcinoma with portal invasion: A meta-analysis. **2022**, 104, 106753
- 90 Iron chelator deferasirox inhibits NF- κ B activity in hepatoma cells and changes sorafenib-induced programmed cell deaths. **2022**, 153, 113363
- 89 Emerging roles and potential clinical applications of long non-coding RNAs in hepatocellular carcinoma. **2022**, 153, 113327 ○
- 88 Synthesis and biological evaluation of 4-(4-aminophenyl)-6-methylisoxazolo[3,4-b] pyridin-3-amine covalent inhibitors as potential agents for the treatment of acute myeloid leukemia. **2022**, 70, 116937
- 87 Feasibility of therapeutic drug monitoring of sorafenib in patients with liver or thyroid cancer. **2022**, 153, 113393
- 86 Immune checkpoint and angiogenic inhibitors for the treatment of hepatocellular carcinoma: It takes two to tangle. **2022**, 27, 100740
- 85 Liver Cancer: Hepatocellular and Fibrolamellar Carcinoma. **2023**, 109-132

- 84 Painful Rashes on the Palms and Soles. **2016**, 45, 479-480
- 83 Current status of and barriers to the treatment of advanced-stage liver cancer in China: a questionnaire-based study from the perspective of doctors. **2022**, 22,
- 82 Investigations of nitazoxanide molecular targets and pathways for the treatment of hepatocellular carcinoma using network pharmacology and molecular docking. 13,
- 81 Peroxisome proliferator-activated receptor gamma as a therapeutic target for hepatocellular carcinoma: Experimental and clinical scenarios. **2022**, 28, 3535-3554
- 80 Metformin Enhances the Anti-Cancer Efficacy of Sorafenib via Suppressing MAPK/ERK/Stat3 Axis in Hepatocellular Carcinoma. **2022**, 23, 8083
- 79 Benefits of step-by-step debulking microwave ablation for huge unresectable hepatocellular carcinoma patients after transcatheter arterial chemoembolization refractoriness. **2022**, 39, 935-945
- 78 Macrotrabecular-Massive Hepatocellular Carcinoma: Light and Shadow in Current Knowledge. Volume 9, 661-670 ○
- 77 Toxicity Profiles of Systemic Therapies for Advanced Hepatocellular Carcinoma. **2022**, 5, e2222721
- 76 Potential feasibility of Atezolizumab-Bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitors. **2022**, ○
- 75 Two Milestone Studies in Liver Cancer Immunotherapy. **2022**, 1,
- 74 Case Report: Exacerbation of varices following atezolizumab plus bevacizumab treatment of hepatocellular carcinoma: A case series and literature review. 12,
- 73 Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor-based combination therapies: a multicenter retrospective study.
- 72 Probing Iron-Mediated Synergistic Change of Cl⁻ and HClO in Liver Cancer Cells with a Dual-Color Fluorescence Reporter.
- 71 Clinical Usefulness of Monitoring Muscle Volume during Atezolizumab Plus Bevacizumab Therapy in Patients with Unresectable Hepatocellular Carcinoma. **2022**, 14, 3551
- 70 Hepatocellular Carcinoma. **2022**,
- 69 Three-Dimensional Quantitative Tumor Response and Survival Analysis of Hepatocellular Carcinoma Patients Who Failed Initial Transarterial Chemoembolization: Repeat or Switch Treatment?. **2022**, 14, 3615
- 68 Approaches to spatially resolving the tumour immune microenvironment of hepatocellular carcinoma. **2022**, 14, 175883592211132
- 67 Statins in Liver Cirrhosis. **2022**, 179-204

- 66 Medical Management of Hepatocellular Carcinoma. **2022**, 1-6
- 65 Efficacy of Transarterial Chemoembolization Combined with Molecular Targeted Agents for Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis. **2022**, 14, 3710
- 64 Prognostic implication of serum AFP in patients with hepatocellular carcinoma treated with regorafenib.
- 63 Hepatectomy combined with targeted and immunotherapy for CNLC stage IIIb hepatocellular carcinoma: a single-arm clinical trials protocol.
- 62 Non-alcoholic fatty liver disease-related hepatocellular carcinoma: Is there a role for immunotherapy?. **2022**, 28, 3595-3607
- 61 The Feasibility of Liver Biopsy for Undefined Nodules in Patients under Surveillance for Hepatocellular Carcinoma: Is Biopsy Really a Useful Tool?. **2022**, 11, 4399
- 60 Prognostic value of exosomal noncoding RNA in hepatocellular carcinoma: a meta-analysis.
- 59 Combination approaches in hepatocellular carcinoma: How systemic treatment can benefit candidates to locoregional modalities. **2022**, 28, 3573-3585
- 58 Three-dimensional (3D) cell culture: a valuable step in advancing treatments for human hepatocellular carcinoma. **2022**, 22,
- 57 Hepatocellular Carcinoma: Aetiology and Mechanisms of Development. A Literature Review. **2022**, 12, 139-150
- 56 Efficacy of percutaneous ethanol injection versus radiofrequency ablation for single hepatocellular carcinoma no larger than 5 cm. **2022**, 50, 030006052211112
- 55 Diagnostik und Therapie des primären Leberzellkarzinoms.
- 54 Immune checkpoint inhibitors and tyrosine kinase inhibitors in patients with advanced hepatocellular carcinoma: Does the sequence matter?.
- 53 Response to PD-1 inhibitor after progression on PD-L1 inhibitor in advanced HCC. **2022**, 15, e250009 ○
- 52 Management of Bilateral Metachronous Adrenal Metastases from Hepatocellular Carcinoma.
- 51 Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. 13,
- 50 The Combining of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors as First-Line Treatment for Advanced Stage Hepatocellular Carcinoma. **2022**, 11, 4874
- 49 Proton therapy in the treatment of hepatocellular carcinoma. 12,

- 48 Advances of cancer-associated fibroblasts in liver cancer. **2022**, 10,
- 47 Blood Biomarkers Predict Survival Outcomes in Patients with Hepatitis B Virus-Induced Hepatocellular Carcinoma Treated with PD-1 Inhibitors. **2022**, 2022, 1-9
- 46 Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150. **2022**, 14, 3938
- 45 CFI-402257, a TTK inhibitor, effectively suppresses hepatocellular carcinoma. **2022**, 119,
- 44 New concepts in the treatment of hepatocellular carcinoma.
- 43 Multimodal Imaging Response after the Singular or Combination Treatments of Vascular Endothelial Growth Factor Inhibitor and Immune Checkpoint Inhibitor.
- 42 Second-line therapy for advanced hepatocellular carcinoma with regorafenib or cabozantinib: Multicenter French clinical experience in real-life after matching. **2022**, 14, 1510-1527
- 41 Stereotactic Body Radiation Therapy for the Management of Hepatocellular Carcinoma: Efficacy and Safety. **2022**, 14, 3892
- 40 SIRT in 2025. o
- 39 Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve.
- 38 Inhibition of LPAR6 overcomes sorafenib resistance by switching glycolysis into oxidative phosphorylation in hepatocellular carcinoma. **2022**,
- 37 Nalidixic acid potentiates the antitumor activity in sorafenib-resistant hepatocellular carcinoma via the tumor immune microenvironment analysis. 13,
- 36 A cross-sectional study of the FDA approved indications and supporting pivotal trials of small-molecular kinase inhibitors in cancer therapies with the biomarker of cancer driver gene.
- 35 Lysine demethylase KDM1A promotes cell growth via FKBP8-BCL2 axis in hepatocellular carcinoma. **2022**, 102374
- 34 Multi-kinase Inhibitors for the Treatment of Asymptomatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Global, Non-Interventional Study (RIFTOS MKI).
- 33 Survival and adverse events of elderly patients treated with sorafenib for hepatocellular carcinoma. 12,
- 32 Opportunities and challenges of targeting c-Met in the treatment of digestive tumors. 12,
- 31 Anti-PD-1/PD-L1 immunotherapy in conversion treatment of locally advanced hepatocellular carcinoma.

- 30 Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib.
- 29 Disruption of Growth Hormone Receptor Signaling Abrogates Hepatocellular Carcinoma Development. Volume 9, 823-837
- 28 Cell-cycle and apoptosis related and proteomics-based signaling pathways of human hepatoma Huh-7 cells treated by three currently used multi-RTK inhibitors. 13,
- 27 Targeted Therapy for Hepatocellular Carcinoma: Old and New Opportunities. **2022**, 14, 4028
- 26 Downregulation of SETD5 Suppresses the Tumorigenicity of Hepatocellular Carcinoma Cells. **2022**, 45, 550-563
- 25 IGF2BP3-NRF2 axis regulates ferroptosis in hepatocellular carcinoma. **2022**,
- 24 Advances in novel systemic therapies for advanced hepatocellular carcinoma.
- 23 Interventional radiology meets immuno-oncology for hepatocellular carcinoma. **2022**,
- 22 Sorafenib and Doxorubicin Show Synergistic Effects in Human and Canine Osteosarcoma Cell Lines. **2022**, 23, 9345
- 21 Conversion surgery after lenvatinib treatment for multiple lung metastases from hepatocellular carcinoma.
- 20 Long term complete response of advanced hepatocellular carcinoma to glypican-3 specific chimeric antigen receptor T-Cells plus sorafenib, a case report. 13,
- 19 Well-Controlled Viremia Predicts the Outcome of Hepatocellular Carcinoma in Chronic Viral Hepatitis Patients Treated with Sorafenib. **2022**, 14, 3971
- 18 Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study. 13,
- 17 Validation of the easy-to-use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib.
- 16 EGFR blockade confers sensitivity to cabozantinib in hepatocellular carcinoma. **2022**, 8,
- 15 Combining stereotactic body radiotherapy with camrelizumab for unresectable hepatocellular carcinoma: a single-arm trial.
- 14 Outcomes of Sorafenib for Recurrent Hepatocellular Carcinoma After Liver Transplantation in the Era of Combined and Sequential Treatments. Publish Ahead of Print,
- 13 Strategies for improving the efficacy of immunotherapy in hepatocellular carcinoma. **2022**,

- 12 Link of sorafenib resistance with the tumor microenvironment in hepatocellular carcinoma: Mechanistic insights. 13,
- 11 Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment.
- 10 miR-23b-3p Modulating Cytoprotective Autophagy and Glutamine Addiction in Sorafenib Resistant HepG2, a Hepatocellular Carcinoma Cell Line. **2022**, 13, 1375
- 9 Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond. **2022**, 29, 5489-5507 ○
- 8 ITGA5 and ITGB1 contribute to Sorafenib resistance by promoting vasculogenic mimicry formation in hepatocellular carcinoma.
- 7 Iridium Complex-Loaded Sorafenib Nanocomposites for Synergistic Chemo-photodynamic Therapy of Hepatocellular Carcinoma. **2022**, 14, 37356-37368
- 6 Real-world outcomes of molecular targeted agents for patients with hepatocellular carcinoma over 80 years old. ○
- 5 Construction and application of liver cancer models in vitro. **2022**, 3, 310-322 ○
- 4 Sorafenib combined with STAT3 knockdown triggers ER stress-induced HCC apoptosis and cGAS-STING-mediated anti-tumor immunity. **2022**, 547, 215880
- 3 Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: A network metanalysis of phase III trials. **2022**, 174, 57-67
- 2 Grandiflorenic acid from *Wedelia trilobata* plant induces apoptosis and autophagy cell death in breast adenocarcinoma (MCF7), lung carcinoma (A549), and hepatocellular carcinoma (HuH7.5) cells lines. **2022**, 217, 112-120
- 1 Sorafenib suppresses radioresistance and synergizes radiotherapy-mediated CD8+ T cell activation to eradicate hepatocellular carcinoma. **2022**, 112, 109110